"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,MX,A,MX PA05008299 A,045-208-335-093-946,2005-11-04,2005,MX PA05008299 A,2004-02-04,US 44508003 P;;US 2004/0003255 W,2003-02-05,MAILER PACKAGE.,"A mailer package (110) formed from a single sheet blank (112) of foldable stock material includes at least one panel (Kuchenbecker) having first and second sides (118', 120'). A closure flap (156) with a tearable pull tab (158) extends from a first edge (119') of the one panel. A compartment flap (122) extends from a second edge (121') and includes an attachment tab (126). The compartment flap forms a compartment (116) having four sequentially adjoining sides (132, 134, 136, Kuchenbecker), formed by folds (121, 127, 129, 131). The compartment has first and second open ends (128, 130), closed by tabs (140, 146, 148) and a cover (114) extending from a third edge (123') of the one panel.",MATTEL INC,CARR LINDA ANN,,https://lens.org/045-208-335-093-946,Patent Application,no,0,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,,0,0,,,,EXPIRED
2,US,A,US 4808165 A,087-916-128-913-05X,1989-02-28,1989,US 9259187 A,1987-09-03,US 9259187 A,1987-09-03,Inflation/deflation device for balloon catheter,"An inflation/deflation device for balloon catheter includes a pair of members pivoted to one another at one end. The first member has a recess and slot opening to one side for receiving the barrel of a syringe and the flange on the barrel, respectively. The second member carries a fitting having a slot opening to one side for receiving the flange of the plunger. The device has handles on the ends of the members remote from the pivot axis whereby the members can be moved toward and away from one another. In this manner, the balloon catheter may be inflated and deflated rapidly and with a force-multiplying effect.",CARR ANN M,CARR ANN M,,https://lens.org/087-916-128-913-05X,Granted Patent,yes,14,89,1,1,0,A61B2017/00783;;A61M25/10182;;A61M25/10182;;A61B2017/00783;;A61M25/1018,A61B17/00;;A61F2/958,604/97;;128/344,0,0,,,,EXPIRED
3,AU,A,AU 2001/051797 A,143-474-118-000-20X,2002-01-03,2002,AU 2001/051797 A,2001-06-07,AU PQ827300 A;;AU 2001/051797 A,2000-06-22,Barbecue cooking device,,IAN JOHN CARR;;CHRISTINE ANN CARR,CARR IAN JOHN;;CARR CHRISTINE ANN,,https://lens.org/143-474-118-000-20X,Patent Application,no,0,0,1,3,0,Y02A40/928,A47J37/07,,0,0,,,,DISCONTINUED
4,US,A1,US 2002/0017289 A1,139-275-115-384-029,2002-02-14,2002,US 88593601 A,2001-06-22,AU PQ827300 A,2000-06-22,Barbecue cooking device,"
   The invention relates to an improved barbecue cooking device. The barbecue cooking device has particular application for use with wood or charcoal fuels and enables the cooking platform to be raised and lowered towards the heat source. 
",CARR IAN JOHN;;CARR CHRISTINE ANN,CARR IAN JOHN;;CARR CHRISTINE ANN,,https://lens.org/139-275-115-384-029,Patent Application,yes,0,14,2,3,0,A47J37/0704;;A47J2037/0795;;A47J37/0704;;A47J2037/0795,A47J37/07,126/25;;X09945;;99/448,0,0,,,,DISCONTINUED
5,US,S,US D0678700 S,178-979-191-281-275,2013-03-26,2013,US 201229428489 F,2012-07-31,US 201229428489 F,2012-07-31,Dress-shaped organizer,,CARR MATTHEW J;;COTT BETH ANN;;UMBRA LLC,CARR MATTHEW J;;COTT BETH ANN,UMBRA LLC (2012-07-30),https://lens.org/178-979-191-281-275,Design Right,no,0,5,3,3,0,,,0606;;D 6513,0,0,,,,ACTIVE
6,US,S,US D0677084 S,096-459-813-783-113,2013-03-05,2013,US 201229430676 F,2012-08-28,US 201229430676 F,2012-08-28,Dress-shaped organizer,,CARR MATTHEW J;;COTT BETH ANN;;UMBRA LLC,CARR MATTHEW J;;COTT BETH ANN,UMBRA LLC (2012-08-27),https://lens.org/096-459-813-783-113,Design Right,no,0,1,2,2,0,,,0606;;D 6513,0,0,,,,ACTIVE
7,US,S,US D0906155 S,002-682-059-755-568,2020-12-29,2020,US 202029722278 F,2020-01-28,US 202029722278 F,2020-01-28,Ring,,JOSTENS INC,FREIBERG JOHN A;;CARR ANN MERZ,JOSTENS INC (2020-02-15),https://lens.org/002-682-059-755-568,Design Right,no,23,14,2,2,0,,,1101;;D11/26,1,0,,,"[Online] “Class Band Collection” https://www.jostens.com/jewelry/class-jewelry/high-school/the-class-band. Retrieved Nov. 20, 2020.",ACTIVE
8,US,S,US D0701706 S,153-105-047-398-327,2014-04-01,2014,US 201329466757 F,2013-09-11,US 201329466757 F,2013-09-11,Dress-shaped organizer,,UMBRA LLC,CARR MATTHEW J;;COTT BETH ANN,UMBRA LLC (2013-08-21),https://lens.org/153-105-047-398-327,Design Right,no,0,2,1,1,0,,,0606;;D 6514,0,0,,,,ACTIVE
9,ZA,B,ZA 848097 B,175-283-232-128-580,1985-06-26,1985,ZA 848097 A,1984-10-17,ZA 848097 A,1984-10-17,"STAND FOR PLATES,GLASSES AND OTHER RECEPTACLES",,MOUNTER JOHN ROBERT;;CARR SHIRLEY ANN;;HANDYSAM PRODUCTS,MOUNTER JOHN ROBERT;;CARR SHIRLEY ANN,,https://lens.org/175-283-232-128-580,Granted Patent,no,0,0,1,1,0,,A47G/;;A47J/,,0,0,,,,EXPIRED
10,US,A1,US 2016/0159518 A1,096-908-254-636-432,2016-06-09,2016,US 201514958628 A,2015-12-03,US 201514958628 A;;US 201462087783 P,2014-12-04,Collapsible Receptacle,"A collapsible receptacle, such as a beverage cup, that is reconfigurable between expanded and collapsed configurations with an inner sleeve with first and second opposed major walls divided by opposed fold lines, an outer sleeve with first and second opposed major walls divided by opposed fold lines, and a liner retained by the inner and outer sleeves. The receptacle is retained in an expanded configuration when the opposed fold lines of the inner and outer sleeves are not aligned, and the receptacle can be collapsed when the opposed fold lines are aligned. A lid can be removably retained by a retaining ring. The opposed fold lines of the inner and outer sleeves can be disposed in groups, such as groups of two fold lines, so that the sleeves have opposed minor walls. The major walls can taper in thickness from their mid-portions to the opposed fold lines.",HOLLIS JOHN REY;;HOLLIS CHRISTINE ANN;;CARR ROGER G,HOLLIS JOHN REY;;HOLLIS CHRISTINE ANN;;CARR ROGER G,DESIGN FOLD LLC (2017-05-11),https://lens.org/096-908-254-636-432,Patent Application,yes,2,5,3,3,0,A45F3/20;;A45F2003/205;;A45F3/20;;A45F2003/205;;A47G19/2205;;A47G2019/2277;;B65D21/086;;B65D43/02,B65D21/08;;A47G19/22;;B65D43/02,,0,0,,,,ACTIVE
11,US,S,US D0470236 S,192-595-036-066-182,2003-02-11,2003,US 16452602 F,2002-07-26,US 16452602 F;;US 13837101 F,2001-03-12,Disposable absorbent article,,KIMBERLY CLARK CO,CARR JAMES MARCUS;;VANDYKE SHERRY ANN;;WHEELER KATHERINE CAROL,,https://lens.org/192-595-036-066-182,Design Right,no,0,0,2,2,0,,,D24/126,0,0,,,,EXPIRED
12,US,B2,US 9694938 B2,013-476-128-065-459,2017-07-04,2017,US 201514958628 A,2015-12-03,US 201514958628 A;;US 201462087783 P,2014-12-04,Collapsible receptacle,"A collapsible receptacle, such as a beverage cup, that is reconfigurable between expanded and collapsed configurations with an inner sleeve with first and second opposed major walls divided by opposed fold lines, an outer sleeve with first and second opposed major walls divided by opposed fold lines, and a liner retained by the inner and outer sleeves. The receptacle is retained in an expanded configuration when the opposed fold lines of the inner and outer sleeves are not aligned, and the receptacle can be collapsed when the opposed fold lines are aligned. A lid can be removably retained by a retaining ring. The opposed fold lines of the inner and outer sleeves can be disposed in groups, such as groups of two fold lines, so that the sleeves have opposed minor walls. The major walls can taper in thickness from their mid-portions to the opposed fold lines.",HOLLIS JOHN REY;;HOLLIS CHRISTINE ANN;;CARR ROGER G;;DESIGN FOLD LLC,HOLLIS JOHN REY;;HOLLIS CHRISTINE ANN;;CARR ROGER G,DESIGN FOLD LLC (2017-05-11),https://lens.org/013-476-128-065-459,Granted Patent,yes,78,5,3,3,0,A45F3/20;;A45F2003/205;;A45F3/20;;A45F2003/205;;A47G19/2205;;A47G2019/2277;;B65D21/086;;B65D43/02,A47G19/22;;A45F3/20;;B65D21/08;;B65D43/02,,9,0,,,"United States Patent & Trademark Office, International Search Report and Written Opinion,PCT/ISA/220, Application No. PCT/US2015/063784, Feb. 11, 2015, U.S. Patent & Trademark Office, Alexandria, VA.;;Tim Johnson Design, Inc., Geocup, website address: http://www.geocup.com, Tim Johnson Design, Inc., Boston, MA, USA, Dec. 3, 2015.;;Collapse a Cup, Collapse a Cup, website address: http://www.collapse-a-cup.com, Collapse a Cup, Hamden, CT, USA, Dec. 3, 2015.;;Nada Bottle, LLC., Nada Bottle, website address: https://www.nadabottle.com, Crested Butte, CO, USA, Dec. 3, 2015.;;Niki Singlaub, Hydaway Bottle, website address: http://hydawaybottle.com/ Bend, Oregon, USA, Dec. 3, 2015.;;Humangear, Inc., GoCup, website address: http://www.humangear.com/gocup/, San Francisco, CA, USA, Dec. 3, 2015.;;Karla Zens, Zip Cup: Revolutionary Collapsible Coffee Cup, website address: http://www.zipcup.com, Dec. 3, 2015.;;Ben Melinger, Stojo the Collapsible Pocket Cup, website address: http://www.stojo.co, Brooklyn, NY, USA, Dec. 3, 2015.;;United States Patent & Trademark Office, International Search Report and Written Opinion,PCT/ISA/220, Application No. PCT/US2015/063784, Feb. 11, 2016, U.S. Patent & Trademark Office, Alexandria, VA.",ACTIVE
13,WO,A1,WO 2023/283220 A1,093-984-577-092-615,2023-01-12,2023,US 2022/0036183 W,2022-07-06,US 202163218565 P,2021-07-06,POWER CONVERTER CIRCUIT TESTING,"One example includes automatic test equipment (ATE) circuitry (104) having a test input (106) and a test output (108). The test input is adapted to be coupled to a digital output (110) of a power converter integrated circuit (IC) (102). The test output is adapted to be coupled to a voltage output (112) of the power converter IC (102). The ATE circuitry also includes a level shifter (116), a buffer (118), pull-up circuitry (122) and a filter (120). The level shifter (116) has a shifter input and a shifter output, in which the shifter input is coupled to the test input. The buffer (118) has a buffer input coupled to the shifter output. The pull-up circuitry (122) is coupled to the buffer input, and the pull-up circuitry (122) is configured to supply a voltage sufficient to enable operation of circuitry in the power converter IC. The filter (120) has an input coupled to the buffer output and a filter output coupled to the test output.",TEXAS INSTRUMENTS INC,CARR GENESIS BENJAMIN;;TRAMBADIYA VASANTKUMAR PRABHUDAS;;WONG KAE ANN,,https://lens.org/093-984-577-092-615,Patent Application,yes,3,0,2,2,0,G01R31/40,G01R31/40,,0,0,,,,PENDING
14,US,B1,US 9652595 B1,194-780-993-096-890,2017-05-16,2017,US 201615362963 A,2016-11-29,US 201615362963 A;;US 201615042087 A;;US 201562117393 P,2015-02-17,Kit that improves impaired hepatic glucose processing in subjects,"A kit for individualized intravenous exogenous insulin-based therapy, which includes a portable data storage in communication with client device processor. The data storage can have computer instructions, a database of metabolic factors, a library of weight management protocols, a diabetic treatment model, and a library of care plan templates. The kit for individualized intravenous exogenous insulin-based therapy includes a blood glucose meter, a plurality of intravenous catheters fluidly engageable with a fluid source, and a plurality of metabolic enhancements.",DIABETES RELIEF LLC,CARR HUNTER MICHAEL ALAN;;HEPFORD SCOTT;;WILSON CAROL ANN,DIABETES RELIEF LLC (2016-11-22);;WELL CELL GLOBAL LLC (2020-07-24),https://lens.org/194-780-993-096-890,Granted Patent,yes,1,2,1,3,0,G16H50/20;;G16H50/20;;G16H10/40;;G16H10/40;;G16H10/60;;G16H10/60;;G16H20/17;;G16H20/17;;G16Z99/00;;G16Z99/00,A61M5/168;;A61M5/00;;G06F19/00,,0,0,,,,ACTIVE
15,US,S,US D0468427 S,177-278-168-262-270,2003-01-07,2003,US 13837201 F,2001-03-12,US 13837201 F,2001-03-12,Disposable absorbent article,,KIMBERLY CLARK CO,CARR JAMES MARCUS;;VANDYKE SHERRY ANN;;WHEELER KATHERINE CAROL,KIMBERLY-CLARK WORLDWIDE INC (2001-04-19),https://lens.org/177-278-168-262-270,Design Right,no,0,2,1,1,0,,,D24/126,0,0,,,,EXPIRED
16,US,S,US D0477404 S,084-463-324-845-332,2003-07-15,2003,US 13837101 F,2001-03-12,US 13837101 F,2001-03-12,Disposable absorbent article,,KIMBERLY CLARK CO,CARR JAMES MARCUS;;VANDYKE SHERRY ANN;;WHEELER KATHERINE CAROL,KIMBERLY-CLARK WORLDWIDE INC (2001-03-12),https://lens.org/084-463-324-845-332,Design Right,no,0,5,2,2,0,,,D24/126,0,0,,,,EXPIRED
17,WO,A1,WO 2016/090162 A1,166-213-017-622-949,2016-06-09,2016,US 2015/0063784 W,2015-12-03,US 201462087783 P,2014-12-04,COLLAPSIBLE RECEPTACLE,"A collapsible receptacle (10), such as a beverage cup, that Is reconfigurable between expanded and collapsed configurations with an inner sleeve (18) with first and second 5 opposed major walls (28) divided by opposed fold lines (32), an outer sleeve (14) with first and second opposed major walls (38) divided by opposed fold lines (42), and a liner (12) retained by the inner and outer sleeves (18, 14). The receptacle (10) is retained in an expanded configuration when the opposed fold lines (32, 42) of the inner and outer sleeves (18, 14) are not aligned, and the receptacle (10) can be collapsed when the opposed fold lines 10 (32, 42) are aligned. The opposed fold lines (32, 42) of the inner and outer sleeves (18, 14) can be disposed in groups, such as groups of two fold lines, so that the sleeves have opposed minor walls (30, 40).",HOLLIS JOHN REY;;HOLLIS CHRISTINE ANN;;CARR ROGER G,HOLLIS JOHN REY;;HOLLIS CHRISTINE ANN;;CARR ROGER G,,https://lens.org/166-213-017-622-949,Patent Application,yes,5,1,3,3,0,A45F3/20;;A45F2003/205;;A45F3/20;;A45F2003/205;;A47G19/2205;;A47G2019/2277;;B65D21/086;;B65D43/02,B65D81/00;;B65D6/00,,0,0,,,,PENDING
18,US,S,US D0473644 S,152-469-029-082-338,2003-04-22,2003,US 13837301 F,2001-03-12,US 13837301 F,2001-03-12,Disposable absorbent article,,KIMBERLY CLARK CO,CARR JAMES MARCUS;;VANDYKE SHERRY ANN;;WHEELER KATHERINE CAROL,KIMBERLY-CLARK WORLDWIDE INC (2001-03-12),https://lens.org/152-469-029-082-338,Design Right,no,0,4,1,1,0,,,D24/126,0,0,,,,EXPIRED
19,CA,A1,CA 3102514 A1,033-722-761-588-067,2021-07-24,2021,CA 3102514 A,2020-12-11,US 202062965408 P,2020-01-24,SYSTEM FOR MANAGING EXPLORATION AND CONSUMPTION OF DIGITAL CONTENT IN CONNECTION WITH A PHYSICAL ARTICLE,"Abstract The invention generally relates to managing and sharing digital content, and, more particularly, to a web- or cloud-based platfomi providing for the contribution, management, and subsequent exploration and consumption of digital content in connection with printed content provided in a physical article, such as a yearbook or other memorabilia. Date Recue/Date Received 2020-12-11",JOSTENS INC,CARR ANN;;WOLF MICHAEL;;STUART-KING CHARLES;;BUERK GAVIN;;BRUNO ZACHARY,,https://lens.org/033-722-761-588-067,Patent Application,no,0,0,3,3,0,G06Q10/107;;G06N20/00;;G06V40/172;;G06F16/535;;G06Q10/107;;G06F16/538;;G06N20/00;;G06F16/51;;G06V40/171;;G06V40/161,G16Z99/00;;G06F16/90;;G06F21/32;;G06F21/40;;G06Q50/20,,0,0,,,,ACTIVE
20,CN,C,CN 100457569 C,193-586-206-198-068,2009-02-04,2009,CN 200480003661 A,2004-02-04,US 44508003 P,2003-02-05,Mailer package,,MATTEL INC,PATRICK CARTY JAMES;;MARIE PETERSON CHRISTINA;;RICHARD WEINTRAUB;;ANN CARR LINDA,,https://lens.org/193-586-206-198-068,Granted Patent,no,10,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D69/00;;B65D5/42,,0,0,,,,EXPIRED
21,KR,B1,KR 100215951 B1,017-022-615-584-749,1999-10-01,1999,KR 19960058335 A,1996-11-27,US 56551895 A,1995-11-30,HYDROXY-FUNCTIONAL TRIAMINE CATALYST COMPOSITIONS FOR POLYURETHANE PRODUCTION,"본 발명은 발포제, 셀안정화제 및 촉매 조성물의 존재하에 유기 폴리이소시아네이트와 폴리올을 반응시키는 것을 포함하는 폴리우레탄 포옴을 제조하는 방법에 관한 것으로서, 상기 촉매 조성물은 하기 화학식 1 의 화합물 0 내지 50몰%와 하기 화학식 2 의 화합물 50 내지 100몰%를 필수 성분으로 한다 : 상기식중, R은 수소, C-C알킬, C-C아릴, 또는 C-C아르알킬기이고; n은 2 내지 8 이다.",AIR PROD & CHEM,VAN COURT CARR RICHARD;;LISTEMANN MARK L;;SAVOCA ANN C L,,https://lens.org/017-022-615-584-749,Granted Patent,no,0,0,10,10,0,C08G18/16;;C08G18/1825;;C08G18/1825;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08G18/18;;C08G18/24;;C08G101/00,,0,0,,,,EXPIRED
22,CA,C,CA 3102514 C,091-148-247-926-043,2023-09-26,2023,CA 3102514 A,2020-12-11,US 202062965408 P,2020-01-24,SYSTEM FOR MANAGING EXPLORATION AND CONSUMPTION OF DIGITAL CONTENT IN CONNECTION WITH A PHYSICAL ARTICLE,"Abstract The invention generally relates to managing and sharing digital content, and, more particularly, to a web- or cloud-based platfomi providing for the contribution, management, and subsequent exploration and consumption of digital content in connection with printed content provided in a physical article, such as a yearbook or other memorabilia. Date Recue/Date Received 2020-12-11",JOSTENS INC,CARR ANN;;WOLF MICHAEL;;STUART-KING CHARLES;;BUERK GAVIN;;BRUNO ZACHARY,,https://lens.org/091-148-247-926-043,Granted Patent,no,0,0,3,3,0,G06Q10/107;;G06N20/00;;G06V40/172;;G06F16/535;;G06Q10/107;;G06F16/538;;G06N20/00;;G06F16/51;;G06V40/171;;G06V40/161,G16Z99/00;;G06F16/90;;G06F21/32;;G06F21/40;;G06Q50/20,,0,0,,,,ACTIVE
23,MX,A,MX 9605963 A,163-621-547-041-088,1998-04-30,1998,MX 9605963 A,1996-11-29,US 56551895 A,1995-11-30,HYDROXY-FUNCTIONAL TRIAMINE CATALYST COMPOSITIONS FOR POLYUREHTANE PRODUCTION.,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition consisting essentially of 0.50 mole percent compound 1 and 50-100 mole percent compound II. (see formula) wherein R is hydrogen, a C1-C4 alkyl, C6-C8 aryl, or C7-C9 aralkyl group; and n is 2 to 8.",AIR PROD & CHEM,CARR RICHARD VAN COURT;;LISTEMANN MARK LEO;;SAVOCA ANN COATES LESCHER,,https://lens.org/163-621-547-041-088,Patent Application,no,0,0,10,10,0,C08G18/16;;C08G18/1825;;C08G18/1825;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08G18/18;;C08G18/24;;C08G101/00,,0,0,,,,PENDING
24,CN,A,CN 1151997 A,171-296-370-047-604,1997-06-18,1997,CN 96119292 A,1996-11-30,US 56551895 A,1995-11-30,Hydroxy-functional triamine catalyst compositions for polyurethane production,,AIR PROD & CHEM,CARR RICHARD VAN COURT;;LISTEMANN MARK LEO;;SAVOCA ANN COATES LESCHER,,https://lens.org/171-296-370-047-604,Patent Application,no,0,1,10,10,0,C08G18/16;;C08G18/1825;;C08G18/1825;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08G18/18;;C08G18/24;;C08G101/00,,0,0,,,,EXPIRED
25,EP,A1,EP 0776919 A1,186-073-063-466-418,1997-06-04,1997,EP 96118935 A,1996-11-26,US 56551895 A,1995-11-30,Hydroxy-functional triamine catalyst compositions for polyurethane production,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition consisting essentially of 0-50 mole% compound I and 50-100 mole% compound II:
   wherein
 R is hydrogen, a C 1 -C 4  alkyl, C 6 -C 8  aryl, or C 7 -C 9  aralkyl group; and n is 2 to 8.",AIR PROD & CHEM,VAN COURT CARR RICHARD;;LISTEMANN MARK LEO;;LESCHER SAVOCA ANN COATES,,https://lens.org/186-073-063-466-418,Patent Application,yes,13,0,10,10,0,C08G18/16;;C08G18/1825;;C08G18/1825;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08G18/18;;C08G18/24;;C08G101/00,,2,2,114-388-153-467-048;;114-388-153-467-048,10.1177/0021955x8702300505;;10.1177/0021955x8702300505,"MALWITZ N ET AL: ""AMINE CATALYSIS OF POLYURETHANE FOAMS"", JOURNAL OF CELLULAR PLASTICS, vol. 23, September 1987 (1987-09-01), pages 461 - 502, XP000615923;;N. MALWITZ ET AL., J. CELL. PLASTICS, vol. 23, 1987, pages 461 - 502",DISCONTINUED
26,US,A,US 5633293 A,072-885-073-111-055,1997-05-27,1997,US 56551895 A,1995-11-30,US 56551895 A,1995-11-30,Hydroxy-functional triamine catalyst compositions for polyurethane production,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition consisting essentially of 0-50 mole % compound I and 50-100 mole % compound II: ##STR1## wherein R is hydrogen, a C.sub.1 -C.sub.4 alkly, C.sub.6 -C.sub.8 aryl, or C.sub.7 -C.sub.9 aralkyl group; and n is 2 to 8.",AIR PROD & CHEM,VAN COURT CARR RICHARD;;LISTEMANN MARK L;;SAVOCA ANN C L,AIR PRODUCTS AND CHEMICALS INC (1995-11-28),https://lens.org/072-885-073-111-055,Granted Patent,yes,8,33,10,10,0,C08G18/16;;C08G18/1825;;C08G18/1825;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08G18/18;;C08G18/24;;C08G101/00,521/118;;521/172;;528/49;;564/503;;502/167,1,1,114-388-153-467-048,10.1177/0021955x8702300505,"N. Malwitz, et al. J. Cell. Plastics, 1987, vol. 23, pp. 461 502.",EXPIRED
27,CN,A,CN 1153184 A,111-753-613-983-208,1997-07-02,1997,CN 96120132 A,1996-09-27,US 53475195 A,1995-09-27,Aminopropylbis(aminoethyl) ether compositions for production of polyurethanes,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;CARR RICHARD VAN COURT,,https://lens.org/111-753-613-983-208,Patent Application,no,0,2,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,EXPIRED
28,BR,A,BR 9605705 A,079-414-386-609-19X,1998-08-18,1998,BR 9605705 A,1996-11-25,US 56551895 A,1995-11-30,Composiçoes de catalisador de triamina hidróxi-funcional para a produçao de poliuretano,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;LISTEMANN MARK LEO;;COURT CARR RICHARD VAN,,https://lens.org/079-414-386-609-19X,Patent Application,no,0,0,10,10,0,C08G18/16;;C08G18/1825;;C08G18/1825;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08G18/18;;C08G18/24;;C08G101/00,,0,0,,,,DISCONTINUED
29,CN,C,CN 1063457 C,022-052-456-325-675,2001-03-21,2001,CN 96119292 A,1996-11-30,US 56551895 A,1995-11-30,Hydroxy-functional triamine catalyst compositions for polyurethane production,,AIR PROD & CHEM,CARR RICHARD VAN COURT;;LISTEMANN MARK LEO;;SAVOCA ANN COATES LEACHER,,https://lens.org/022-052-456-325-675,Granted Patent,no,9,0,10,10,0,C08G18/16;;C08G18/1825;;C08G18/1825;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08G18/18;;C08G18/24;;C08G101/00,,1,0,,,"JOURNAL OF CELLULAR PLASTICS,23卷,1987年9月 1987.9.1 N.malwitz,'amine catalysis lf polyurethane foams'",EXPIRED
30,US,A1,US 2021/0232805 A1,119-059-510-280-973,2021-07-29,2021,US 202017118812 A,2020-12-11,US 202017118812 A;;US 202062965408 P,2020-01-24,SYSTEM FOR MANAGING EXPLORATION AND CONSUMPTION OF DIGITAL CONTENT IN CONNECTION WITH A PHYSICAL ARTICLE,"The invention generally relates to managing and sharing digital content, and, more particularly, to a web- or cloud-based platform providing for the contribution, management, and subsequent exploration and consumption of digital content in connection with printed content provided in a physical article, such as a yearbook or other memorabilia.",JOSTENS INC,CARR ANN MERZ;;WOLF MICHAEL;;STUART-KING CHARLES;;BUERK GAVIN;;BRUNO ZACHARY,JOSTENS INC (2021-01-04),https://lens.org/119-059-510-280-973,Patent Application,yes,13,0,3,3,0,G06Q10/107;;G06N20/00;;G06V40/172;;G06F16/535;;G06Q10/107;;G06F16/538;;G06N20/00;;G06F16/51;;G06V40/171;;G06V40/161,G06K9/00;;G06F16/51;;G06F16/535;;G06F16/538;;G06N20/00;;G06Q10/10,,0,0,,,,PENDING
31,US,A1,US 2015/0002608 A1,194-013-101-982-399,2015-01-01,2015,US 201313930233 A,2013-06-28,US 201313930233 A,2013-06-28,VIDEOCAST SERVICE ARCHITECTURE,"A videocast service may include at least one computing device configured to provide operations including: receiving an indication, from a videocast subscriber device connected to a communications network of network service provider, to begin providing a videocast from the videocast subscriber device according to selection of a videocast control from a user interface of the videocast subscriber device; validating the subscriber device as having opted into use of the videocast service by way of the network service provider; and if the subscriber device is opted in, initiating the videocast without requiring further user interface interaction from the videocast subscriber device.",CELLCO PARTNERSHIP DBA VERIZON,MCLAUGHLIN ANN V;;VITOLO JR THEODORE C;;FISH WILLIAM ANDREW;;CARR THOMAS MICHAEL,CELLCO PARTNERSHIP D/B/A VERIZON WIRELESS (2013-06-27),https://lens.org/194-013-101-982-399,Patent Application,yes,20,2,2,2,0,H04N7/147;;H04N7/147;;H04N7/181;;H04N7/181;;H04N21/2187;;H04N21/2187,H04N7/14,348/14.03,0,0,,,,ACTIVE
32,US,B2,US 10533990 B2,014-005-185-044-342,2020-01-14,2020,US 201715710537 A,2017-09-20,US 201715710537 A;;US 201615042087 A;;US 201562117393 P,2015-02-17,Physiologic insulin-sensitivity improvement,"An individualized intravenous exogenous insulin-based therapy for infusing insulin intravenously to a subject or a patient to improve impaired hepatic glucose processing. The therapy includes treatment sessions involving the assessment of metabolic factors, forming a subject profile, and matching the subject profile to a diabetic treatment model. Using the diabetic treatment model, a quantity and frequency of intravenous insulin bolus, dosage amounts of magnesium, and dosage amounts of potassium can be calculated. The methods that improve impaired hepatic glucose processing in subjects and patients can simultaneously introduce separated insulin bolus from an insulin reservoir, dosage amounts of magnesium, and dosage amounts of potassium. The subject profile can create a weight management protocol that uses a metabolic enhancement, wherein the individualized intravenous exogenous insulin-based therapy produces a subject or a patient with improved cellular ATP functioning.",DIABETES RELIEF LLC,CARR HUNTER MICHAEL ALAN;;HEPFORD SCOTT;;WILSON CAROL ANN;;LEWIS JR STANLEY TORIES,DIABETES RELIEF LLC (2022-10-14);;WELL CELL GLOBAL LLC (2020-07-24),https://lens.org/014-005-185-044-342,Granted Patent,yes,1,0,2,3,0,G01N33/60;;G01N33/5091;;G01N33/48792;;G01N33/5038;;G01N2800/042;;G16H50/50;;G16H20/17;;G16H30/40;;G01N33/5091;;G01N33/48792;;G01N33/5038;;G01N2800/042;;G01N2800/70;;G16H20/17;;G01N33/60;;G16H30/40;;G16H50/50;;G16H70/00,G01N33/50;;G01N33/487;;G01N33/60;;G16H20/17;;G16H30/40;;G16H50/50,,0,0,,,,ACTIVE
33,US,B2,US 9071726 B2,169-927-717-888-629,2015-06-30,2015,US 201313930233 A,2013-06-28,US 201313930233 A,2013-06-28,Videocast service architecture,"A videocast service may include at least one computing device configured to provide operations including: receiving an indication, from a videocast subscriber device connected to a communications network of network service provider, to begin providing a videocast from the videocast subscriber device according to selection of a videocast control from a user interface of the videocast subscriber device; validating the subscriber device as having opted into use of the videocast service by way of the network service provider; and if the subscriber device is opted in, initiating the videocast without requiring further user interface interaction from the videocast subscriber device.",CELLCO PARTNERSHIP DBA VERIZON,MCLAUGHLIN ANN V;;VITOLO JR THEODORE C;;FISH WILLIAM ANDREW;;CARR THOMAS MICHAEL,CELLCO PARTNERSHIP D/B/A VERIZON WIRELESS (2013-06-27),https://lens.org/169-927-717-888-629,Granted Patent,yes,21,0,2,2,0,H04N7/147;;H04N7/147;;H04N7/181;;H04N7/181;;H04N21/2187;;H04N21/2187,H04N7/14;;H04N7/18;;H04N21/2187,,0,0,,,,ACTIVE
34,CN,A,CN 116194155 A,198-203-818-170-34X,2023-05-30,2023,CN 202180057456 A,2021-06-04,EP 20178179 A;;EP 2021065056 W,2020-06-04,Urea-based ligands targeting PSMA for prostate cancer radiotherapy and imaging,"The present invention provides novel urea-based ligands targeting PSMA, which bind to prostate specific membrane antigen (PSMA), which are 8 to 12 fold higher expression in prostate cancer cells when compared to healthy tissue. The urea-based ligands targeting PSMA comprise a chelating agent, which may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the urea-based ligands targeting PSMA of the invention, to precursors of urea-based ligands targeting PSMA and to the use of urea-based ligands targeting PSMA in radiation therapy, imaging and therapeutic diagnostics.",UNIV COPENHAGEN;;UNIV DENMARK TECH DTU;;DEUTSCHES KREBSFORSCHUNGSZENTRUM F 1R CANCER RECHTS;;UNIV FREIBURG ALBERT LUDWIGS,CARR ANDREW;;HERTY MELISSA M;;JENSEN ALLAN I;;M ADEL;;ADEL ANN-CAROLINE,,https://lens.org/198-203-818-170-34X,Patent Application,no,0,1,7,7,0,A61K51/0497;;A61K51/0402;;A61K51/0402;;A61K51/0406;;A61K51/044;;A61K2123/00,A61K51/04,,0,0,,,,PENDING
35,US,A1,US 2019/0086394 A1,053-745-232-647-356,2019-03-21,2019,US 201715710537 A,2017-09-20,US 201715710537 A;;US 201615042087 A;;US 201562117393 P,2015-02-17,METHOD OF METABOLIC RESTORATION,"An individualized intravenous exogenous insulin-based therapy for infusing insulin intravenously to a subject or a patient to improve impaired hepatic glucose processing. The therapy includes treatment sessions involving the assessment of metabolic factors, forming a subject profile, and matching the subject profile to a diabetic treatment model. Using the diabetic treatment model, a quantity and frequency of intravenous insulin bolus, dosage amounts of magnesium, and dosage amounts of potassium can be calculated. The methods that improve impaired hepatic glucose processing in subjects and patients can simultaneously introduce separated insulin bolus from an insulin reservoir, dosage amounts of magnesium, and dosage amounts of potassium. The subject profile can create a weight management protocol that uses a metabolic enhancement, wherein the individualized intravenous exogenous insulin-based therapy produces a subject or a patient with improved cellular ATP functioning.",DIABETES RELIEF LLC,CARR HUNTER MICHAEL ALAN;;HEPFORD SCOTT;;WILSON CAROL ANN;;LEWIS JR STANLEY TORIES,,https://lens.org/053-745-232-647-356,Patent Application,yes,0,0,2,3,0,G01N33/60;;G01N33/5091;;G01N33/48792;;G01N33/5038;;G01N2800/042;;G16H50/50;;G16H20/17;;G16H30/40;;G01N33/5091;;G01N33/48792;;G01N33/5038;;G01N2800/042;;G01N2800/70;;G16H20/17;;G01N33/60;;G16H30/40;;G16H50/50;;G16H70/00,G01N33/50;;G01N33/487,,0,0,,,,ACTIVE
36,EP,A3,EP 2347963 A3,184-588-130-538-689,2011-10-19,2011,EP 11165159 A,2004-02-04,EP 04708224 A;;US 44508003 P,2003-02-05,Mailer package,"A mailer package (10) formed from a single sheet blank (12) of foldable stock material comprising: a compartment (16) formed by first and second parallel panels(18, 20) spaced from each other and joined together by first and second parallel sides (22, 24) smaller than the first and second panels, the first and second sides extending along opposing edges (19', 21', 23', 25') of each of the first and second panels, the compartment having opposing first and second open ends (28, 30); a number of tabs (32, 40) at each of the first and second open ends sufficient to cover and close each of the first and second open ends, each separate tab extending from a separate one of the first and second panels or one of the first and second parallel sides at the open end; and a cover (14) extending from one of the edges (25', 51') between one of the first and second sides and one of the first and second panels, the cover having a closure flap (56) with a tearable pull tab (58), the cover being foldable about the one edge between a closed position wherein the cover overlies a major portion of one (18) of the first and second panels and one (22) of the first and second parallel sides adjacent to the one edge and an open position folded away from the compartment, the cover being formed from two mutually overlying layers (50, 52) of the stock material, the cover being releasably secured in the closed position by attachment of the closure flap to another (22) of the first and second panels and the first and second sides and the secured cover being releasable to the open position with release of the pull tab.
",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/184-588-130-538-689,Search Report,yes,6,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42;;B65D5/54,,0,0,,,,EXPIRED
37,WO,A3,WO 2009/070648 A3,023-597-500-749-253,2009-12-23,2009,US 2008/0084805 W,2008-11-26,US 99040107 P,2007-11-27,HUMANIZED ANTI-AMYLOID BETA ANTIBODIES,Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.,MEDTRONIC INC;;SHAFER LISA LYNN;;CARR FRANCIS JOSESPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,SHAFER LISA LYNN;;CARR FRANCIS JOSESPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,,https://lens.org/023-597-500-749-253,Search Report,yes,9,0,5,18,0,A61K2039/505;;C07K16/18;;C07K2317/24,C07K16/00,,0,0,,,,PENDING
38,TW,U,TW M255225 U,146-280-004-135-142,2005-01-11,2005,TW 93201567 U,2004-02-04,US 44508003 P,2003-02-05,Mailer package,,MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/146-280-004-135-142,Limited Patent,no,0,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,,0,0,,,,EXPIRED
39,US,B2,US 8614298 B2,184-288-141-520-949,2013-12-24,2013,US 201113052597 A,2011-03-21,US 201113052597 A;;US 32368208 A;;US 12026908 A;;US 99040107 P;;US 91791107 P;;US 98477507 P,2007-05-14,Humanized anti-amyloid beta antibodies,Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.,SHAFER LISA LYNN;;CARR FRANCIS JOSEPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM;;MEDTRONIC INC,SHAFER LISA LYNN;;CARR FRANCIS JOSEPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,,https://lens.org/184-288-141-520-949,Granted Patent,yes,9,0,4,18,133,A61K2039/505;;A61K2039/505;;A61K2039/54;;A61K2039/54;;A61K2039/545;;A61K2039/545;;A61P25/00;;A61P25/28;;C07K16/18;;C07K16/18;;C07K2317/24;;C07K2317/24;;C07K2317/56;;C07K2317/56,C07K16/46;;A61K9/08;;A61K39/395;;A61M5/14;;C07K16/18,530/387.3;;530/388.1;;530/388.25;;530/387.1;;604/891.1;;424/133.1;;424/139.1;;424/141.1,1,0,,,"PCT Search Report and Written Opinion dated Nov. 4, 2009.",ACTIVE
40,US,B2,US 6923316 B2,050-220-897-314-109,2005-08-02,2005,US 99623304 A,2004-11-23,US 99623304 A;;US 42757103 A;;US 44508003 P,2003-02-05,Mailer package,"A mailer package formed from a single sheet of foldable stock material includes a compartment formed by first and second parallel panels joined together by first and second parallel sides. The sides extend along opposing edges of the panels. The compartment has opposing first and second open ends, with a number of tabs sufficient to cover and close each open end. A cover extends from an edge between one of the sides and panels. The cover has a closure flap with a tearable pull tab and is foldable between a closed position overlying a panel or side adjacent to the edge from which it extends, and an open position folded away from the compartment. The cover is releasably secured in the closed position by attachment of the closure flap to another panel or side. The secured cover is moveable to the open position with release of the pull tab.",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,MATTEL INC (2003-04-25),https://lens.org/050-220-897-314-109,Granted Patent,yes,25,10,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,206/232;;206/45.29;;229/240,0,0,,,,EXPIRED
41,EP,A4,EP 1597153 A4,054-222-965-386-45X,2009-03-04,2009,EP 04708224 A,2004-02-04,US 2004/0003255 W;;US 44508003 P,2003-02-05,MAILER PACKAGE,,MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/054-222-965-386-45X,Search Report,no,4,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,,1,0,,,See also references of WO 2004071881A2,EXPIRED
42,EP,B1,EP 2347963 B1,063-753-001-759-951,2013-09-25,2013,EP 11165159 A,2004-02-04,EP 04708224 A;;US 44508003 P,2003-02-05,Mailer package,,MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/063-753-001-759-951,Granted Patent,yes,6,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42;;B65D5/54,,0,0,,,,EXPIRED
43,US,A1,US 2023/0257629 A1,083-388-369-228-65X,2023-08-17,2023,US 202218088361 A,2022-12-23,US 202218088361 A;;US 202263309284 P;;US 202263420958 P,2022-02-11,ROOFING MATERIALS WITH ASPHALT SHINGLE WASTE,"A method comprises obtaining a virgin asphalt and obtaining an asphalt shingle waste. The asphalt shingle waste comprises 5 wt. % to 40 wt. % of asphalt based on the total weight of the asphalt shingle waste. The asphalt shingle waste comprises 60 wt. % to 95 wt. % of limestone, granules, and/or impurities based on the total weight of the asphalt shingle waste. The method comprises obtaining a phase modifier. The method comprises mixing the virgin asphalt, the asphalt shingle waste, and the phase modifier to form an asphalt mixture. The phase modifier is present in an amount of 0.25 wt. % to 25 wt. % based on the total weight of the asphalt mixture. The asphalt mixture is configured to be applied to a roof substrate to obtain a roofing shingle.",BMIC LLC,HAMER ANN;;QIN QIAN;;SHAHA CYNTHIA;;CARR KEVIN;;MERCADO RAMIL;;KRAJCA JAROD;;MEZA AZIEL,BMRC LLC (2024-02-28),https://lens.org/083-388-369-228-65X,Patent Application,yes,2,0,4,4,0,C09D7/65;;C09D7/61;;C09D195/00;;C08L95/00;;C09D195/00;;C09D7/65;;C09D7/61;;C08L95/00;;C08L2205/025,C09D7/61;;C09D195/00;;C09D7/65,,0,0,,,,ACTIVE
44,US,A1,US 2011/0177076 A1,109-588-861-291-237,2011-07-21,2011,US 201113052597 A,2011-03-21,US 201113052597 A;;US 32368208 A;;US 12026908 A;;US 99040107 P;;US 91791107 P;;US 98477507 P,2007-05-14,HUMANIZED ANTI-AMYLOID BETA ANTIBODIES,Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.,MEDTRONIC INC,SHAFER LISA LYNN;;CARR FRANCIS JOSEPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,,https://lens.org/109-588-861-291-237,Patent Application,yes,0,0,4,18,133,A61K2039/505;;A61K2039/505;;A61K2039/54;;A61K2039/54;;A61K2039/545;;A61K2039/545;;A61P25/00;;A61P25/28;;C07K16/18;;C07K16/18;;C07K2317/24;;C07K2317/24;;C07K2317/56;;C07K2317/56,A61M5/14;;A61K39/395;;A61P25/00;;A61P25/28;;C07H21/04;;C07K16/18;;C12N5/07;;C12N15/63,424/137.1;;435/329;;435/320.1;;530/387.5;;536/23.53;;604/93.01;;604/500,0,0,,,,ACTIVE
45,US,B2,US 10990515 B2,174-257-894-983-505,2021-04-27,2021,US 201916700261 A,2019-12-02,US 201916700261 A;;US 201815913159 A;;US 201862623760 P,2018-01-30,Automated unit testing in a mainframe environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP;;BMC SOFTWARE INC,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/174-257-894-983-505,Granted Patent,yes,6,1,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F9/44;;B32B25/04;;C08K3/38;;F16F1/36;;G06F11/36;;G06F16/188;;G06F16/25;;G06F40/205,,0,0,,,,ACTIVE
46,US,A1,US 2023/0257584 A1,169-754-978-410-049,2023-08-17,2023,US 202218088386 A,2022-12-23,US 202218088386 A;;US 202263309284 P;;US 202263420958 P,2022-02-11,METHODS OF FORMING ROOFING MATERIALS WITH ASPHALT SHINGLE WASTE,"A method comprises obtaining a virgin asphalt and obtaining an asphalt shingle waste. The asphalt shingle waste comprises 5 wt. % to 40 wt. % of asphalt based on the total weight of the asphalt shingle waste. The asphalt shingle waste comprises 60 wt. % to 95 wt. % of limestone, granules, and/or impurities based on the total weight of the asphalt shingle waste. The method comprises obtaining a phase modifier. The method comprises mixing the virgin asphalt, the asphalt shingle waste, and the phase modifier to form an asphalt mixture. The phase modifier is present in an amount of 0.25 wt. % to 25 wt. % based on the total weight of the asphalt mixture. The asphalt mixture is configured to be applied to a roof substrate to obtain a roofing shingle.",BMIC LLC,HAMER ANN;;QIN QIAN;;SHAHA CYNTHIA;;CARR KEVIN;;MERCADO RAMIL;;KRAJCA JAROD;;MEZA AZIEL,BMRC LLC (2024-02-28),https://lens.org/169-754-978-410-049,Patent Application,yes,1,0,4,4,0,C09D7/65;;C09D7/61;;C09D195/00;;C08L95/00;;C09D195/00;;C09D7/65;;C09D7/61;;C08L95/00;;C08L2205/025,C08L95/00,,0,0,,,,PENDING
47,US,B2,US 7931899 B2,043-930-891-614-138,2011-04-26,2011,US 32368208 A,2008-11-26,US 32368208 A;;US 12026908 A;;US 99040107 P;;US 91791107 P;;US 98477507 P,2007-05-14,Humanized anti-amyloid beta antibodies,Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.,MEDTRONIC INC,SHAFER LISA LYNN;;CARR FRANCIS JOSEPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,MEDTRONIC INC (2008-11-25),https://lens.org/043-930-891-614-138,Granted Patent,yes,9,4,4,18,133,A61K2039/505;;A61K2039/505;;A61K2039/54;;A61K2039/54;;A61K2039/545;;A61K2039/545;;A61P25/00;;A61P25/28;;C07K16/18;;C07K16/18;;C07K2317/24;;C07K2317/24;;C07K2317/56;;C07K2317/56,A61K39/395;;C12P21/08,424/133.1;;424/139.1;;424/141.1;;424/152.1;;530/387.3;;530/388.1,1,0,,,"PCT Search Report and Written Opinion dated Nov. 4, 2009.",INACTIVE
48,US,B2,US 11802219 B2,141-064-282-556-731,2023-10-31,2023,US 202218088361 A,2022-12-23,US 202218088361 A;;US 202263309284 P;;US 202263420958 P,2022-02-11,Roofing materials with asphalt shingle waste,"A method comprises obtaining a virgin asphalt and obtaining an asphalt shingle waste. The asphalt shingle waste comprises 5 wt. % to 40 wt. % of asphalt based on the total weight of the asphalt shingle waste. The asphalt shingle waste comprises 60 wt. % to 95 wt. % of limestone, granules, and/or impurities based on the total weight of the asphalt shingle waste. The method comprises obtaining a phase modifier. The method comprises mixing the virgin asphalt, the asphalt shingle waste, and the phase modifier to form an asphalt mixture. The phase modifier is present in an amount of 0.25 wt. % to 25 wt. % based on the total weight of the asphalt mixture. The asphalt mixture is configured to be applied to a roof substrate to obtain a roofing shingle.",BMIC LLC,HAMER ANN;;QIN QIAN;;SHAHA CYNTHIA;;CARR KEVIN;;MERCADO RAMIL;;KRAJCA JAROD;;MEZA AZIEL,BMRC LLC (2024-02-28),https://lens.org/141-064-282-556-731,Granted Patent,yes,88,0,4,4,0,C09D7/65;;C09D7/61;;C09D195/00;;C08L95/00;;C09D195/00;;C09D7/65;;C09D7/61;;C08L95/00;;C08L2205/025,C09D195/00;;C08L95/00;;C09D7/61;;C09D7/65,,2,1,098-318-956-339-558,10.1021/ef100822f,"Pauli, Adam T., Asphalt Compatibility Testing Using the Automated Heithaus Titration Test, Western Research nstitute, 1996.;;Schabron, John F., et al., Asphaltene Determinator Method for Automated On-col. Precipitation and Redissolution of Pericondensed Aromatic Asphaltene Components, Energy and Fuels, 2010, 24, 5984-5996.",ACTIVE
49,US,A1,US 2020/0104249 A1,107-649-477-579-918,2020-04-02,2020,US 201916700261 A,2019-12-02,US 201916700261 A;;US 201815913159 A;;US 201862623760 P,2018-01-30,Automated Unit Testing In A Mainframe Environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/107-649-477-579-918,Patent Application,yes,0,0,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F11/36;;G06F16/188;;G06F16/25,,0,0,,,,ACTIVE
50,BR,A,BR 9500675 A,010-453-437-023-972,1995-10-31,1995,BR 9500675 A,1995-02-17,US 19939694 A,1994-02-22,Processo para catalisar a reação de um poliisocianato consigo mesmo ou com um composto contendo hidrogênio ativo processo para preparação de espuma de poliuretano e composição de catalisador,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;WRESSELL AMY LYNNE;;LISTEMANN MARK LEO;;COURT CARR RICHARD VAN,,https://lens.org/010-453-437-023-972,Patent Application,no,0,0,13,13,0,C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02;;C08G18/20;;C08J9/04;;C08G18/00;;C08G18/18;;C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02,C08G18/18;;C08G18/20,,0,0,,,,EXPIRED
51,EP,A2,EP 2347963 A2,023-485-579-501-077,2011-07-27,2011,EP 11165159 A,2004-02-04,EP 04708224 A;;US 44508003 P,2003-02-05,Mailer package,"A mailer package (10) formed from a single sheet blank (12) of foldable stock material comprising: a compartment (16) formed by first and second parallel panels(18, 20) spaced from each other and joined together by first and second parallel sides (22, 24) smaller than the first and second panels, the first and second sides extending along opposing edges (19', 21', 23', 25') of each of the first and second panels, the compartment having opposing first and second open ends (28, 30); a number of tabs (32, 40) at each of the first and second open ends sufficient to cover and close each of the first and second open ends, each separate tab extending from a separate one of the first and second panels or one of the first and second parallel sides at the open end; and a cover (14) extending from one of the edges (25', 51') between one of the first and second sides and one of the first and second panels, the cover having a closure flap (56) with a tearable pull tab (58), the cover being foldable about the one edge between a closed position wherein the cover overlies a major portion of one (18) of the first and second panels and one (22) of the first and second parallel sides adjacent to the one edge and an open position folded away from the compartment, the cover being formed from two mutually overlying layers (50, 52) of the stock material, the cover being releasably secured in the closed position by attachment of the closure flap to another (22) of the first and second panels and the first and second sides and the secured cover being releasable to the open position with release of the pull tab.
",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/023-485-579-501-077,Patent Application,yes,1,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42;;B65D5/54,,0,0,,,,EXPIRED
52,CA,C,CA 2515050 C,055-689-322-890-527,2011-06-28,2011,CA 2515050 A,2004-02-04,US 44508003 P;;US 2004/0003255 W,2003-02-05,MAILER PACKAGE,"A mailer package (110) formed from a single sheet blank (112) of foldable stock material includes at least one panel (Kuchenbecker) having first and second sides (118', 120'). A closure flap (156) with a tearable pull tab (158) extends from a first edge (119') of the one panel. A compartment flap (122) extends from a second edge (121') and includes an attachment tab (126). The compartment flap forms a compartment (116) having four sequentially adjoining sides (132, 134, 136, Kuchenbecker), formed by folds (121, 127, 129, 131). The compartment has first and second open ends (128, 130), closed by tabs (140, 146, 148) and a cover (114) extending from a third edge (123') of the one panel.",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/055-689-322-890-527,Granted Patent,no,0,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D69/00;;B65D5/42,,0,0,,,,EXPIRED
53,CA,A1,CA 2737433 A1,070-400-603-486-073,2004-08-26,2004,CA 2737433 A,2004-02-04,US 44508003 P;;CA 2515050 A,2003-02-05,MAILER PACKAGE,,MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/070-400-603-486-073,Patent Application,no,0,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/20;;B65D5/42;;B65D69/00,,0,0,,,,EXPIRED
54,EP,A2,EP 1597153 A2,100-297-258-794-06X,2005-11-23,2005,EP 04708224 A,2004-02-04,US 2004/0003255 W;;US 44508003 P,2003-02-05,MAILER PACKAGE,,MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/100-297-258-794-06X,Patent Application,yes,0,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42;;B65D5/54,,0,0,,,,EXPIRED
55,US,A1,US 2004/0149601 A1,174-847-757-703-191,2004-08-05,2004,US 42757103 A,2003-05-01,US 42757103 A;;US 44508003 P,2003-02-05,Mailer Package,"
   A mailer package formed from a single sheet of foldable stock material includes a compartment formed by first and second parallel panels joined together by first and second parallel sides. The sides extend along opposing edges of the panels. The compartment has opposing first and second open ends, with a number of tabs sufficient to cover and close each open end. A cover extends from an edge between one of the sides and panels. The cover has a closure flap with a tearable pull tab and is foldable between a closed position overlying a panel or side adjacent to the edge from which it extends, and an open position folded away from the compartment. The cover is releasably secured in the closed position by attachment of the closure flap to another panel or side. The secured cover is moveable to the open position with release of the pull tab. 
",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,MATTEL INC (2003-04-25),https://lens.org/174-847-757-703-191,Patent Application,yes,17,6,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,206/232;;206/776,0,0,,,,EXPIRED
56,US,B1,US 7693087 B1,109-312-507-399-66X,2010-04-06,2010,US 67484807 A,2007-02-14,US 67484807 A,2007-02-14,Selection and optimization of potential hub candidates within a network,"A method, system, and medium are provided for selecting one or more hub aggregation points from a number of candidates on a network. The method begins by obtaining selection criteria for each of the candidates. Using the obtained criteria a score for each candidate is determined. This determination involves assigning intermediate scores for each criteria and applying a weighted multiplier to the intermediate score. The total of the intermediate scores is the overall score for any candidate. The method continues by selecting potential hub aggregation points for further consideration based upon the determined score of each candidate. The method then calculates a least cost route for each point on the network under consideration to each of the selected hub aggregation points. Different combinations of selected hub aggregation points can then be used to iterate through the least cost routing analysis to arrive at a final selection of hub aggregation points.",SPRINT COMMUNICATIONS CO,CARR MARIANNE;;PRICE SARAH E;;SPAIN DEREK M;;STRECKER MARY ANN;;LAI SHUN CALVIN,SPRINT COMMUNICATIONS COMPANY L.P (2007-02-13),https://lens.org/109-312-507-399-66X,Granted Patent,yes,3,2,1,1,0,H04L41/12;;H04L41/145;;H04L41/12;;H04L41/145,H04L12/26,370/252;;370/229;;370/230;;370/235,0,0,,,,INACTIVE
57,WO,A2,WO 2009/070648 A2,032-857-273-590-872,2009-06-04,2009,US 2008/0084805 W,2008-11-26,US 99040107 P,2007-11-27,HUMANIZED ANTI-AMYLOID BETA ANTIBODIES,Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.,MEDTRONIC INC;;SHAFER LISA LYNN;;CARR FRANCIS JOSESPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,SHAFER LISA LYNN;;CARR FRANCIS JOSESPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,,https://lens.org/032-857-273-590-872,Patent Application,yes,0,3,5,18,133,A61K2039/505;;C07K16/18;;C07K2317/24,C07K16/00,,0,0,,,,PENDING
58,US,B2,US 6868964 B2,135-574-727-302-762,2005-03-22,2005,US 42757103 A,2003-05-01,US 42757103 A;;US 44508003 P,2003-02-05,Mailer package,"A mailer package formed from a single sheet of foldable stock material includes a compartment formed by first and second parallel panels joined together by first and second parallel sides. The sides extend along opposing edges of the panels. The compartment has opposing first and second open ends, with a number of tabs sufficient to cover and close each open end. A cover extends from an edge between one of the sides and panels. The cover has a closure flap with a tearable pull tab and is foldable between a closed position overlying a panel or side adjacent to the edge from which it extends, and an open position folded away from the compartment. The cover is releasably secured in the closed position by attachment of the closure flap to another panel or side. The secured cover is moveable to the open position with release of the pull tab.",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,MATTEL INC (2003-04-25),https://lens.org/135-574-727-302-762,Granted Patent,yes,17,20,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,206/232;;206/45.29;;229/240,0,0,,,,EXPIRED
59,EP,A1,EP 0816408 A1,021-026-356-651-11X,1998-01-07,1998,EP 97111044 A,1997-07-02,US 67512796 A,1996-07-03,Hydroxyalkylbis(aminoethyl)ether compositions for the production of polyurethanes,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition comprising a compound having the following formula I:
  
 where R 1  is hydrogen or a linear or branched C1-C4 alkyl or a C1-C4 hydroxyalkyl group; 
R 2  and R 3  independently are hydrogen, hydroxy, a linear or branched C1-C4 alkyl or a linear or branched C1-C4 hydroxyalkyl group; and 
R 4  is a linear or branched C1-C10 hydroxyalkyl group.",AIR PROD & CHEM,LESCHER SAVOCA ANN COATES;;VAN COURT CARR RICHARD;;UNDERWOOD RICHARD PAUL;;EMERICK JAMES STEPHEN,,https://lens.org/021-026-356-651-11X,Patent Application,yes,1,10,6,6,0,C08G18/18;;C08G18/1833;;C08G18/1833;;C07C217/08;;C07C217/08;;C07C217/08;;C08G18/1825;;C08G18/1825;;C08G18/1825;;C08G18/1833;;C08G18/242;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08J9/04;;C07C217/08;;C08G18/18;;C08G101/00,,1,0,,,"S. WONG ET AL.: ""Studies of Catalysed Isocyanate Reactions by High Performance Liquid Chromatography"", PROG. RUBBER PLAST. TECHNOL., vol. 7, no. 3, 1991, pages 243 - 270, XP002041873",DISCONTINUED
60,MX,A,MX 9705017 A,088-195-694-857-143,1998-01-31,1998,MX 9705017 A,1997-07-02,MX 9705017 A,1997-07-02,HYDROXYALKYLBIS(AMINOETHYL)ETHER COMPOSITIONS FOR THE PRODUCTION OF POLYURETHANES.,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition comprising a compound having the following formula I:(see formula)Where R1 is hydrogen or a linear or branched C1,C4 alkyl or a C1-C4 hydroxyalkyl group; R2 and R3 independently are hydrogen hydroxy, a linear or branched C1-C4 alkyl or a linear or branched C1-C4 hydroxyalkyl group; and R4 is a linear or branched C1-C10 hydroxyalkyl group.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;CARR RICHARD VAN COURT;;EMERICK JAMES STEPHEN,,https://lens.org/088-195-694-857-143,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
61,US,A1,US 2009/0175923 A1,188-905-683-187-227,2009-07-09,2009,US 32368208 A,2008-11-26,US 32368208 A;;US 12026908 A;;US 99040107 P;;US 91791107 P;;US 98477507 P,2007-05-14,HUMANIZED ANTI-AMYLOID BETA ANTIBODIES,Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.,MEDTRONIC INC,SHAFER LISA LYNN;;CARR FRANCIS JOSEPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,MEDTRONIC INC (2008-11-25),https://lens.org/188-905-683-187-227,Patent Application,yes,0,2,4,18,133,A61K2039/505;;A61K2039/505;;A61K2039/54;;A61K2039/54;;A61K2039/545;;A61K2039/545;;A61P25/00;;A61P25/28;;C07K16/18;;C07K16/18;;C07K2317/24;;C07K2317/24;;C07K2317/56;;C07K2317/56,A61F2/00;;A61K39/395;;C07H21/04;;C07K16/00;;C12N5/10;;C12N15/63,424/423;;530/388.1;;424/130.1;;536/23.53;;435/320.1;;435/325,0,0,,,,INACTIVE
62,US,A,US 5756558 A,037-154-498-957-621,1998-05-26,1998,US 67512796 A,1996-07-03,US 67512796 A,1996-07-03,Hydroxyalkylbis(aminoethyl) ether compositions for the production of polyurethanes,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition comprising a compound having the following formula I: ##STR1## where R.sup.1 is hydrogen or a linear or branched C1-C4 alkyl or a C1-C4 hydroxyalkyl group; R.sup.2 and R.sup.3 independently are hydrogen, hydroxy, a linear or branched C1-C4 alkyl or a linear or branched C1-C4 hydroxyalkyl group; and R.sup.4 is a linear or branched C1-C10 hydroxyalkyl group.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;CARR RICHARD VAN COURT;;EMERICK JAMES STEPHEN,AIR PRODUCTS AND CHEMICALS INC (1996-07-02),https://lens.org/037-154-498-957-621,Granted Patent,yes,4,16,6,6,0,C08G18/18;;C08G18/1833;;C08G18/1833;;C07C217/08;;C07C217/08;;C07C217/08;;C08G18/1825;;C08G18/1825;;C08G18/1825;;C08G18/1833;;C08G18/242;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08J9/04;;C07C217/08;;C08G18/18;;C08G101/00,521/167;;528/49;;528/53;;528/85;;521/115;;564/471;;564/473;;564/507;;564/508,1,1,114-388-153-467-048,10.1177/0021955x8702300505,"N. Malwitz, et al. Amine Catalysts of Polyurethane Foam , Journal of Cellular Plastics, 23, pp. 461 502, 1987.",EXPIRED
63,EP,A2,EP 2586797 A2,132-422-087-607-979,2013-05-01,2013,EP 13152910 A,2008-11-26,US 99040107 P;;EP 08854674 A,2007-11-27,Humanized anti-amyloid beta antibodies,"Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.
",MEDTRONIC INC,SHAFER LISA LYNN;;CARR FRANCIS JOSEPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,,https://lens.org/132-422-087-607-979,Patent Application,yes,28,0,5,18,119,A61K2039/505;;C07K16/18;;C07K2317/24,C07K16/18,,27,14,021-485-212-364-595;;110-088-048-889-302;;009-471-901-851-880;;065-815-544-501-870;;026-446-005-256-030;;056-587-465-802-757;;008-587-496-850-953;;051-940-176-386-905;;014-978-026-283-267;;047-294-079-836-486;;040-499-003-503-647;;040-134-246-256-474;;019-355-142-013-345;;046-160-628-416-100,10.1093/protein/8.10.1057;;8771187;;10.1007/978-3-642-78432-3_11;;pmc47248;;10.1073/pnas.90.16.7889;;8356098;;10.1128/jb.130.2.946-947.1977;;400800;;pmc235301;;10.1016/0076-6879(90)85043-n;;2381329;;3194019;;10.1038/336348a0;;886304;;10.1099/0022-1317-36-1-59;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;386136;;10.1038/281544a0;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;10.1152/ajpheart.01090.2001;;12234795;;10.1385/0896031780;;15450132;;10.1089/1079990041992686;;10.1089/jir.2004.24.560;;15869596;;10.1111/j.1538-7836.2005.01309.x,"ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062;;PLUCKTHUN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;MARASCO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7889 - 7893;;M. BUTLER,: ""Mammalian Cell Biotechnology: a Practical Anproach"", 1991, IRL PRESS;;""Molecular Cloning, A Laboratory Manual"", vol. 1-3, 2001, COLD SPRING HARBOR LABORATORY PRESS;;SAMBROOK AND RUSSCL: ""Molecular Cloning, A Laboratory Manual."", vol. 1-3, 2001, COLD SPRING HARBOR LABORATORY PRESS;;GRAHAM; VAN DER EB, VIROLOGY, vol. 52, 1978, pages 456 - 457;;VAN SOLINGCN ET AL., J. BACT., vol. 130, 1977, pages 946;;HSIAO ET AL., PROC. NATL. ACAD. SCI. (USA, vol. 76, 1979, pages 3829;;KEOWN ET AL., METHODS IN ENZYMOLOGY, vol. 185, 1990, pages 527 - 537;;MANSOUR ET AL., NATURE, vol. 336, 1988, pages 348 - 352;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;MATHER, BIOL. RCPROD, vol. 23, 1980, pages 243 - 251;;CHANG ET AL., NATURE, vol. 275, 1978, pages 615;;GOEDDEL ET AL., NATURE, vol. 281, 1979, pages 544;;GOEDDEL, NUCLEIC ACIDS RES., vol. 8, 1980, pages 4057;;DCBOER, PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 21 - 25;;LAPOINTE ET AL.: ""Left Ventricular Targeting of Reporter Gene Expression In Vivo by Human BNP Promoter in an Adenoviral Vector"", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 283, 2002, pages H1439 - 45;;KMEIC: ""Gene Targeting Protocols 2ed.,"", 2002, pages: 1 - 35;;MURRAY: ""Gene Transfer and Expression Protocols"", vol. 7, 1991, pages: 81 - 89;;""Remington's Pharmaceutical Science (15th ed.,"", 1980, MACK PUBLISHING COMPANY;;""Remington's Pharmaceutical Sciences, 14th Ed."", MACK PUBLISHING CO, article ""Chapter 43,"";;AUSUBEL,: ""Current Protocols in Molecular Biology"", JOHN WILEY AND SONS;;JONES ET AL., J INTERFERON CYTOKINE RES., vol. 24, no. 9, 2004, pages 560 - 72;;JONES ET AL., J THROMB HAEMOST., vol. 3, no. 5, 2005, pages 991 - 1000;;BAKER; JONES, CURR. OPIN. DRUG. DISC. DEV., vol. 10, 2007, pages 219 - 217",DISCONTINUED
64,WO,A3,WO 2004/071881 A3,002-104-646-374-95X,2004-12-29,2004,US 2004/0003255 W,2004-02-04,US 44508003 P,2003-02-05,MAILER PACKAGE,"A mailer package (110) formed from a single sheet blank (112) of foldable stock material includes at least one panel (Kuchenbecker) having first and second sides (118&apos;, 120&apos;). A closure flap (156) with a tearable pull tab (158) extends from a first edge (119&apos;) of the one panel. A compartment flap (122) extends from a second edge (121&apos;) and includes an attachment tab (126). The compartment flap forms a compartment (116) having four sequentially adjoining sides (132, 134, 136, Kuchenbecker), formed by folds (121, 127, 129, 131). The compartment has first and second open ends (128, 130), closed by tabs (140, 146, 148) and a cover (114) extending from a third edge (123&apos;) of the one panel.",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/002-104-646-374-95X,Search Report,yes,5,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,,0,0,,,,PENDING
65,US,B2,US 10528457 B2,192-554-239-749-222,2020-01-07,2020,US 201815913159 A,2018-03-06,US 201815913159 A;;US 201862623760 P,2018-01-30,Automated unit testing in a mainframe environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/192-554-239-749-222,Granted Patent,yes,5,2,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F9/44;;G06F11/36;;G06F16/188;;G06F16/25,,0,0,,,,ACTIVE
66,WO,A2,WO 2004/071881 A2,040-025-394-123-830,2004-08-26,2004,US 2004/0003255 W,2004-02-04,US 44508003 P,2003-02-05,MAILER PACKAGE,"A mailer package (110) formed from a single sheet blank (112) of foldable stock material includes at least one panel (Kuchenbecker) having first and second sides (118&apos;, 120&apos;). A closure flap (156) with a tearable pull tab (158) extends from a first edge (119&apos;) of the one panel. A compartment flap (122) extends from a second edge (121&apos;) and includes an attachment tab (126). The compartment flap forms a compartment (116) having four sequentially adjoining sides (132, 134, 136, Kuchenbecker), formed by folds (121, 127, 129, 131). The compartment has first and second open ends (128, 130), closed by tabs (140, 146, 148) and a cover (114) extending from a third edge (123&apos;) of the one panel.",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/040-025-394-123-830,Patent Application,yes,1,1,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,,0,0,,,,PENDING
67,EP,B1,EP 1597153 B1,044-710-425-638-898,2015-04-08,2015,EP 04708224 A,2004-02-04,US 2004/0003255 W;;US 44508003 P,2003-02-05,MAILER PACKAGE,,MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/044-710-425-638-898,Granted Patent,yes,9,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42;;B65D5/54,,0,0,,,,EXPIRED
68,CA,A1,CA 2515050 A1,163-647-970-708-850,2004-08-26,2004,CA 2515050 A,2004-02-04,US 44508003 P;;US 2004/0003255 W,2003-02-05,MAILER PACKAGE,,MATTEL INC,OSNATO JEFFREY S;;WEINTRAUB RICHARD;;CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;CARR LINDA ANN,,https://lens.org/163-647-970-708-850,Patent Application,no,0,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/42,,0,0,,,,EXPIRED
69,CA,C,CA 2737433 C,009-119-260-040-443,2013-04-16,2013,CA 2737433 A,2004-02-04,US 44508003 P;;CA 2515050 A,2003-02-05,MAILER PACKAGE,"A mailer package (110) formed from a single sheet blank (112) of foldable stock material includes at least one panel (111) having first and second sides (118',120'). A closure flap (156) with a tearable pull tab (158) extends from a first edge (119') of the one panel. A compartment flap (122) extends from a second edge (121') and includes attachment tab (126). The compartment flap forms a compartment (116) having four sequentially adjoining sides (132, 134, 136, 111), formed by folds (121, 127, 129, 131). The compartment has first and second open ends (128, 130), closed by tabs (140, 146, 148). A cover (114) extending from a third edge (123') of the one panel is foldable between a closed position overlying the other of the first and second sides of the one panel and an open position folded away from the one panel. The cover is releasably secured in the closed position by attachment of the closure flap to the cover, and is releasable to the open position with release of the pull tab.",MATTEL INC,CARTY JAMES PATRICK;;PETERSON CHRISTINA MARIE;;WEINTRAUB RICHARD;;OSNATO JEFFREY S;;CARR LINDA ANN,,https://lens.org/009-119-260-040-443,Granted Patent,no,0,0,22,22,0,B65D5/422;;B65D5/541;;B65D5/422;;B65D5/541,B65D5/20;;A63H33/00;;B65D5/42;;B65D69/00,,0,0,,,,EXPIRED
70,US,A1,US 2019/0235999 A1,046-000-092-153-708,2019-08-01,2019,US 201815913159 A,2018-03-06,US 201815913159 A;;US 201862623760 P,2018-01-30,Automated Unit Testing In A Mainframe Environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/046-000-092-153-708,Patent Application,yes,5,6,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F11/36;;G06F17/27,,0,0,,,,ACTIVE
71,JP,A,JP H1060074 A,091-547-218-756-530,1998-03-03,1998,JP 17664097 A,1997-07-02,US 67512796 A,1996-07-03,HYDROXYALKYLBIS(AMINOETHYL) ETHER COMPOSITION FOR PRODUCING POLYURETHANE,"PROBLEM TO BE SOLVED: To obtain a catalyst composition capable of carrying out trimerization of isocyanate and reaction of isocyanate with a reactive hydrogen-containing compound so as to have low odor and high activity without releasing a catalyst from a final product by including a specific nitrogen-containing ether compound. SOLUTION: This catalyst composition contains (A) a compound of the formula [R<1> is H or a 1-4C (branched) (hydroxy)alkyl; R<2> and R<3> are each OH or R<1> ; R<4> is a 1-10C (branched)hydroxyalkyl], e.g. N,N,N'-trimethyl-N'-(4- hydroxybutyl)bis(aminoethyl) ether as an essential component and further, as necessary, contains (B) a tertiary amine, (C) an organic tin and (D) a carboxylate urethane catalyst and the composition is used for foaming and gelation reaction when producing a polyurethane.",AIR PROD & CHEM,LESCHER SAVOCA ANN COATES;;RICHARD PAUL UNDERWOOD;;RICHARD VAN COURT CARR;;EMERICK JAMES STEPHEN,,https://lens.org/091-547-218-756-530,Patent Application,no,0,0,6,6,0,C08G18/18;;C08G18/1833;;C08G18/1833;;C07C217/08;;C07C217/08;;C07C217/08;;C08G18/1825;;C08G18/1825;;C08G18/1825;;C08G18/1833;;C08G18/242;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08J9/04;;C07C217/08;;C08G18/18;;C08G101/00,,0,0,,,,PENDING
72,EP,A2,EP 2222700 A2,165-486-582-222-486,2010-09-01,2010,EP 08854674 A,2008-11-26,US 2008/0084805 W;;US 99040107 P,2007-11-27,HUMANIZED ANTI-AMYLOID BETA ANTIBODIES,,MEDTRONIC INC,SHAFER LISA LYNN;;CARR FRANCIS JOSESPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,,https://lens.org/165-486-582-222-486,Patent Application,yes,0,0,5,18,0,A61K2039/505;;C07K16/18;;C07K2317/24,C07K16/00,,1,0,,,See references of WO 2009070648A3,DISCONTINUED
73,CA,A1,CA 3189474 A1,197-541-688-935-45X,2023-08-11,2023,CA 3189474 A,2023-02-10,US 202263309284 P;;US 202263420958 P,2022-02-11,ROOFING SHINGLES WITH ASPHALT SHINGLE WASTE,"A method comprises obtaining a virgin asphalt and obtaining an asphalt shingle waste. The asphalt shingle waste comprises 5 wt. % to 40 wt. % of asphalt based on the total weight of the asphalt shingle waste. The asphalt shingle waste comprises 60 wt. % to 95 wt. % of limestone, granules, and/or impurities based on the total weight of the asphalt shingle waste. The method comprises obtaining a phase modifier. The method comprises mixing the virgin asphalt, the asphalt shingle waste, and the phase modifier to form an asphalt mixture. The phase modifier is present in an amount of 0.25 wt. % to 25 wt. % based on the total weight of the asphalt mixture. The asphalt mixture is configured to be applied to a roof substrate to obtain a roofing shingle.",BMIC LLC,HAMER ANN;;QIN QIAN;;SHAHA CYNTHIA;;CARR KEVIN;;MERCADO RAMIL;;KRAJCA JAROD;;MEZA AZIEL,,https://lens.org/197-541-688-935-45X,Patent Application,no,0,0,4,4,0,C09D7/65;;C09D7/61;;C09D195/00;;C08L95/00;;C09D195/00;;C09D7/65;;C09D7/61;;C08L95/00;;C08L2205/025,E04D1/00;;B09B3/00;;B32B11/02;;C04B18/167;;C04B26/26;;E04D1/22,,0,0,,,,PENDING
74,BR,A,BR 9703797 A,067-744-536-790-980,1998-11-10,1998,BR 9703797 A,1997-06-30,US 67512796 A,1996-07-03,Composições de éter hidroxi-alcoil-bis (amino-etílico) para a produção de poliuretanos e processo para sua preparação,,AIR PROD & CHEM,EMERICK JAMES STEPHEN;;UNDERWOOD RICHARD PAUL;;COURT CARR RICHARD VAN;;SAVOCA ANN COATES LESCHER,,https://lens.org/067-744-536-790-980,Patent Application,no,0,0,6,6,0,C08G18/18;;C08G18/1833;;C08G18/1833;;C07C217/08;;C07C217/08;;C07C217/08;;C08G18/1825;;C08G18/1825;;C08G18/1825;;C08G18/1833;;C08G18/242;;C08G2110/0008;;C08G2110/0008;;C08G2110/005;;C08G2110/005;;C08G2110/0083;;C08G2110/0083;;C08G2115/02;;C08G2115/02;;C08J9/04,C08J9/04;;C07C217/08;;C08G18/18;;C08G101/00,,0,0,,,,DISCONTINUED
75,EP,A3,EP 2586797 A3,104-976-413-080-463,2013-07-24,2013,EP 13152910 A,2008-11-26,US 99040107 P;;EP 08854674 A,2007-11-27,Humanized anti-amyloid beta antibodies,"Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.
",MEDTRONIC INC,SHAFER LISA LYNN;;CARR FRANCIS JOSEPH;;GREGSON JAMES PETER;;BEMBRIDGE DAWN ANN;;JONES TIM,,https://lens.org/104-976-413-080-463,Search Report,yes,9,0,5,18,0,A61K2039/505;;C07K16/18;;C07K2317/24,C07K16/18,,0,0,,,,DISCONTINUED
76,EP,A1,EP 3260586 A1,033-957-513-342-291,2017-12-27,2017,EP 17182967 A,2010-07-02,US 49716609 A;;EP 16153130 A;;EP 10794808 A;;US 2010/0040872 W,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.
",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/033-957-513-342-291,Patent Application,yes,6,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
77,ES,T3,ES 2718799 T3,142-505-456-160-639,2019-07-04,2019,ES 17182967 T,2010-07-02,US 49716609 A,2009-07-02,Máquina de enrollamiento para balón estriado,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/142-505-456-160-639,Granted Patent,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
78,BR,A2,BR PI1016255 A2,142-592-227-072-465,2016-04-26,2016,BR PI1016255 A,2010-07-02,US 2010/0040872 W;;US 49716609 A,2009-07-02,máquina de enrolamento com balão verificador,,BARD INC C R,GRAVES DAVID M;;KELLY JO ANN;;CARR PHILLIP E;;LERDAHL ROBERT G;;PARMENTIER WILLIAM E,,https://lens.org/142-592-227-072-465,Patent Application,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
79,US,A1,US 2011/0000604 A1,194-131-883-308-645,2011-01-06,2011,US 49716609 A,2009-07-02,US 49716609 A,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filaments the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,C.R. BARD INC (2009-06-30),https://lens.org/194-131-883-308-645,Patent Application,yes,16,2,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,B32B37/02;;A61F2/06;;A61F2/958;;A61M25/10,156/143;;156/425,0,0,,,,ACTIVE
80,WO,A1,WO 2011/003053 A1,128-248-383-345-680,2011-01-06,2011,US 2010/0040872 W,2010-07-02,US 49716609 A,2009-07-02,CHECKERING BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R;;GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/128-248-383-345-680,Patent Application,yes,3,2,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;D02G3/36;;A61F2/958;;A61M25/10,,1,0,,,See also references of EP 2449157A4,PENDING
81,EP,B1,EP 3492637 B1,138-202-007-114-909,2023-06-07,2023,EP 19152764 A,2010-07-02,EP 17182967 A;;EP 16153130 A;;EP 10794808 A;;US 49716609 A;;US 2010/0040872 W,2009-07-02,CHECKER BALLOON WINDING MACHINE,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,"C. R. BARD, INC. (2022-12-07)",https://lens.org/138-202-007-114-909,Granted Patent,yes,1,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36,,0,0,,,,ACTIVE
82,CN,A,CN 102471953 A,174-341-215-458-330,2012-05-23,2012,CN 201080029477 A,2010-07-02,US 2010/0040872 W;;US 49716609 A,2009-07-02,Checker balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;ANN KELLY JO,,https://lens.org/174-341-215-458-330,Patent Application,no,9,3,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
83,CA,C,CA 2766733 C,182-789-887-843-667,2017-10-24,2017,CA 2766733 A,2010-07-02,US 49716609 A;;US 2010/0040872 W,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/182-789-887-843-667,Granted Patent,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;A61F2/958;;A61M25/10;;B29C70/32,,0,0,,,,ACTIVE
84,US,B2,US 10350393 B2,129-454-785-812-353,2019-07-16,2019,US 201715495462 A,2017-04-24,US 201715495462 A;;US 201414188066 A;;US 201213563126 A;;US 49716609 A,2009-07-02,Checker balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/129-454-785-812-353,Granted Patent,yes,4,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;A61F2/958;;A61M25/10;;B21F3/02;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,,0,0,,,,ACTIVE
85,EP,B1,EP 3031964 B1,182-529-174-792-440,2017-08-23,2017,EP 16153130 A,2010-07-02,US 49716609 A;;EP 10794808 A,2009-07-02,CHECKER BALLOON WINDING MACHINE,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/182-529-174-792-440,Granted Patent,yes,6,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
86,CA,A1,CA 2766733 A1,071-959-972-973-516,2011-01-06,2011,CA 2766733 A,2010-07-02,US 49716609 A;;US 2010/0040872 W,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/071-959-972-973-516,Patent Application,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10;;B29C70/32,,0,0,,,,ACTIVE
87,US,B2,US 8673200 B2,086-649-003-959-281,2014-03-18,2014,US 201213563126 A,2012-07-31,US 201213563126 A;;US 49716609 A,2009-07-02,Checker balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN;;BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/086-649-003-959-281,Granted Patent,yes,4,2,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;B32B37/02;;A61F2/958;;A61M25/10,264/293;;156/361;;156/425;;156/143,0,0,,,,ACTIVE
88,EP,A1,EP 2449157 A1,120-586-009-046-69X,2012-05-09,2012,EP 10794808 A,2010-07-02,US 2010/0040872 W;;US 49716609 A,2009-07-02,CHECKERING BALLOON WINDING MACHINE,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,"C.R. BARD, INC. (2015-11-04)",https://lens.org/120-586-009-046-69X,Patent Application,yes,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
89,US,B2,US 8236223 B2,079-570-983-351-38X,2012-08-07,2012,US 49716609 A,2009-07-02,US 49716609 A,2009-07-02,Checker balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filaments the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN;;BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,C.R. BARD INC (2009-06-30),https://lens.org/079-570-983-351-38X,Granted Patent,yes,16,6,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;B32B37/02;;A61F2/958;;A61M25/10,264/293;;156/143;;156/425,0,0,,,,ACTIVE
90,AU,B2,AU 2010/266176 B2,136-250-194-967-491,2015-02-19,2015,AU 2010/266176 A,2010-07-02,US 49716609 A;;US 2010/0040872 W,2009-07-02,Checkering balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/136-250-194-967-491,Granted Patent,no,4,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
91,AU,A1,AU 2015/202641 A1,160-265-504-548-500,2015-06-04,2015,AU 2015/202641 A,2015-05-15,AU 2010/266176 A;;AU 2015/202641 A,2010-07-02,Checkering balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/160-265-504-548-500,Patent Application,no,0,0,2,4,0,,D02G3/36,,0,0,,,,ACTIVE
92,EP,A1,EP 3031964 A1,081-705-051-855-972,2016-06-15,2016,EP 16153130 A,2010-07-02,US 49716609 A;;EP 10794808 A,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.
",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/081-705-051-855-972,Patent Application,yes,6,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
93,MX,A,MX 2012000088 A,154-455-826-519-163,2012-06-12,2012,MX 2012000088 A,2010-07-02,US 49716609 A;;US 2010/0040872 W,2009-07-02,CHECKERING BALLOON WINDING MACHINE.,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,LERDAHL ROBERT G;;GRAVES DAVID M;;PARMENTIER WILLIAM E;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/154-455-826-519-163,Patent Application,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
94,AU,A1,AU 2010/266176 A1,075-835-922-095-744,2012-02-02,2012,AU 2010/266176 A,2010-07-02,US 49716609 A;;US 2010/0040872 W,2009-07-02,Checkering balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/075-835-922-095-744,Patent Application,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
95,ES,T3,ES 2585349 T3,005-822-855-733-766,2016-10-05,2016,ES 10794808 T,2010-07-02,US 49716609 A;;US 2010/0040872 W,2009-07-02,Máquina de enrollamiento para balón estriado,"Un dispositivo para enrollar un filamento (212) alrededor de una estructura dispuesta concéntricamente alrededor de una superficie exterior de un extremo distal de un catéter de balón (222) para proporcionar un patrón predeterminado de entalladuras superficiales en una superficie exterior de la estructura, que comprende: un controlador (102); un elemento de sujeción rotatorio (106a, b) para retener al menos un extremo distal de un catéter de balón en los extremos opuestos de un balón dispuesto en el extremo distal del catéter; y un carro de enrollamiento trasladable (108) para enrollar un filamento alrededor de una superficie exterior del balón dispuesto en el extremo distal del catéter; en el que el controlador (102) hace que el carro de enrollamiento trasladable se mueva a lo largo de una dimensión longitudinal del catéter de balón para enrollar el filamento alrededor del catéter de balón a un paso predeterminado.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/005-822-855-733-766,Granted Patent,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
96,ES,T3,ES 2643419 T3,141-157-442-492-590,2017-11-22,2017,ES 16153130 T,2010-07-02,US 49716609 A,2009-07-02,Máquina de enrollamiento para balón estriado,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/141-157-442-492-590,Granted Patent,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
97,EP,C0,EP 3492637 C0,106-351-339-614-828,2023-06-07,2023,EP 19152764 A,2010-07-02,EP 17182967 A;;EP 16153130 A;;EP 10794808 A;;US 49716609 A;;US 2010/0040872 W,2009-07-02,CHECKER BALLOON WINDING MACHINE,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,"C. R. BARD, INC. (2022-12-07)",https://lens.org/106-351-339-614-828,Unknown,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36,,0,0,,,,ACTIVE
98,US,A1,US 2014/0166152 A1,015-787-993-289-968,2014-06-19,2014,US 201414188066 A,2014-02-24,US 201414188066 A;;US 201213563126 A;;US 49716609 A,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/015-787-993-289-968,Patent Application,yes,1,3,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,B21F3/02;;A61F2/06;;A61F2/958;;A61M25/10,140/102.5,0,0,,,,ACTIVE
99,US,A1,US 2012/0291957 A1,052-862-288-111-637,2012-11-22,2012,US 201213563126 A,2012-07-31,US 201213563126 A;;US 49716609 A,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/052-862-288-111-637,Patent Application,yes,4,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;B65H81/08;;A61F2/958;;A61M25/10,156/361,0,0,,,,ACTIVE
100,EP,A4,EP 2449157 A4,141-825-213-648-193,2015-08-26,2015,EP 10794808 A,2010-07-02,US 2010/0040872 W;;US 49716609 A,2009-07-02,CHECKERING BALLOON WINDING MACHINE,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,"C.R. BARD, INC. (2015-11-04)",https://lens.org/141-825-213-648-193,Search Report,no,3,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,1,0,,,See also references of WO 2011003053A1,ACTIVE
101,BR,B1,BR PI1016255 B1,180-191-407-539-684,2019-12-17,2019,BR PI1016255 A,2010-07-02,US 2010/0040872 W;;US 49716609 A,2009-07-02,dispositivo para enrolar um filamento,"dispositivo para enrolar um filamento a presente invenção refere-se a um dispositivo (100) para enrolar um filamento (212) em torno da estrutura disposta de maneira concêntrica em torno de uma extremidade distal do cateter com balão (222) inclui um suporte giratório (106a, 106b) para reter uma extremidade distal do cateter com balão (222), um transporte com enrolamento traduzível (108) para enrolar de maneira helicoidal o filamento (212) tensionado em torno da extremidade distal do cateter com balão (222), um aquecedor (224) para aplicar uma quantidade predeterminada de calor 6 . seção do cateter com balão (222) que possui o filamento (212) enrolado em torno do mesmo, e um controlador (102) para controlar pelo menos uma taxa de rotação do suporte (106a, 106b), a força tensionadora aplicada ao filamento (212), a quantidade de calor aplicada pelo aquecedor (224), e uma taxa de trajetória do transporte com enrolamento traduzível (108) ao longo da dimensão longitudinal do cateter com balão (222). pelo uso do dispositivo (100), o balão é ajustado com calor e um padrão quadriculado predeterminado de identações de superfície é fornecido na superfície exterior da estrutura em uma passagem única.",BARD INC C R,DAVID M GRAVES;;JO ANN KELLY;;PHILLIP E CARR;;ROBERT G LERDAHL;;WILLIAM E PARMENTIER,,https://lens.org/180-191-407-539-684,Granted Patent,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
102,AU,A1,AU 2016/231607 A1,036-236-809-324-673,2016-10-27,2016,AU 2016/231607 A,2016-09-22,AU 2016/231607 A;;AU 2015/202641 A;;AU 2010/266176 A,2010-07-02,Checkering balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal 5 end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the 10 tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass. --- -- -- -Ile",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/036-236-809-324-673,Patent Application,no,0,0,2,4,0,,D02G3/36,,0,0,,,,ACTIVE
103,AU,B2,AU 2015/202641 B2,024-462-109-876-303,2016-07-14,2016,AU 2015/202641 A,2015-05-15,AU 2010/266176 A;;AU 2015/202641 A,2010-07-02,Checkering balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/024-462-109-876-303,Granted Patent,no,0,0,2,4,0,,D02G3/36,,0,0,,,,ACTIVE
104,CN,B,CN 102471953 B,086-446-462-263-304,2014-11-05,2014,CN 201080029477 A,2010-07-02,US 2010/0040872 W;;US 49716609 A,2009-07-02,Checker balloon winding machine,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/086-446-462-263-304,Granted Patent,no,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
105,EP,B1,EP 3260586 B1,108-398-150-894-37X,2019-02-27,2019,EP 17182967 A,2010-07-02,US 49716609 A;;EP 16153130 A;;EP 10794808 A;;US 2010/0040872 W,2009-07-02,CHECKER BALLOON WINDING MACHINE,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/108-398-150-894-37X,Granted Patent,yes,6,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
106,EP,A1,EP 3492637 A1,002-781-740-869-279,2019-06-05,2019,EP 19152764 A,2010-07-02,EP 17182967 A;;EP 16153130 A;;EP 10794808 A;;US 49716609 A;;US 2010/0040872 W,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.
",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,"C. R. BARD, INC. (2022-12-07)",https://lens.org/002-781-740-869-279,Patent Application,yes,5,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
107,US,A1,US 2017/0224966 A1,028-608-472-759-552,2017-08-10,2017,US 201715495462 A,2017-04-24,US 201715495462 A;;US 201414188066 A;;US 201213563126 A;;US 49716609 A,2009-07-02,CHECKER BALLOON WINDING MACHINE,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/028-608-472-759-552,Patent Application,yes,0,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;A61F2/958;;A61M25/10;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,,0,0,,,,ACTIVE
108,AU,B2,AU 2016/231607 B2,060-942-377-734-027,2018-09-13,2018,AU 2016/231607 A,2016-09-22,AU 2016/231607 A;;AU 2015/202641 A;;AU 2010/266176 A,2010-07-02,Checkering balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal 5 end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the 10 tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass. --- -- -- -Ile",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/060-942-377-734-027,Granted Patent,no,1,0,2,4,0,,D02G3/36,,0,0,,,,ACTIVE
109,EP,B1,EP 2449157 B1,147-565-065-063-31X,2016-05-11,2016,EP 10794808 A,2010-07-02,US 2010/0040872 W;;US 49716609 A,2009-07-02,CHECKERING BALLOON WINDING MACHINE,,BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,"C.R. BARD, INC. (2015-11-04)",https://lens.org/147-565-065-063-31X,Granted Patent,yes,6,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,D02G3/36;;A61F2/06;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
110,US,B2,US 9643235 B2,176-988-036-717-958,2017-05-09,2017,US 201414188066 A,2014-02-24,US 201414188066 A;;US 201213563126 A;;US 49716609 A,2009-07-02,Checker balloon winding machine,"A device for winding a filament around a structure disposed concentrically around a distal end of a balloon catheter includes a rotatable holder for retaining a distal end of the balloon catheter, a translatable winding carriage for helically winding the tensioned filament around the balloon catheter distal end, a heater for applying a predetermined amount of heat to a section of the balloon catheter having the filament wound therearound, and a controller for controlling at least the rate of rotation of the holder, the tensioning force applied to the filament, the amount of heat applied by the heater, and the rate of travel of the translatable winding carriage along the longitudinal dimension of the balloon catheter. By use of the device, the balloon is heat set and a predetermined checkering pattern of surface indentations are provided in the structure exterior surface in a single pass.",BARD INC C R,GRAVES DAVID M;;PARMENTIER WILLIAM E;;LERDAHL ROBERT G;;CARR PHILLIP E;;KELLY JO ANN,,https://lens.org/176-988-036-717-958,Granted Patent,yes,4,0,32,32,0,A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;A61F2/958;;A61M25/1027;;A61M2025/1086;;A61M25/1029;;B21F3/02;;A61M2025/1031;;B65H54/28;;B65H57/02;;B65H57/14;;B65H71/00,A61F2/06;;B21F3/02;;A61F2/958;;A61M25/10,,0,0,,,,ACTIVE
111,EP,A1,EP 0668303 A1,125-930-658-735-542,1995-08-23,1995,EP 95102351 A,1995-02-20,US 19939694 A,1994-02-22,Hydroxy and amino functional pyrrolizidine catalyst compositions for the production of polyurethanes.,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, cell stabilizer and a catalyst composition consisting essentially of a pyrrolizidine of the formula:
  
 where R 1  and R 2  independently are -H, -OH,
  or-NR 4 R 5 , R 3  is hydrogen, a C 1 -C 1 2  alkyl, C 5 -C 6  cycloalkyl, C 6 -C 1  o aryl, or C 7 -C 11  arylalkyl group, and R 4  and R 5  independently represent H, a C 1 -C 12  alkyl group, C 5 -C 10  cycloalkyl, C 6 -C 10  aryl, or C 7 -C 11  arylalkyl group, 
provided that at least R 1  or R 2  is not hydrogen.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;WRESSELL AMY LYNNE;;LISTEMANN MARK LEO;;CARR RICHARD VAN COURT;;MERCANDO LISA ANN;;LASSILA KEVIN RODNEY;;MINNICH KRISTEN ELAINE,,https://lens.org/125-930-658-735-542,Patent Application,yes,3,0,13,13,0,C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02;;C08G18/20;;C08J9/04;;C08G18/00;;C08G18/18;;C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02,C08G18/18;;C08G18/20,,0,0,,,,EXPIRED
112,EP,B1,EP 0668303 B1,051-761-282-890-626,2000-08-23,2000,EP 95102351 A,1995-02-20,US 19939694 A,1994-02-22,Hydroxy functional pyrrolizidine catalyst compositions for the production of polyurethanes,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;WRESSELL AMY LYNNE;;LISTEMANN MARK LEO;;CARR RICHARD VAN COURT;;MERCANDO LISA ANN;;LASSILA KEVIN RODNEY;;MINNICH KRISTEN ELAINE,,https://lens.org/051-761-282-890-626,Granted Patent,yes,3,0,13,13,0,C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02;;C08G18/20;;C08J9/04;;C08G18/00;;C08G18/18;;C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02,C08G18/18;;C08G18/20,,0,0,,,,EXPIRED
113,DE,D1,DE 69518448 D1,119-458-157-129-524,2000-09-28,2000,DE 69518448 T,1995-02-20,US 19939694 A,1994-02-22,Hydroxyfunktionalisierte Pyrrolizidinkatalysator-Zusammensetzungen für die Herstellung von Polyurethanen,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;WRESSELL AMY LYNNE;;LISTEMANN MARK LEO;;CARR RICHARD VAN COURT;;MERCANDO LISA ANN;;LASSILA KEVIN RODNEY;;MINNICH KRISTEN ELAINE,,https://lens.org/119-458-157-129-524,Granted Patent,no,0,0,13,13,0,C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02;;C08G18/20;;C08J9/04;;C08G18/00;;C08G18/18;;C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02,C08G18/18;;C08G18/20,,0,0,,,,EXPIRED
114,DE,T2,DE 69518448 T2,048-305-399-695-448,2001-01-04,2001,DE 69518448 T,1995-02-20,US 19939694 A,1994-02-22,Hydroxyfunktionalisierte Pyrrolizidinkatalysator-Zusammensetzungen für die Herstellung von Polyurethanen,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;WRESSELL AMY LYNNE;;LISTEMANN MARK LEO;;CARR RICHARD VAN COURT;;MERCANDO LISA ANN;;LASSILA KEVIN RODNEY;;MINNICH KRISTEN ELAINE,,https://lens.org/048-305-399-695-448,Granted Patent,no,0,0,13,13,0,C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02;;C08G18/20;;C08J9/04;;C08G18/00;;C08G18/18;;C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02,C08G18/18;;C08G18/20,,0,0,,,,EXPIRED
115,EP,B1,EP 3430380 B1,089-092-365-289-063,2021-08-04,2021,EP 17713113 A,2017-03-10,US 201662307981 P;;US 2017/0021824 W,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,,MASSACHUSETTS INST TECHNOLOGY,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;VALDEZ TULIO A;;CARR JESSICA ANN;;FRANKE DANIEL;;AELLEN MARIANNE,,https://lens.org/089-092-365-289-063,Granted Patent,yes,8,0,8,8,0,A61B5/0071;;G01N21/6456;;G01N21/6486;;A61B2503/40;;A61B5/0071;;A61B2503/40;;G01N21/6456;;G01N21/6486,G01N21/64;;A61B5/00,,6,6,009-346-975-204-122;;015-881-393-882-160;;041-281-556-196-848;;015-881-393-882-160;;041-281-556-196-848;;009-346-975-204-122,pmc3736359;;23873342;;10.1038/ncomms3199;;635011;;10.1088/0031-9155/23/1/017;;25296382;;10.1039/c4cc06542e;;635011;;10.1088/0031-9155/23/1/017;;25296382;;10.1039/c4cc06542e;;pmc3736359;;23873342;;10.1038/ncomms3199,"D. J. NACZYNSKI ET AL: ""Rare-earth-doped biological composites as in vivo shortwave infrared reporters"", NATURE COMMUNICATIONS, vol. 4, 22 July 2013 (2013-07-22), XP055380832, DOI: 10.1038/ncomms3199;;R. C. BENSON ET AL: ""Fluorescence Properties of indocyanine green as related to angiography"", PHYS. MED. BIOL., vol. 23, no. 1, 1 December 1978 (1978-12-01), pages 159 - 163, XP055383138, DOI: 10.1088/0031-9155/23/1/017;;Y. TSUKASAKI ET AL: ""A short-wavelength infrared emitting multimodal probe for non-invasive visualization of phagocyte cell migration in living mice"", CHEMICAL COMMUNICATIONS, vol. 50, no. 92, 1 January 2014 (2014-01-01), pages 14356 - 14359, XP055380788, ISSN: 1359-7345, DOI: 10.1039/C4CC06542E;;R. C. BENSON ET AL: ""Fluorescence Properties of indocyanine green as related to angiography"", PHYS. MED. BIOL., vol. 23, no. 1, 1 December 1978 (1978-12-01), pages 159 - 163, XP055383138, DOI: 10.1088/0031-9155/23/1/017;;Y. TSUKASAKI ET AL: ""A short-wavelength infrared emitting multimodal probe for non-invasive visualization of phagocyte cell migration in living mice"", CHEMICAL COMMUNICATIONS, vol. 50, no. 92, 1 January 2014 (2014-01-01), pages 14356 - 14359, XP055380788, ISSN: 1359-7345, DOI: 10.1039/C4CC06542E;;D. J. NACZYNSKI ET AL: ""Rare-earth-doped biological composites as in vivo shortwave infrared reporters"", NATURE COMMUNICATIONS, vol. 4, 22 July 2013 (2013-07-22), XP055380832, DOI: 10.1038/ncomms3199",ACTIVE
116,US,B1,US 7985892 B1,198-829-981-436-149,2011-07-26,2011,US 16819405 A,2005-06-28,US 16819405 A;;US 58432404 P,2004-06-29,Truncated Cry35 proteins,"This invention provides truncated Cry35 proteins that surprisingly and unexpectedly have increased pesticidal activity as compared to full-length Cry35 proteins. The subject invention also includes polynucleotides that encode these truncated proteins, transgenic plants comprising a truncated gene of the subject invention, and transgenic plants that produce these truncated proteins. This invention further provides methods of controlling plant pests, including rootworms, with these truncated proteins. The truncated Cry35 proteins of the subject invention are preferably used in combination with Cry34 proteins, which are known in the art. Various surprising advantages of the subject invention will be apparent in light of this disclosure.",DOW AGROSCIENCES LLC,GAO YONG;;HERMAN ROD AARON;;CARR ANDREW WILLIAM;;SCHWEDLER DEBORAH ANN;;XU XIOAPING;;SCHWAB GEORGE ERWIN,DOW AGROSCIENCES LLC (2005-08-11),https://lens.org/198-829-981-436-149,Granted Patent,yes,6,2,3,3,7,C07K14/325;;C12N15/8286;;Y02A40/146;;C12N15/8286;;C07K14/325,A01H5/00;;C12N15/09;;C12N15/32,800/302;;536/23.71;;424/93.2,21,14,039-124-626-540-421;;055-003-061-629-507;;021-941-959-050-136;;054-539-313-560-243;;119-150-974-251-000;;029-315-305-449-378;;032-701-990-695-57X;;000-911-568-933-987;;028-862-168-091-90X;;054-539-313-560-243;;056-480-253-596-832;;001-501-496-218-638;;019-779-601-634-917;;013-181-635-285-001,10.1038/90282;;11433280;;10.1073/pnas.0403255101;;pmc438954;;15197260;;pmc492402;;10.1128/aem.70.8.4889-4898.2004;;15294828;;pmc123759;;11872461;;10.1128/aem.68.3.1137-1145.2002;;8633760;;10.1021/ac00117a024;;10.1128/jb.172.12.6759-6763.1990;;2254252;;pmc210790;;9926404;;10.1016/s1044-0305(98)00145-7;;11275324;;10.1016/s0168-9525(01)02237-5;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;pmc123759;;11872461;;10.1128/aem.68.3.1137-1145.2002;;12076012;;10.1603/0022-0493-95.3.635;;10.1128/mr.53.2.242-255.1989;;10.1128/mmbr.53.2.242-255.1989;;2666844;;pmc372730;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1073/pnas.87.6.2264;;2315319;;pmc53667,"Moellenbeck et al (2001, Nature Biotechnol. 19:668-672).;;Guo et al (2004, Proc. Natl. Acad. Sci. USA 101: 9205-9210).;;Baum et al, 2004, Appl. Environ. Microbiol. 70:4889-4898.;;Ellis et al (2002, Appl. Environ. Microbiol. 68:1137-1145).;;Patterson et al, 1995, Anal. Chem. 67:3971-3978.;;Clark et al (1990, J. Bacteriol. 172:6759-6763).;;Chaurand et al (1998, J. Am. Soc. Mass. Spectrom. 10:91-103).;;de Maagd et al, 2001, Trends Genet. 17: 193-199.;;Altschul, S.F. et al. ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs"" Nucleic Acids Research, 1997, pp. 3389-3402, vol. 25, No. 17.;;Ellis, R.T. ""Novel Bacillus thuringiensis Binary Insecticidal Crystal Proteins Active on WEstern Corn Rootworm, Diabrotica virgifera virgifera LeConte"" Applied and Environmental Microbiology, Mar. 2002, pp. 1137-1145, vol. 68, No. 3.;;Herman, R.A. et al. ""Binary Insecticidal Crystal Protein from Bacillus thuringiensis, Strain PS149B1: Effects of Individual Protein Components and Mixtures in Laboratory Bioassays"" Journal of Economic Entomology, 2002, pp. 635-639, vol. 95, No. 3.;;Hofte, H. and Whiteley, H.R. ""Insecticidal Crystal Proteins of Bacillus thuringiensis"" Microbiological Reviews, Jun. 1989, pp. 242-255, vol. 53, No. 2.;;Karlin, S. and Altschul, S.F. ""Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences"" Proc. Natl. Acad., Jun. 1993, pp. 5873-5877, vol. 90.;;Karlin, S. and Altschul, S.F. ""Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes"" Proc. Natl. Acad. Sci., Mar. 1990, pp. 2264-2268, vol. 87.;;Crickmore et al. Bacillus thuringiensis Toxin Nomenclature Official Website, Full Toxin List, Cry35 proteins (Aug. 2, 2005).;;NCBI Accession No. AAG41672; Publication Date: Sep. 26, 2002.;;NCBI Accession No. AAG50117; Publication Date: Mar. 4, 2002.;;NCBI Accession No. AAG50342; Publication Date: Mar. 4, 2002.;;NCBI Accession No. AAK64561; Publication Date: Jul. 29, 2004.;;NCBI Accession No. AAK64563; Publication Date: Jul. 29, 2004.;;NCBI Accession No. AAK64566; Publication Date: Jul. 29, 2004.",INACTIVE
117,US,B2,US 10996170 B2,139-678-582-035-748,2021-05-04,2021,US 201716083588 A,2017-03-10,US 201716083588 A;;US 201662307981 P;;US 2017/0021824 W,2016-03-14,Device and method for imaging shortwave infrared fluorescence,Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed.,MASSACHUSETTS INST TECHNOLOGY,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;VALDEZ TULIO A;;CARR JESSICA ANN;;FRANKE DANIEL;;AELLEN MARIANNE,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2017-09-28),https://lens.org/139-678-582-035-748,Granted Patent,yes,9,0,8,8,0,A61B5/0071;;G01N21/6456;;G01N21/6486;;A61B2503/40;;A61B5/0071;;A61B2503/40;;G01N21/6456;;G01N21/6486,G01N21/64;;A61B5/00,,8,4,041-281-556-196-848;;015-881-393-882-160;;009-346-975-204-122;;107-126-538-657-615,25296382;;10.1039/c4cc06542e;;635011;;10.1088/0031-9155/23/1/017;;pmc3736359;;23873342;;10.1038/ncomms3199;;10.1002/anie.201507473;;26460151,"Tsukasaki, Y. et al., “A short-wavelength infrared emitting multimodal probe for non-invasive visualization of phagocyte cell migration in living mice”, 2014, Royal Society of Chemistry, Chem. Commun. 2014, 50, pp. 14356-14359. (Year: 2014).;;Benson, R.C., et al., “Fluorescence Properties of Indocyanine Green as Related to Angiography”, 1978, Phys. Med. Biol. vol. 23, No. 1, pp. 159-163. (Year: 1978).;;Invitation to Pay Additional Fees dated Jun. 28, 2017 for Application No. PCT/US2017/021824.;;International Search Report and Written Opinion dated Aug. 24, 2017 for Application No. PCT/US2017/021824.;;International Preliminary Report on Patentability dated Sep. 27, 2018 for Application No. PCT/US2017/021824.;;Naczynski et al., Rare-earth-doped biological composites as in vivo shortwave infrared reporters. Nat Commun. Jul. 22, 2013;4:2199(1-10).;;International Search Report and Written Opinion dated Jun. 29, 2017 for Application No. PCT/US2017/021845.;;Diao et al., Fluorescence Imaging In Vivo at Wavelengths beyond 1500 nm. Angew Chem Int Ed Engl. Dec. 1, 2015;54(49):14758-62. doi: 10.1002/anie.201507473. Epub Oct. 13, 2015. PMID: 26460151.",ACTIVE
118,US,B2,US 11579088 B2,069-650-002-407-348,2023-02-14,2023,US 201716083603 A,2017-03-10,US 201716083603 A;;US 201662307997 P;;US 2017/0021845 W,2016-03-14,Device and method for imaging shortwave infrared fluorescence,"Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed. In some embodiments, for example, a method may include exposing a portion of tissue that does not include a fluorescent probe to an excitation source of the tissue, wherein at least a portion of the tissue has an autofluorescence spectrum which includes wavelengths greater than 900 nm, and imaging the tissue with a detector that is sensitive to electromagnetic radiation with wavelengths greater than or equal to 900 nm. In certain other embodiments, a system comprises a fluorescent probe including a fluorescent component attached to a carrier, an excitation source, and a detector that detects a tail portion of the fluorescence of the fluorescent component. Methods associated with such a system are also disclosed.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;CARR JESSICA ANN;;VAN LEYEN KLAUS;;ZHENG YI;;AELLEN MARIANNE,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2017-10-12);;THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2018-02-12),https://lens.org/069-650-002-407-348,Granted Patent,yes,10,0,6,6,0,A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;G01N21/6428,G01N21/64;;A61B5/00,,10,7,002-470-229-722-044;;088-439-436-228-73X;;015-881-393-882-160;;107-126-538-657-615;;009-346-975-204-122;;041-281-556-196-848;;144-899-235-776-912,10.1002/jrs.4714;;10.1016/j.avsg.2013.02.011;;23972435;;635011;;10.1088/0031-9155/23/1/017;;10.1002/anie.201507473;;26460151;;pmc3736359;;23873342;;10.1038/ncomms3199;;25296382;;10.1039/c4cc06542e;;10.1111/j.1600-0846.2012.00632.x;;22724585,"Santos, I. P., Caspers, P. J., Bakker Schut, T., van Doorn, R., Koljenović, S., & Puppels, G. J. (2015). Implementation of a novel low-noise InGaAs detector enabling rapid near-infrared multichannel Raman spectroscopy of pigmented biological samples. Journal of Raman Spectroscopy, 46(7), 652-660. (Year: 2015).;;Terasaki, H., Inoue, Y., Sugano, N., Jibiki, M., Kudo, T., Lepäntalo, M., & Venermo, M. (2013). A quantitative method for evaluating local perfusion using indocyanine green fluorescence imaging. Annals of vascular surgery, 27(8), 1154-1161. (Year: 2013).;;IRDye Infrared Dyes Advancing Discovery With Infrared Imaging, LI-COR, https://www.ld.ru/w/licor/IRDye_brochure_web.pdf, date accessed—Oct. 28, 2021, wayback machine capture date—Dec. 22, 2014 (Year: 2014).;;International Search Report and Written Opinion dated Jun. 29, 2017 for Application No. PCT/US2017/021845.;;International Preliminary Report on Patentability dated May 6, 2018 for Application No. PCT/US2017/021845.;;Benson et al., Fluorescence properties of indocyanine green as related to angiography. Phys Med Biol. Dec. 1978;23(1):159-63.;;Diao et al., Fluorescence imaging in vivo at wavelengths beyond 1500 nm. Angew Chem Intl Ed. Oct. 13, 2015;54(49):14758-62.;;Naczynski et al., Rare-earth-doped biological composites as in vivo shortwave infrared reporters. Nat Commun. Jul. 22, 2013;4:2199(1-10).;;Tsukasaki et al., A short-wavelength infrared emitting multimodal probe for non-invasive visualization of phagocyte cell migration in living mice. Chem Commun. Jan. 2014;50(92): 14356-9.;;Wang et al., In vivo near-infrared autofluorescence imaging of pigmented skin lesions: methods, technical improvements and preliminary clinical results. Skin Res Technol. Feb. 2013;19(1):20-6. doi: 10.1111/j.1600-0846.2012.00632.x. Epub Jun. 22, 2012.",ACTIVE
119,US,A1,US 2019/0079010 A1,178-900-247-368-624,2019-03-14,2019,US 201716083603 A,2017-03-10,US 201716083603 A;;US 201662307997 P;;US 2017/0021845 W,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed.,MASSACHUSETTS INST TECHNOLOGY;;THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL;;THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETS GENERAL HOSPITAL,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;CARR JESSICA ANN;;VAN LEYEN KLAUS;;ZHENG YI;;AELLEN MARIANNE,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2017-10-12);;THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2018-02-12),https://lens.org/178-900-247-368-624,Patent Application,yes,1,6,6,6,0,A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;G01N21/6428,A61B5/00;;G01N21/64,,0,0,,,,ACTIVE
120,WO,A1,WO 2017/160639 A1,086-351-138-391-003,2017-09-21,2017,US 2017/0021824 W,2017-03-10,US 201662307981 P,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed.,MASSACHUSETTS INST TECHNOLOGY,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;VALDEZ TULIO A;;CARR JESSICA ANN;;FRANKE DANIEL;;AELLEN MARIANNE,,https://lens.org/086-351-138-391-003,Patent Application,yes,5,3,8,8,0,A61B5/0071;;G01N21/6456;;G01N21/6486;;A61B2503/40;;A61B5/0071;;A61B2503/40;;G01N21/6456;;G01N21/6486,A61B5/00;;G01N21/64,,1,1,009-346-975-204-122,pmc3736359;;23873342;;10.1038/ncomms3199,"D. J. NACZYNSKI ET AL: ""Rare-earth-doped biological composites as in vivo shortwave infrared reporters"", NATURE COMMUNICATIONS, vol. 4, 22 July 2013 (2013-07-22), XP055380832, DOI: 10.1038/ncomms3199",PENDING
121,US,A1,US 2020/0041417 A1,050-965-598-185-876,2020-02-06,2020,US 201716083588 A,2017-03-10,US 201716083588 A;;US 201662307981 P;;US 2017/0021824 W,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed.,MASSACHUSETTS INST TECHNOLOGY,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;VALDEZ TULIO A;;CARR JESSICA ANN;;FRANKE DANIEL;;AELLEN MARIANNE,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2017-09-28),https://lens.org/050-965-598-185-876,Patent Application,yes,0,5,8,8,0,A61B5/0071;;G01N21/6456;;G01N21/6486;;A61B2503/40;;A61B5/0071;;A61B2503/40;;G01N21/6456;;G01N21/6486,G01N21/64,,0,0,,,,ACTIVE
122,WO,A4,WO 2017/160639 A4,199-830-259-360-102,2017-11-23,2017,US 2017/0021824 W,2017-03-10,US 201662307981 P,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed.,MASSACHUSETTS INST TECHNOLOGY,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;VALDEZ TULIO A;;CARR JESSICA ANN;;FRANKE DANIEL;;AELLEN MARIANNE,,https://lens.org/199-830-259-360-102,Patent Application,yes,0,0,8,8,0,A61B5/0071;;G01N21/6456;;G01N21/6486;;A61B2503/40;;A61B5/0071;;A61B2503/40;;G01N21/6456;;G01N21/6486,A61B5/00;;G01N21/64,,0,0,,,,PENDING
123,WO,A1,WO 2017/160643 A1,042-474-054-121-712,2017-09-21,2017,US 2017/0021845 W,2017-03-10,US 201662307997 P,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed.,MASSACHUSETTS INST TECHNOLOGY;;THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;CARR JESSICA ANN;;VAN LEYEN KLAUS;;ZHENG YI;;AELLEN MARIANNE,,https://lens.org/042-474-054-121-712,Patent Application,yes,3,3,6,6,0,A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;G01N21/6428,G01N21/64;;A61B5/00,,4,4,041-281-556-196-848;;015-881-393-882-160;;107-126-538-657-615;;009-346-975-204-122,25296382;;10.1039/c4cc06542e;;635011;;10.1088/0031-9155/23/1/017;;10.1002/anie.201507473;;26460151;;pmc3736359;;23873342;;10.1038/ncomms3199,"Y. TSUKASAKI ET AL: ""A short-wavelength infrared emitting multimodal probe for non-invasive visualization of phagocyte cell migration in living mice"", CHEMICAL COMMUNICATIONS - CHEMCOM., vol. 50, no. 92, 1 January 2014 (2014-01-01), pages 14356 - 14359, XP055380788, ISSN: 1359-7345, DOI: 10.1039/C4CC06542E;;R. C. BENSON ET AL: ""Fluorescence Properties of indocyanine green as related to angiography"", PHYS. MED. BIOL., vol. 23, no. 1, 1 December 1978 (1978-12-01), pages 159 - 163, XP055383138;;SHUO DIAO ET AL: ""Fluorescence Imaging In Vivo at Wavelengths beyond 1500?nm"", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 54, no. 49, 13 October 2015 (2015-10-13), pages 14758 - 14762, XP055383175, ISSN: 1433-7851, DOI: 10.1002/anie.201507473;;D. J. NACZYNSKI ET AL: ""Rare-earth-doped biological composites as in vivo shortwave infrared reporters"", NATURE COMMUNICATIONS, vol. 4, 22 July 2013 (2013-07-22), XP055380832, DOI: 10.1038/ncomms3199",PENDING
124,EP,A1,EP 3430381 A1,023-406-687-277-975,2019-01-23,2019,EP 17713114 A,2017-03-10,US 201662307997 P;;US 2017/0021845 W,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,,MASSACHUSETTS INST TECHNOLOGY;;THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;CARR JESSICA ANN;;VAN LEYEN KLAUS;;ZHENG YI;;AELLEN MARIANNE,,https://lens.org/023-406-687-277-975,Patent Application,yes,0,0,6,6,0,A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;A61B5/0071;;G01N2021/6439;;A61B2503/40;;G01N21/6456;;G01N21/6428,G01N21/64;;A61B5/00,,0,0,,,,DISCONTINUED
125,EP,A1,EP 3430380 A1,022-122-838-396-365,2019-01-23,2019,EP 17713113 A,2017-03-10,US 201662307981 P;;US 2017/0021824 W,2016-03-14,DEVICE AND METHOD FOR IMAGING SHORTWAVE INFRARED FLUORESCENCE,,MASSACHUSETTS INST TECHNOLOGY,BAWENDI MOUNGI G;;BRUNS OLIVER THOMAS;;VALDEZ TULIO A;;CARR JESSICA ANN;;FRANKE DANIEL;;AELLEN MARIANNE,,https://lens.org/022-122-838-396-365,Patent Application,yes,0,0,8,8,0,A61B5/0071;;G01N21/6456;;G01N21/6486;;A61B2503/40;;A61B5/0071;;A61B2503/40;;G01N21/6456;;G01N21/6486,G01N21/64;;A61B5/00,,0,0,,,,ACTIVE
126,US,B2,US 8455430 B2,172-056-187-695-981,2013-06-04,2013,US 201113187953 A,2011-07-21,US 201113187953 A;;US 16819405 A;;US 58432404 P,2004-06-29,Truncated Cry35 proteins,"This invention provides truncated Cry 35 proteins that surprisingly and unexpectedly have increased pesticidal activity as compared to full-length Cry 35 proteins. The subject invention also includes polynucleotides that encode these truncated proteins, transgenic plants comprising a truncated gene of the subject invention, and transgenic plants that produce these truncated proteins. This invention further provides methods of controlling plant pests, including rootworms, with these truncated proteins. The truncated Cry35 proteins of the subject invention are preferably used in combination with Cry34 proteins, which are known in the art. Various surprising advantages of the subject invention will be apparent in light of this disclosure.",GAO YONG;;HERMAN ROD AARON;;SCHWEDLER DEBORAH ANN;;XU XIOAPING;;CARR ANDREW WILLIAM;;SCHWAB GEORGE ERWIN;;DOW AGROSCIENCES LLC,GAO YONG;;HERMAN ROD AARON;;SCHWEDLER DEBORAH ANN;;XU XIOAPING;;CARR ANDREW WILLIAM;;SCHWAB GEORGE ERWIN,,https://lens.org/172-056-187-695-981,Granted Patent,yes,0,0,3,3,7,C07K14/325;;C12N15/8286;;Y02A40/146;;C12N15/8286;;C07K14/325,A01N37/18;;C07K14/325,514/4.5,3,3,039-124-626-540-421;;054-539-313-560-243;;029-315-305-449-378,10.1038/90282;;11433280;;pmc123759;;11872461;;10.1128/aem.68.3.1137-1145.2002;;10.1128/jb.172.12.6759-6763.1990;;2254252;;pmc210790,"Moellenbeck et al (2001, Nature Biotechnol. 19:668-672).;;Ellis et al (2002, Appl. Environ. Microbiol. 68:1137-1145).;;Clark et al (1990, J. Bacteriol. 172:6759-6763).",INACTIVE
127,US,A1,US 2011/0275557 A1,156-589-739-456-359,2011-11-10,2011,US 201113187953 A,2011-07-21,US 201113187953 A;;US 16819405 A;;US 58432404 P,2004-06-29,TRUNCATED Cry35 PROTEINS,"This invention provides truncated Cry 35 proteins that surprisingly and unexpectedly have increased pesticidal activity as compared to full-length Cry 35 proteins. The subject invention also includes polynucleotides that encode these truncated proteins, transgenic plants comprising a truncated gene of the subject invention, and transgenic plants that produce these truncated proteins. This invention further provides methods of controlling plant pests, including rootworms, with these truncated proteins. The truncated Cry35 proteins of the subject invention are preferably used in combination with Cry34 proteins, which are known in the art. Various surprising advantages of the subject invention will be apparent in light of this disclosure.",DOW AGROSCIENCES LLC,GAO YONG;;HERMAN ROD AARON;;SCHWEDLER DEBORAH ANN;;XU XIOAPING;;CARR ANDREW WILLIAM;;SCHWAB GEORGE ERWIN,,https://lens.org/156-589-739-456-359,Patent Application,yes,0,1,3,3,7,C07K14/325;;C12N15/8286;;Y02A40/146;;C12N15/8286;;C07K14/325,A01N37/18;;A01P7/04;;C07K14/32,514/4.5;;530/350,3,3,039-124-626-540-421;;054-539-313-560-243;;029-315-305-449-378,10.1038/90282;;11433280;;pmc123759;;11872461;;10.1128/aem.68.3.1137-1145.2002;;10.1128/jb.172.12.6759-6763.1990;;2254252;;pmc210790,"Moellenbeck et al (2001, Nature Biotechnol. 19:668-672);;Ellis et al (2002, Appl. Environ. Microbiol. 68:1137-1145);;Clark et al (1990, J. Bacteriol. 172:6759-6763)",INACTIVE
128,DE,D1,DE 69607711 D1,061-555-438-518-245,2000-05-18,2000,DE 69607711 T,1996-09-25,US 53475195 A,1995-09-27,Aminopropylbis(aminoethyl)etherzusammensetzungen zur Herstellung von Polyurethanen,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;VAN COURT CARR RICHARD;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,,https://lens.org/061-555-438-518-245,Granted Patent,no,0,0,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,EXPIRED
129,MX,A,MX 9604243 A,161-561-486-221-530,1998-04-30,1998,MX 9604243 A,1996-09-23,US 53475195 A,1995-09-27,AMINOPROPYLBIS(AMINOETHYL) ETHER COMPOSITIONS FOR THE PRODUCTION OF POLYURETHANES.,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition consisting essentially of a compound having the following formula I: (see formula) where R1 is hydrogen or a C1-C4 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; R2 is hydrogen or a C1-C6 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; and R3 and R4 are independently hidrogen or a C1-C10 linear or branched alkyl, hydroxyalkyl or aminoalkyl group which may contain ether functionally.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;CARR RICHARD VAN COURT;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,,https://lens.org/161-561-486-221-530,Patent Application,no,0,0,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,PENDING
130,KR,B1,KR 100215953 B1,074-707-660-868-109,1999-08-16,1999,KR 19960041969 A,1996-09-24,US 53475195 A,1995-09-27,AMINOPROPYLBIS(AMINOETHYL)ETHER COMPOSITIONS FOR THE PRODUCTION OF POLYURETHANES,"본 발명은 유기 폴리이소시아네이트와 폴리올을 발포제, 기포 안정화제 및 하기 화학식 1의 화합물을 주성분으로 하는 촉매 조성물의 존재하에서 반응시키는 것을 포함하는 폴리우레탄 포옴을 제조하는 방법에 관한 것이다: [화학식 1] 상기 식에서, R은 수소이거나, 또는 C1-C4의 선형 또는 분기된 알킬, 히드록시알킬 또는 아미노알길기이고: R는 수소이거나, 또는 C1-C6의 선형 또는 분지된 알길, 히드록시알킬 또는 아미노알킬기이고: R및 R는 각각 수소이거나, 또는 에테르 작용기를 포함할 수 있는 C1-C10의 선형 또는 분지된 알킬, 히드록시알킬 또는 아미노알킬기이다.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;VAN COURT CARR RICHARD;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,,https://lens.org/074-707-660-868-109,Granted Patent,no,0,0,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,EXPIRED
131,DE,T2,DE 69607711 T2,103-810-688-850-280,2000-08-03,2000,DE 69607711 T,1996-09-25,US 53475195 A,1995-09-27,Aminopropylbis(aminoethyl)etherzusammensetzungen zur Herstellung von Polyurethanen,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;VAN COURT CARR RICHARD;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,,https://lens.org/103-810-688-850-280,Granted Patent,no,0,0,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,EXPIRED
132,US,A,US 6051527 A,089-778-199-753-575,2000-04-18,2000,US 25131899 A,1999-02-17,US 25131899 A;;US 53475195 A,1995-09-27,Aminopropylbis(aminoethyl) ether compositions for the production of polyurethanes,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition consisting essentially of a compound having the following formula I: ##STR1## where R.sup.1 is hydrogen or a C1-C4 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; R.sup.2 is hydrogen or a C1-C6 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; and R.sup.3 and R.sup.4 are independently hydrogen or a C1-C10 linear or branched alkyl, hydroxyalkyl or aminoalkyl group which may contain ether functionality.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;CARR RICHARD VAN COURT;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,,https://lens.org/089-778-199-753-575,Granted Patent,yes,8,16,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,502/167;;502/200;;521/115;;521/116;;521/128;;521/129,0,0,,,,EXPIRED
133,BR,A,BR 9603847 A,164-648-171-892-074,1998-06-02,1998,BR 9603847 A,1996-09-23,US 53475195 A,1995-09-27,Processo e composições de éter amino-propil-bis(amino-etilico) para a produção de poliuretanos,,AIR PROD & CHEM,LISTEMANN MARK LEO;;SAVOCA ANN COATES LESCHER;;EMERICK JAMES STEPHEN;;VAN COURT CARR RICHARD;;UNDERWOOD RICHARD PAUL,,https://lens.org/164-648-171-892-074,Patent Application,no,0,0,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,EXPIRED
134,EP,B1,EP 0765892 B1,030-860-149-862-740,2000-04-12,2000,EP 96115409 A,1996-09-25,US 53475195 A,1995-09-27,Aminopropylbis(aminoethyl)ether compositions for the production of polyurethanes,,AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;VAN COURT CARR RICHARD;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,,https://lens.org/030-860-149-862-740,Granted Patent,yes,2,0,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,EXPIRED
135,US,A,US 5874483 A,081-821-406-475-599,1999-02-23,1999,US 53475195 A,1995-09-27,US 53475195 A,1995-09-27,Aminopropylbis (aminoethyl) ether compositions for the production of polyurethanes,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition consisting essentially of a compound having the following formula I: ##STR1## where R.sup.1 is hydrogen or a C1-C4 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; R.sup.2 is hydrogen or a C1-C6 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; and R.sup.3 and R.sup.4 are independently hydrogen or a C1-C10 linear or branched alkyl, hydroxyalkyl or aminoalkyl group which may contain ether functionality.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;CARR RICHARD VAN COURT;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,AIR PRODUCTS AND CHEMICALS INC (1995-09-27),https://lens.org/081-821-406-475-599,Granted Patent,yes,7,32,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,521/115;;521/116;;521/128;;521/129;;521/163;;521/164;;521/167,0,0,,,,EXPIRED
136,EP,A1,EP 0765892 A1,047-142-947-240-314,1997-04-02,1997,EP 96115409 A,1996-09-25,US 53475195 A,1995-09-27,Aminopropylbis(aminoethyl)ether compositions for the production of polyurethanes,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, a cell stabilizer and a catalyst composition consisting essentially of a compound having the following formula  I :
   where
 R 1  is hydrogen or a C1-C4 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; R 2  is hydrogen or a C1-C6 linear or branched alkyl, hydroxyalkyl or aminoalkyl group; and R 3  and R 4  are independently hydrogen or a C1-C10 linear or branched alkyl, hydroxyalkyl or aminoalkyl group which may contain ether functionality.",AIR PROD & CHEM,SAVOCA ANN COATES LESCHER;;UNDERWOOD RICHARD PAUL;;VAN COURT CARR RICHARD;;EMERICK JAMES STEPHEN;;LISTEMANN MARK LEO,,https://lens.org/047-142-947-240-314,Patent Application,yes,2,6,16,16,0,C08G18/1825;;C08G18/1833;;C08G2110/0083;;C08G2110/005;;C08G2110/0008;;C08G18/16;;C08G18/08;;C08G18/1825;;C08G18/1833;;C08G2110/005;;C08G2110/0008;;C08G2110/0083,B01J31/02;;C08G18/18;;C08G18/22;;C08G18/24;;C08G18/32;;C08G101/00,,0,0,,,,EXPIRED
137,EP,A1,EP 2304688 A1,078-181-776-242-273,2011-04-06,2011,EP 09753641 A,2009-05-20,EP 2009003612 W;;IE 20080422 A,2008-05-27,AUTOMATED BUILDING OUTLINE DETECTION,,TRINITY COLLEGE DUBLIN;;UNIV COLLEGE DUBLIN NAT UNIVERSITY OF IRELAND DUBLIN,HINKS TOMMY;;CARR HAMISH;;LAEFER DEBRA;;MORVAN YANN PIERRE JOSEPH;;O'SULLIVAN CAROL ANN;;TRUONG LINH HONG;;CERIBASI SEYIT,HOLGER FALTER MECHANISCHE ERFINDUNG (2011-06-08),https://lens.org/078-181-776-242-273,Patent Application,yes,0,1,3,3,0,G06T7/13;;G06T7/521;;G06T2207/10044;;G06T2207/20068;;G06T2207/30184,G06T7/00,,1,0,,,See references of WO 2009143986A1,ACTIVE
138,WO,A1,WO 2009/143986 A1,000-339-597-331-817,2009-12-03,2009,EP 2009003612 W,2009-05-20,IE 20080422 A,2008-05-27,AUTOMATED BUILDING OUTLINE DETECTION,"A method for detecting outlines of buildings from aerially acquired data comprising a plurality of points, each comprising an (x, y, z)-tuple, comprises defining a reference plane, dividing the reference plane into an array of bins and mapping each point of the laser data to a bin of the reference plane. A discrimination function is applied to each bin to provide a scalar value. Outlines of buildings and portions of buildings ar then determined from the scalar values. Specific discrimination functions are also described including ones that enable transformation of the data into a format compatible with computation modeling software.",TRINITY COLLEGE DUBLIN;;UNIV DUBLIN;;HINKS TOMMY;;CARR HAMISH;;LAEFER DEBRA;;MORVAN YANN PIERRE JOSEPH;;O'SULLIVAN CAROL ANN;;TRUONG LINH HONG;;CERIBASI SEYIT,HINKS TOMMY;;CARR HAMISH;;LAEFER DEBRA;;MORVAN YANN PIERRE JOSEPH;;O'SULLIVAN CAROL ANN;;TRUONG LINH HONG;;CERIBASI SEYIT,,https://lens.org/000-339-597-331-817,Patent Application,yes,0,13,3,3,0,G06T7/13;;G06T7/521;;G06T2207/10044;;G06T2207/20068;;G06T2207/30184,G06T7/00,,5,2,000-245-483-446-301;;140-863-557-409-445,10.1109/cvpr.2006.12;;10.1109/isvd.2007.40,"VERMA V; KUMAR R; HSU S: ""3D Building Detection and Modeling from Aerial LIDAR Data"", COMPUTER VISION AND PATTERN RECOGNITION, 2006 IEEE COMPUTER SOCIETY CO NFERENCE ON NEW YORK, NY, USA 17-22 JUNE 2006, 20060617 - 20060622 PISCATAWAY, NJ, USA,IEEE, vol. 2, 17 June 2006 (2006-06-17), pages 2213 - 2220, XP010923125, ISBN: 978-0-7695-2597-6;;REBECCA (O C) TSE; CHRIS GOLD; DAVE KIDNER ED - ANONYMOUS: ""Using the Delaunay Triangulation/ Voronoi Diagram to extract Building Information from Raw LIDAR Data"", VORONOI DIAGRAMS IN SCIENCE AND ENGINEERING, 2007. ISVD '07. 4TH INTERNATIONAL SYMPOSIUM ON, IEEE, PI, 1 July 2007 (2007-07-01), pages 222 - 229, XP031118997, ISBN: 978-0-7695-2869-4;;ABDULLATIF ALHARTHY, JAMES BETHEL: ""Heuristic Filtering and 3D Feature Extraction from LIDAR Data"", ISPRS COMMISSION III, SYMPOSIUM 2002, 9 September 2002 (2002-09-09) - 13 September 2002 (2002-09-13), Graz, Austria, XP002542676;;YU, X. AND HYYPPA, H. AND KAARTINEN, H. AND HYYPPA, J. AND AHOKAS, E. AND KAASALAINEN, S.: ""Applicability of first pulse derived digital terrain models for boreal forest studies"", WORKSHOP ON LASER SCANNING 2005, 12 September 2005 (2005-09-12) - 14 September 2005 (2005-09-14), Enschede, Netherlands, XP002542677;;KARSTEN JACOBSEN AND PETER LOHMANN: ""Segmented Filtering of Laser Scanner DSMs"", WORKSHOP 3-D RECONSTRUCTION FROM AIRBORNE LASERSCANNER AND INSAR DATA, 8 October 2003 (2003-10-08) - 10 October 2003 (2003-10-10), Dresden, Germany, XP002542678",PENDING
139,EP,B1,EP 2304688 B1,031-758-854-292-961,2012-10-03,2012,EP 09753641 A,2009-05-20,EP 2009003612 W;;IE 20080422 A,2008-05-27,AUTOMATED BUILDING OUTLINE DETECTION,,HOLGER FALTER MECHANISCHE ERFINDUNGEN,HINKS TOMMY;;CARR HAMISH;;LAEFER DEBRA;;MORVAN YANN PIERRE JOSEPH;;O'SULLIVAN CAROL ANN;;TRUONG LINH HONG;;CERIBASI SEYIT,HOLGER FALTER MECHANISCHE ERFINDUNG (2011-06-08),https://lens.org/031-758-854-292-961,Granted Patent,yes,0,3,3,3,0,G06T7/13;;G06T7/521;;G06T2207/10044;;G06T2207/20068;;G06T2207/30184,G06T7/00,,5,0,,,"VERMA V; KUMAR R; HSU S: ""3D Building Detection and Modeling from Aerial LIDAR Data"" COMPUTER VISION AND PATTERN RECOGNITION, 2006 IEEE COMPUTER SOCIETY CO NFERENCE ON NEW YORK, NY, USA 17-22 JUNE 2006, 20060617 - 20060622 PISCATAWAY, NJ, USA,IEEE, vol. 2, 17 June 2006 (2006-06-17), pages 2213-2220, XP010923125 ISBN: 978-0-7695-2597-6;;REBECCA (O C) TSE; CHRIS GOLD; DAVE KIDNER ED - ANONYMOUS: ""Using the Delaunay Triangulation/ Voronoi Diagram to extract Building Information from Raw LIDAR Data"" VORONOI DIAGRAMS IN SCIENCE AND ENGINEERING, 2007. ISVD '07. 4TH INTERNATIONAL SYMPOSIUM ON, IEEE, PI, 1 July 2007 (2007-07-01), pages 222-229, XP031118997 ISBN: 978-0-7695-2869-4;;ABDULLATIF ALHARTHY, JAMES BETHEL: ""Heuristic Filtering and 3D Feature Extraction from LIDAR Data"" ISPRS COMMISSION III, SYMPOSIUM 2002, 9 September 2002 (2002-09-09), - 13 September 2002 (2002-09-13) XP002542676 Graz, Austria;;YU, X. AND HYYPPA, H. AND KAARTINEN, H. AND HYYPPA, J. AND AHOKAS, E. AND KAASALAINEN, S.: ""Applicability of first pulse derived digital terrain models for boreal forest studies"" WORKSHOP ON LASER SCANNING 2005, 12 September 2005 (2005-09-12), - 14 September 2005 (2005-09-14) XP002542677 Enschede, Netherlands;;KARSTEN JACOBSEN AND PETER LOHMANN: ""Segmented Filtering of Laser Scanner DSMs"" WORKSHOP 3-D RECONSTRUCTION FROM AIRBORNE LASERSCANNER AND INSAR DATA, 8 October 2003 (2003-10-08), - 10 October 2003 (2003-10-10) XP002542678 Dresden, Germany",ACTIVE
140,US,A1,US 2019/0307390 A1,022-354-958-799-313,2019-10-10,2019,US 201916379290 A,2019-04-09,US 201916379290 A;;US 201862654665 P,2018-04-09,DEVICE AND METHOD FOR DETECTING DISEASE STATES ASSOCIATED WITH LIPOPIGMENTS,Systems and methods for measuring autofluorescent signals from lipopigments associated with various disease states are disclosed.,MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,BAWENDI MOUNGI G;;JAIN RAKESH;;BRUNS OLIVER THOMAS;;CARR JESSICA ANN;;VAN LEYEN KLAUS;;KWANTEN WILHELMUS;;CHEN IVY XIAOYU,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2019-07-03);;THE GENERAL HOSPITAL CORPORATION (2019-05-22),https://lens.org/022-354-958-799-313,Patent Application,yes,9,2,6,6,0,A61B5/4842;;A61B5/4244;;A61B5/0071;;A61B5/742;;A61B2503/40;;A61B2576/00;;G16H30/40;;G01J3/2823;;G01J3/4406;;A61B2503/40;;A61B5/742;;A61B5/0071;;A61B5/4842;;A61B5/4244,A61B5/00;;G01J3/28;;G01J3/44,,4,4,054-787-877-024-596;;040-368-528-149-820;;141-942-007-617-444;;102-804-840-164-190,28857464;;10.1002/cyto.a.23199;;10.4081/ejh.2014.2461;;25578980;;pmc4289852;;10.1002/jbio.201500271;;26576035;;15189097;;10.1117/1.1688812,"Shilova ON, Shilov ES, Deyev SM. The effect of Trypan blue treatment on autofluorescence of fixed cells. Cytometry A. 2017; 91A: 917– 25. https://doi.org/10.1002/cyto.a.23199. (Year: 2017);;CROCE et al., Autofluorescence spectroscopy and imaging: a tool for biomedical research and diagnosis. Eur J Histochem. 2014 Dec 12;58(4):2461 (320-337). doi: 10.4081/ejh.2014.2461. (Year: 2014);;del Rosal, B., Villa, I., Jaque, D. and Sanz-Rodríguez, F. (2016), In vivo autofluorescence in the biological windows: the role of pigmentation. J. Biophoton, 9: 1059-1067. https://doi.org/10.1002/jbio.201500271. (Year: 2016);;Demos, Stavros & Gandour-Edwards, Regina & Ramsamooj, Rajen & White, Ralph. (2004). Near-infrared autofluorescence imaging for detection of cancer. Journal of biomedical optics. 9. 587-92. 10.1117/1.1688812. (Year: 2004)",DISCONTINUED
141,EP,A1,EP 3775852 A1,128-872-298-896-671,2021-02-17,2021,EP 19784535 A,2019-04-09,US 201862654665 P;;US 2019/0026550 W,2018-04-09,DEVICE AND METHOD FOR DETECTING DISEASE STATES ASSOCIATED WITH LIPOPIGMENTS,,MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,BAWENDI MOUNGI G;;JAIN RAKESH;;BRUNS OLIVER THOMAS;;CARR JESSICA ANN;;VAN LEYEN KLAUS;;KWANTEN WILHELMUS;;CHEN IVY XIAOYU,,https://lens.org/128-872-298-896-671,Patent Application,yes,0,0,6,6,0,A61B5/4842;;A61B5/4244;;A61B5/0071;;A61B5/742;;A61B2503/40;;A61B2576/00;;G16H30/40;;G01J3/2823;;G01J3/4406;;A61B2503/40;;A61B5/742;;A61B5/0071;;A61B5/4842;;A61B5/4244,G01N21/64,,0,0,,,,DISCONTINUED
142,US,S,US D0789236 S,089-597-413-566-103,2017-06-13,2017,US 201629588668 F,2016-12-22,US 201629588668 F;;US 201529518208 F,2015-02-20,Tag,,JOSTENS INC,BIBEAULT JOHN;;ARMUTLU MIRAN;;CARR ANN M;;SAARELA TIMOTHY D;;KARSKY KELLY L;;CINAR SAFAK;;FREIBERG JOHN A;;STEWART BLAINE,JOSTENS INC (2015-03-04),https://lens.org/089-597-413-566-103,Design Right,no,0,6,3,3,0,,,1101;;D11/79,0,0,,,,ACTIVE
143,US,S,US D0780042 S,164-173-031-636-101,2017-02-28,2017,US 201529518208 F,2015-02-20,US 201529518208 F,2015-02-20,Tag,,JOSTENS INC,BIBEAULT JOHN;;ARMUTLU MIRAN;;CARR ANN M;;SAARELA TIMOTHY D;;KARSKY KELLY L;;CINAR SAFAK;;FREIBERG JOHN A;;STEWART BLAINE,JOSTENS INC (2015-03-04),https://lens.org/164-173-031-636-101,Design Right,no,0,6,3,3,0,,,1101;;D11/79,0,0,,,,ACTIVE
144,CA,A1,CA 2142584 A1,165-853-824-449-731,1995-08-23,1995,CA 2142584 A,1995-02-15,US 19939694 A,1994-02-22,HYDROXY AND AMINO FUNCTIONAL PYRROLIZIDINE CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYURETHANES,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, cell stabilizer and a catalyst composition consisting essentially of a pyrrolizidine of the formula: , where R1 and R2 independently are -H, -OH, , , or -NR4R5, R3 is hydrogen, a C1-C12 alkyl, C5-C6 cycloalkyl, C6-C10 aryl, or C7-C11 arylalkyl group, and R4 and R5 independently represent H, a C1-C12 alkyl group, C5-C10 cycloalkyl, C6-C10 aryl, or C7-C11 arylalkyl group, provided that at least R1 or R2 is not hydrogen.",AIR PROD & CHEM,SAVOCA ANN C L;;WRESSELL AMY L;;LISTEMANN MARK L;;VAN COURT CARR RICHARD;;MERCANDO LISA A;;LASSILA KEVIN R;;MINNICH KRISTEN E,,https://lens.org/165-853-824-449-731,Patent Application,no,0,0,13,13,0,C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02;;C08G18/20;;C08J9/04;;C08G18/00;;C08G18/18;;C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02,C08G18/18;;C08G18/20,,0,0,,,,DISCONTINUED
145,US,B1,US 11754378 B1,013-036-626-510-093,2023-09-12,2023,US 201916399453 A,2019-04-30,US 201916399453 A;;US 201862664825 P,2018-04-30,Deployable flap for high-G maneuvers,"A tail for a projectile includes a body having a longitudinal axis. A steering assembly is secured to the body. The steering assembly includes a flap movable from a first position in which the flap does not extend radially beyond the body to a second position in which the flap extends radially beyond the body and at an angle relative to the longitudinal axis, and a flap release mechanism. A projectile including a tail according to the present disclosure is also provided.",CHARLES STARK DRAPER LABORATORY INC,THOREN GLENN RICHARD;;MCFARLAND WILLIAM WHITCOMB;;DEFRONZO REBECCA ANN;;BELLIO STEPHEN LOUIS;;CARR JESSE M;;DELISIO JEFFERY BRANDON;;FRITZ GREGORY M;;GEORGE SEAN,THE CHARLES STARK DRAPER LABORATORY INC (2022-04-13),https://lens.org/013-036-626-510-093,Granted Patent,yes,8,0,1,1,0,F42B10/14;;F42B10/64;;F42B15/01;;F42B10/14,F42B10/14,,0,0,,,,ACTIVE
146,US,A,US 5512603 A,083-966-697-421-063,1996-04-30,1996,US 19939694 A,1994-02-22,US 19939694 A,1994-02-22,Hydroxy and amino functional pyrrolizidine catalyst compositions for the production of polyurethanes,"A method for preparing a polyurethane foam which comprises reacting an organic polyisocyanate and a polyol in the presence of a blowing agent, cell stabilizer and a catalyst composition consisting essentially of a pyrrolizidine of the formula: ##STR1## where R.sub.1 and R.sub.2 independently are --H, --OH, ##STR2## or --NR.sub.4 R.sub.5, R.sub.3 is hydrogen, a C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.6 cycloalkyl, C.sub.6 -C.sub.10 aryl, or C.sub.7 -C.sub.11 arylalkyl group, and R.sub.4 and R.sub.5 independently represent H, a C.sub.1 -C.sub.12 alkyl group, C.sub.5 -C.sub.10 cycloalkyl, C.sub.6 -C.sub.10 aryl, or C.sub.7 -C.sub.11 arylalkyl group, provided that at least R.sub.1 or R.sub.2 is not hydrogen.",AIR PROD & CHEM,CARR RICHARD V C;;LASSILA KEVIN R;;LISTEMANN MARK L;;MERCANDO LISA A;;MINNICH KRISTEN E;;SAVOCA ANN C L;;WRESSELL AMY L,AIR PRODUCTS AND CHEMICALS INC (1994-03-25),https://lens.org/083-966-697-421-063,Granted Patent,yes,14,16,13,13,0,C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02;;C08G18/20;;C08J9/04;;C08G18/00;;C08G18/18;;C08G18/1825;;C08G18/2054;;C08G2101/00;;Y10S521/902;;C08G2115/02,C08G18/18;;C08G18/20,521/118;;521/129;;521/163;;521/166;;521/902;;528/54;;528/49;;528/73;;528/74;;528/85;;544/193;;544/222;;560/24;;560/25;;560/26;;560/115;;560/157;;560/158;;560/330;;560/355;;560/358;;564/32,0,0,,,,EXPIRED
147,EP,A1,EP 2256106 A1,045-170-319-886-54X,2010-12-01,2010,EP 10175329 A,2004-07-22,EP 04743512 A;;GB 0317127 A;;US 48904603 P;;US 56976304 P,2003-07-22,"3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators","The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dcpcndcnt kinase and glycogen synthase kinase-3.
  In formula (0): 
X is a group R 1 -A-NR 4 - or a 5- or 6-membered carbocyclic or heterocyclic ring; 
A is a bond, SO 2 , C=O, NR g (C=O) or O(C=O) wherein R g  is hydrogen or C 1-4  hydrocarbyl optionally substituted by hydroxy or C 1-4  alkoxy; 
Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; 
R 1  is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8  hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4  hydrocarbyloxy, amino, mono- or di-C 1-4  hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; 
R 2  is hydrogen; halogen; C 1-4  alkoxy (e.g. methoxy); or a C 1-4  hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4  alkoxy (e.g. methoxy); 
R 3  is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and 
R 4  is hydrogen or a C 1-4  hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4  alkoxy (e.g. methoxy).",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,"ASTEX THERAPEUTICS LIMITED, GB (2016-01-15);;ASTEX THERAPEUTICS LIMITED (2015-07-08)",https://lens.org/045-170-319-886-54X,Patent Application,yes,65,0,46,65,0,A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61P1/16;;A61P11/00;;A61P13/12;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D231/38;;C07D403/12;;A61K31/4155;;A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61K45/06,C07D231/38;;A61K31/4155;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/40;;C07D231/42;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,46,27,012-865-156-438-120;;001-661-891-531-467;;015-505-100-135-710;;051-255-997-632-880;;005-521-719-112-587;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;077-365-619-775-156;;004-137-705-827-976;;077-295-491-167-117;;046-777-072-258-96X;;007-378-255-811-868;;124-153-998-836-964;;056-848-802-620-026;;056-848-802-620-026;;011-674-727-534-32X;;050-476-538-810-273;;021-634-052-025-91X;;013-322-445-914-037;;143-158-089-688-29X;;037-370-591-087-508;;000-724-265-079-185;;019-078-987-150-365;;009-760-608-802-570;;027-745-118-667-14X;;007-421-226-677-859,7768349;;0007768349;;10.1096/fasebj.9.8.7768349;;10.1126/science.1862342;;0001862342;;1862342;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(93)90144-f;;8387896;;pmc395100;;8194527;;10.1002/j.1460-2075.1994.tb06519.x;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;10.1002/0471220574;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1074/jbc.m313407200;;14701826;;10.1038/nature02313;;14999283;;10.1038/nature02313;;14999283;;12183400;;10.1016/0076-6879(87)52071-7;;3657592;;10.1385/1-59259-760-2:077;;15064486;;10733493;;10.1016/s1525-1578(10)60494-1;;15096562;;pmc1867470;;14633913;;10.1373/clinchem.2003.024695;;10667604;;7805863;;10.1016/0014-5793(94)01298-9;;10559988;;010559988;;10.1038/15674;;12501191;;10.1021/bi0268910;;9692848;;10.1016/s0022-1759(98)00028-3,"HARDIE, G.; HANKS, S.: ""The Protein Kinase Facts Book. I and II"", 1995, ACADEMIC PRESS;;HANKS, S.K.; HUNTER, T., FASEB J., vol. 9, 1995, pages 576 - 596;;KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596;;GARCIA-BUSTOS ET AL., EMBO J., vol. 13, 1994, pages 2352 - 2361;;JERRY MARCH: ""Advanced Organic Chemistry, 4th Edition,"", 1992, WILEY INTERSCIENCE, pages: 131 - 133;;P. HEINRICH STAHL,CAMILLE G. WERMUTH: ""Pharmaceutical Salts: Properties, Selection, and Use"", August 2002, pages: 388;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Advanced Organic Chemistry"", WILEY INTERSCIENCE;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry, 4th Edition,"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN; INGOLD; PRELOG, ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415;;SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;JERRY MARCH: ""Advanced Organic Chemistry, 4th Edition,"", 1992, JOHN WILEY & SONS;;JEREMIAH P. FREEMAN: ""Organic Syntheses"", vol. 1-8, 1995, JOHN WILEY;;JERRY MARCH: ""Advanced Organic Chemistry, 4th Edition"", 1992, JOHN WILEY & SONS, pages: 898 - 900;;JERRY MARCH: ""Advanced Organic Chemistry, 4th edition,"", 1992, JOHN WILEY & SONS, pages: 723;;MARY FIESER: ""Fiesers' Reagentsfor Organic Synthesis"", vol. 1-17, JOHN WILEY;;SCHMIDT, HELV. CHIM. ACTA., vol. 39, 1956, pages 986 - 991;;HELV. CHIM. ACTA., vol. 41, 1958, pages 306 - 309;;T. GREEN; P. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;ROSENTRETER U; HUBER U.: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9;;HARWELL RM; MULL BB; PORTER DC; KEYOMARSI K., J BIOL CHEM., vol. 279, no. 13, 26 March 2004 (2004-03-26), pages 12695 - 705;;RAJAGOPALAN H; JALLEPALLI PV; RAGO C; VELCULESCU VE; KINZLER KW; VOGELSTEIN B; LENGAUER C., NATURE, vol. 428, no. 6978, 4 March 2004 (2004-03-04), pages 77 - 81;;RAJAGOPALAN ET AL., NATURE, vol. 428, no. 6978, 4 March 2004 (2004-03-04), pages 77 - 81;;SPRUCK ET AL., CANCER RES., vol. 62, no. 16, 15 August 2002 (2002-08-15), pages 4535 - 9;;AUSUBEL, F.M. ET AL.,: ""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC.;;INNIS, M.A. ET-AL.,: ""PCR Protocols: a guide to methods and applications"", 1990, ACADEMIC PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;AUSUBEL, F.M. ET AL: ""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC;;JOHN M. S. BARTLETT: ""Molecular Diagnosis of Cancer, Methods and Protocols, 2nd ed.;"", March 2004, article ""Fluorescence In Situ Hybridization: Technical Overview"", pages: 077 - 088;;YATABE ET AL., BLOOD., vol. 95, no. 7, 1 April 2000 (2000-04-01), pages 2253 - 61;;JONES ET AL., J MOL DIAGN., vol. 6, no. 2, May 2004 (2004-05-01), pages 84 - 9;;HOWE ET AL., CLIN CHEM., vol. 50, no. 1, January 2004 (2004-01-01), pages 80 - 7;;HARWELL ET AL., CANCER RES, vol. 60, 2000, pages 481 - 489;;HELLMICH ET AL., FEBS LETT, vol. 356, 1994, pages 317 - 21;;BROWN ET AL., NAT. CELL BIOL., vol. 1, 1999, pages 438 - 443;;LOWE, E.D. ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 15625 - 15634;;NOCIARI, M. M; SHALEV, A.; BENIAS, P.; RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, 1998, pages 157 - 167",ACTIVE
148,US,A1,US 2021/0065292 A1,092-472-582-499-22X,2021-03-04,2021,US 202017000669 A,2020-08-24,US 202017000669 A;;US 201962894082 P,2019-08-30,ENHANCED EDUCATION AND COMPETITIVE REWARD TOOLS FOR RESOURCE ACCOUNTS,"The present disclosure embraces a system, methods and computer program products for the intelligent on-boarding, support, education of non-conventional resource account users. In particular, the present disclosure includes tools for aggregation and intelligent data sharing between multiple users and associated resource accounts in order to generate a comparison between resource accounts and identify and incentivize potential earning opportunities. The competitive comparison may be continuously updated as earning opportunities are completed by the various users, and educational modules are provided via a resource account interface related to various topics of resource management responsibility for guided and reinforced learning.",BANK OF AMERICA,LILLIE CHRISTINA ANN;;BURRELL CHARLES JASON;;CARR SARA SUZANNE;;COOK JANE ELIZABETH;;DUPONT JUSTIN RILEY;;GUPTA KAJAL;;HOLLAND BRADLEY RYAN;;HUGGINS ROBERT NYELAND;;SIDDIQUI KASHIF M,BANK OF AMERICA CORPORATION (2020-06-18),https://lens.org/092-472-582-499-22X,Patent Application,yes,0,1,3,3,0,G06Q30/0215;;G06Q30/0631;;G06Q10/063114;;G06Q40/02;;G06Q30/0185;;G06Q30/0203;;G06Q10/06316;;G06Q40/06;;G06Q10/10;;G06Q50/205;;G09B5/06;;G06N20/00;;A63F13/352;;A63F13/85;;G06F9/50;;G09B19/00;;G06Q20/2295;;G06Q10/063114;;G06Q40/06;;G06Q10/06316;;G06Q20/405;;G06Q30/0215;;G06Q30/0203;;G06Q50/205;;G06N20/00;;G06F3/04842;;G06Q30/0631;;G06Q30/0185;;G06Q20/363;;G06Q20/204;;G06Q20/3278;;G06Q40/02;;A63F13/352;;A63F13/5255;;G06F16/906;;G06F16/9035;;G06F9/5011;;G09B7/06;;G06Q10/10;;G09B19/18;;G09B5/06,G06Q40/02;;G06F3/0484;;G06Q10/10;;G09B19/18,,0,0,,,,DISCONTINUED
149,US,A1,US 2021/0064663 A1,041-229-780-314-089,2021-03-04,2021,US 202017000710 A,2020-08-24,US 202017000710 A;;US 201962894082 P,2019-08-30,SYSTEMS AND METHODS FOR COLLABORATIVE RESOURCE ACTIONS BETWEEN RESOURCE ACCOUNTS,"The present disclosure embraces a system, methods and computer program products for the intelligent on-boarding, support, education of supervised resource account users. The systems described herein allow for intelligent linkage of supervised resource accounts with existing accounts of a supervising user, creating tools for enhanced transfer of resources to a supervised user. The system offers interactivity and education opportunity along with resource transfers by determining resource allocation recommendations and providing goal-tracking capabilities.",BANK OF AMERICA,LILLIE CHRISTINA ANN;;BURRELL CHARLES JASON;;CARR SARA SUZANNE;;COOK JANE ELIZABETH;;DUPONT JUSTIN RILEY;;GUPTA KAJAL;;HOLLAND BRADLEY RYAN;;HUGGINS ROBERT NYELAND;;SIDDIQUI KASHIF M,BANK OF AMERICA CORPORATION (2020-06-18),https://lens.org/041-229-780-314-089,Patent Application,yes,5,1,3,3,0,G06Q30/0215;;G06Q30/0631;;G06Q10/063114;;G06Q40/02;;G06Q30/0185;;G06Q30/0203;;G06Q10/06316;;G06Q40/06;;G06Q10/10;;G06Q50/205;;G09B5/06;;G06N20/00;;A63F13/352;;A63F13/85;;G06F9/50;;G09B19/00;;G06Q20/2295;;G06Q10/063114;;G06Q40/06;;G06Q10/06316;;G06Q20/405;;G06Q30/0215;;G06Q30/0203;;G06Q50/205;;G06N20/00;;G06F3/04842;;G06Q30/0631;;G06Q30/0185;;G06Q20/363;;G06Q20/204;;G06Q20/3278;;G06Q40/02;;A63F13/352;;A63F13/5255;;G06F16/906;;G06F16/9035;;G06F9/5011;;G09B7/06;;G06Q10/10;;G09B19/18;;G09B5/06,G06F16/9035;;A63F13/352;;A63F13/5255;;G06F9/50;;G06F16/906;;G09B7/06,,0,0,,,,PENDING
150,US,A1,US 2021/0065576 A1,097-144-426-931-315,2021-03-04,2021,US 202017000624 A,2020-08-24,US 202017000624 A;;US 201962894082 P,2019-08-30,SYSTEMS AND METHODS FOR GUIDED CREATION AND DEVELOPMENT OF SUPERVISED USER RESOURCE ACCOUNTS,"The present disclosure embraces a system, methods and computer program products for the intelligent onboarding, support, education of supervised resource account users. The system, methods, and computer program products provide innovative tools for the development and management of supervised user resource accounts by a supervising user, and various embodiments providing unique pathways for resource management and education via the use of the disclosed resource management system.",BANK OF AMERICA,LILLIE CHRISTINA ANN;;BURRELL CHARLES JASON;;CARR SARA SUZANNE;;COOK JANE ELIZABETH;;DUPONT JUSTIN RILEY;;GUPTA KAJAL;;HOLLAND BRADLEY RYAN;;HUGGINS ROBERT NYELAND;;SIDDIQUI KASHIF M,BANK OF AMERICA CORPORATION (2020-06-18),https://lens.org/097-144-426-931-315,Patent Application,yes,5,3,3,3,0,G06Q30/0215;;G06Q30/0631;;G06Q10/063114;;G06Q40/02;;G06Q30/0185;;G06Q30/0203;;G06Q10/06316;;G06Q40/06;;G06Q10/10;;G06Q50/205;;G09B5/06;;G06N20/00;;A63F13/352;;A63F13/85;;G06F9/50;;G09B19/00;;G06Q20/2295;;G06Q10/063114;;G06Q40/06;;G06Q10/06316;;G06Q20/405;;G06Q30/0215;;G06Q30/0203;;G06Q50/205;;G06N20/00;;G06F3/04842;;G06Q30/0631;;G06Q30/0185;;G06Q20/363;;G06Q20/204;;G06Q20/3278;;G06Q40/02;;A63F13/352;;A63F13/5255;;G06F16/906;;G06F16/9035;;G06F9/5011;;G09B7/06;;G06Q10/10;;G09B19/18;;G09B5/06,G09B19/00;;G06F3/0484;;G06N20/00;;G06Q10/06;;G06Q20/40;;G06Q30/02;;G06Q40/02;;G06Q40/06;;G06Q50/20,,0,0,,,,DISCONTINUED
151,PL,T3,PL 2256106 T3,121-954-690-871-676,2015-08-31,2015,PL 10175329 T,2004-07-22,GB 0317127 A;;US 48904603 P;;US 56976304 P;;EP 10175329 A;;EP 04743512 A,2003-07-22,"3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators",,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM;;O'BRIEN MICHAEL ALISTAIR,,https://lens.org/121-954-690-871-676,Patent Application,no,0,0,46,65,0,A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61P1/16;;A61P11/00;;A61P13/12;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D231/38;;C07D403/12;;A61K31/4155;;A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61K45/06,C07D231/38;;A61K31/4155;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/40;;C07D231/42;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,PENDING
152,CY,T1,CY 1116298 T1,157-655-142-272-978,2017-02-08,2017,CY 151100448 T,2015-05-18,EP 10175329 A;;GB 0317127 A;;US 48904603 P;;US 56976304 P,2003-07-22,"ΕΝΩΣΕΙΣ 3,4-ΔΙΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ 1Η-ΠΥΡΑΖΟΛΙΟΥ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΩΣ ΡΥΘΜΙΣΤΕΣ ΚΙΝΑΣΩΝ ΠΟΥ ΕΞΑΡΤΩΝΤΑΙ ΑΠΟ ΚΥΚΛΙΝΗ (CDK) ΚΑΙ ΚΙΝΑΣΗΣ-3 ΣΥΝΘΑΣΗΣ ΓΛΥΚΟΓΟΝΟΥ (GSK-3)","Η εφεύρεση παρέχει ενώσεις του τύπου (0) ή άλατα ή ταυτομερή ή Ν-οξείδια ή διαλυτώματα αυτών για χρήση στην προφύλαξη ή τη θεραπεία καταστάσεων ασθένειας και καταστάσεων όπως καρκίνων που προκαλούνται από κινάση εξαρτώμενη από κυκλίνη και κινάση-3 συνθάσης γλυκογόνου. Στον τύπο (0): το Χ είναι μια ομάδα R1A-NR4 ή 5-μελής ή 6-μελής καρβοκυκλικός ή ετεροκυκλικός δακτύλιος· το Α είναι δεσμός, SO2, C=O, NRg(C=O) ή O(C=O), όπου το Rg είναι υδρογόνο ή C1-4 υδροκαρβύλ προαιρετικά υποκατεστημένο με υδρόξυ ή C1-4 αλκόξυ· το Υ είναι ένας δεσμός ή αλκυλένο άλυσος μήκους 1, 2 ή 3 ατόμων άνθρακα · το R1 είναι υδρογόνο, καρβοκυκλική ή ετεροκυκλική ομάδα έχουσα από 3 έως 12 μέλη στον δακτύλιο· ή C1-8 υδροκαρβύλ ομάδα προαιρετικώς υποκατεστημένη με έναν ή περισσότερους υποκατάστατες επιλεγόμενους από αλογόνο (π.χ. φθόριο), υδρόξυ, C1-4 υδροκαρβυλόξυ, άμινο, μονο- ή δι-C1-4 υδροκαρβυλάμινο και καρβοκυκλικές ή ετεροκυκλικές ομάδες που έχουν από 3 έως 12 μέλη στον δακτύλιο και όπου 1 ή 2 από τα άτομα άνθρακα της υδροκαρβύλ ομάδας μπορεί προαιρετικά να αντικαθίστανται με ένα άτομο ή ομάδα επιλεγόμενη από Ο, S, ΝΗ, SO, SO2· το R2 είναι υδρογόνο· αλογόνο· C1-4 αλκόξυ (π.χ. μεθόξυ)· ή C1-4 υδροκαρβύλ ομάδα προαιρετικά υποκατεστημένη με αλογόνο (π.χ. φθόριο), υδροξύλ ή C1-4 αλκόξυ (π.χ. μεθόξυ) · το R3 επιλέγεται από υδρογόνο και καρβοκυκλικές και ετεροκυκλικές ομάδες που έχουν από 3 έως 12 μέλη στον δακτύλιο· και το R4 είναι υδρογόνο ή C1-4 υδροκαρβύλ ομάδα προαιρετικά υποκατεστημένη με αλογόνο (π.χ. φθόριο), υδροξύλ ή C1-4 αλκόξυ (π.χ. μεθόξυ).",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/157-655-142-272-978,Granted Patent,no,0,0,46,65,0,A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61P1/16;;A61P11/00;;A61P13/12;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D231/38;;C07D403/12;;A61K31/4155;;A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61K45/06,C07D231/38;;A61K31/4155;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/40;;C07D231/42;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,ACTIVE
153,ES,T3,ES 2539480 T3,047-724-840-566-322,2015-07-01,2015,ES 10175329 T,2004-07-22,GB 0317127 A;;US 48904603 P;;US 56976304 P,2003-07-22,"Compuestos 1H-pirazol 3,4-disustituidos y su uso como moduladores de las quinasas dependientes de ciclina (CDK) y glucógeno sintasa quinasa-3 (GSK-3)","The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R1-A-NR4-or a 5-or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/047-724-840-566-322,Granted Patent,no,0,0,19,65,0,C04B35/632;;C07D231/14;;C07D231/38;;C07D231/40;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,C07D231/38;;A61K31/4155;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/40;;C07D231/42;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,ACTIVE
154,DK,T3,DK 2256106 T3,042-331-683-927-497,2015-06-01,2015,DK 10175329 T,2004-07-22,GB 0317127 A;;US 48904603 P;;US 56976304 P;;EP 04743512 A,2003-07-22,"3,4-disubstituterede 1 H-pyrazolforbindelser og anvendelse heraf som cyclin-afhængige kinaser (CDK) og glycogensyntase kinase-3- (GSK-3) modulatorer","The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R1-A-NR4-or a 5-or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM;;O'BRIEN MICHAEL ALISTAIR;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY,,https://lens.org/042-331-683-927-497,Granted Patent,no,0,0,19,65,0,C04B35/632;;C07D231/14;;C07D231/38;;C07D231/40;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,C07D231/38;;A61K31/4155;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/40;;C07D231/42;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,ACTIVE
155,EP,B1,EP 2256106 B1,050-491-581-784-15X,2015-05-06,2015,EP 10175329 A,2004-07-22,EP 04743512 A;;GB 0317127 A;;US 48904603 P;;US 56976304 P,2003-07-22,"3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators",,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,"ASTEX THERAPEUTICS LIMITED, GB (2016-01-15);;ASTEX THERAPEUTICS LIMITED (2015-07-08)",https://lens.org/050-491-581-784-15X,Granted Patent,yes,5,0,46,65,0,A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61P1/16;;A61P11/00;;A61P13/12;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D231/38;;C07D403/12;;A61K31/4155;;A61K31/4152;;A61K31/416;;A61K31/454;;C04B35/632;;C07D231/14;;C07D231/40;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04;;C07D231/38;;C07D401/12;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/4196;;A61K31/4439;;A61K31/496;;A61K31/5377;;A61K31/541;;A61K45/06,C07D231/38;;A61K31/4155;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/40;;C07D231/42;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,ACTIVE
156,PT,E,PT 2256106 E,190-868-317-857-085,2015-07-22,2015,PT 10175329 T,2004-07-22,GB 0317127 A;;US 48904603 P;;US 56976304 P,2003-07-22,"3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS","The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R1-A-NR4-or a 5-or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;WYATT PAUL GRAHAM;;CARR MARIA GRAZIA;;WOODHEAD ANDREW JAMES;;O'BRIEN MICHAEL ALISTAIR;;EARLY THERESA RACHEL;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;GILL ADRIAN LIAM,,https://lens.org/190-868-317-857-085,Granted Patent,no,0,0,19,65,0,C04B35/632;;C07D231/14;;C07D231/38;;C07D231/40;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,C07D231/38;;A61K31/4155;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/40;;C07D231/42;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,ACTIVE
157,HU,T2,HU E025425 T2,020-581-628-370-976,2016-02-29,2016,HU E10175329 A,2004-07-22,GB 0317127 A;;US 48904603 P;;US 56976304 P,2003-07-22,"3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators","The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R1-A-NR4-or a 5-or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/020-581-628-370-976,Amended Patent,no,0,0,19,65,0,C04B35/632;;C07D231/14;;C07D231/38;;C07D231/40;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D231/14;;C07D231/38;;C07D231/40;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,PENDING
158,SI,T1,SI 2256106 T1,145-516-290-979-339,2015-10-30,2015,SI 200432244 T,2004-07-22,GB 0317127 A;;US 48904603 P;;US 56976304 P;;EP 10175329 A,2003-07-22,"3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators","The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R1-A-NR4-or a 5-or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/145-516-290-979-339,Granted Patent,no,0,0,19,65,0,C04B35/632;;C07D231/14;;C07D231/38;;C07D231/40;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/12;;C07D409/14;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,C07D231/00;;A61K31/00;;A61P25/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/00;;A61P37/00;;A61P37/00;;C07D231/14;;C07D231/38;;C07D231/40;;C07D401/00;;C07D401/12;;C07D401/14;;C07D403/00;;C07D403/04;;C07D403/12;;C07D405/00;;C07D405/12;;C07D405/14;;C07D409/00;;C07D409/12;;C07D409/14;;C07D413/00;;C07D413/12;;C07D413/14;;C07D453/02;;C07D471/04,,0,0,,,,ACTIVE
159,MX,A,MX 9704993 A,057-867-396-923-813,1998-06-28,1998,MX 9704993 A,1996-10-30,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 9617512 W,1995-10-30,METHOD OF INHIBITING CATHEPSIN K.,"A novel cathepsin K crystalline structure is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial characteristics.",SMITHKLINE BEECHAM CORP,ABDEL-MEGUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERLY ANN;;MARQUIS ROBERT WELLS JR;;OH HYE-JA;;RU YU,,https://lens.org/057-867-396-923-813,Patent Application,no,0,0,1,133,0,,,,0,0,,,,DISCONTINUED
160,PT,E,PT 2332909 E,140-640-841-684-26X,2014-12-17,2014,PT 11158930 T,2006-04-13,GB 0507474 A;;GB 0604111 A;;US 67089705 P;;US 77798906 P,2005-04-13,HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90,,ASTEX THERAPEUTICS LTD,DOWNHAM ROBERT;;CARR MARIA GRAZIA;;WOODHEAD ANDREW JAMES;;FREDERICKSON MARTYN;;CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;MURRAY CHRISTOPHER;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOOLFORD ALISON JO-ANN,,https://lens.org/140-640-841-684-26X,Granted Patent,no,0,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,ACTIVE
161,EP,A1,EP 2332909 A1,191-593-068-862-970,2011-06-15,2011,EP 11158930 A,2006-04-13,EP 06726780 A;;GB 0507474 A;;US 67089705 P;;GB 0604111 A;;US 77798906 P,2005-04-13,HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90,"The invention provides compounds of the formula (I):
  or salts, tautomers, solvates and N-oxides thereof; wherein R 1  is hydroxy or hydrogen; R 2  is hydroxy; methoxy or hydrogen; provided that at least one of R 1  and R 2  is hydroxy; R 3  is selected from hydrogen; halogen; cyano; optionally substituted C 1-5  hydrocarbyl and optionally substituted C 1-5  hydrocarbyloxy; R 4  is selected from hydrogen; a group -(O) n -R 7  where n is 0 or 1 and R 7  is an optionally substituted acyclic C 1-5  hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C 1-5  hydrocarbylamino; or R 3  and R 4  together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR 5 R 6  forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The compounds have activity as Hsp90 inhibitors.",ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/191-593-068-862-970,Patent Application,yes,29,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,65,36,008-968-941-772-850;;101-631-109-622-640;;068-047-531-025-094;;070-356-442-220-390;;032-825-198-868-048;;161-692-168-115-484;;071-118-446-365-012;;000-233-270-280-143;;058-255-509-198-240;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;010-574-326-166-138;;004-587-736-437-151;;051-425-933-870-758;;002-157-754-525-814;;076-399-046-817-556;;007-525-100-008-349;;127-128-134-410-477;;063-170-858-743-057;;027-388-435-789-527;;017-921-765-609-621;;082-375-881-737-34X;;077-365-619-775-156;;004-137-705-827-976;;064-792-862-161-861;;077-295-491-167-117;;046-777-072-258-96X;;007-378-255-811-868;;075-596-410-145-597;;050-476-538-810-273;;021-634-052-025-91X;;028-549-557-335-225;;164-621-541-384-297;;019-649-163-471-031;;007-421-226-677-859,10.1074/jbc.272.38.23843;;9295332;;10.1038/nature01913;;14508491;;15239664;;10.1021/jm0306125;;10.1093/jnci/92.19.1564;;11018092;;pmc480905;;15199125;;10.1128/mcb.24.13.5667-5676.2004;;14718169;;10.1016/s0092-8674(03)01027-4;;1694264;;10.1038/345672a0;;10.1016/0092-8674(95)90340-2;;7736582;;10.1126/science.7604285;;7604285;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;12351420;;10.1182/blood-2002-05-1361;;15150124;;10.1158/0008-5472.can-04-0006;;10.1038/nature00766;;12068308;;pmc1895907;;10.1182/blood-2005-03-1158;;16234364;;10.1093/hmg/10.12.1307;;11406612;;10.1016/j.bbrc.2004.05.214;;15240121;;12571865;;10.1002/art.10780;;10.1161/01.atv.0000147894.22300.4c;;pmc2633590;;15486309;;15199114;;10.1093/jnci/djh168;;15505117;;10.1161/01.hyp.0000147559.10261.a7;;pmc61144;;10.1073/pnas.241510898;;11707594;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;10.1021/cr00039a007;;10.1002/0471220574;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1023/b:pham.0000016235.32639.23;;15032302;;10.1016/0076-6879(87)52071-7;;3657592;;10.1385/1-59259-760-2:077;;15064486;;12725864;;10.1016/s1074-5521(03)00075-9;;14640663;;10.1021/ja036166s;;10625516;;10.1006/abio.1999.4402;;9692848;;10.1016/s0022-1759(98)00028-3,"GRENERT, J BIOL CHEM., vol. 272, 1997, pages 23834 - 23850;;KAMAL, NATURE, vol. 425, 2003, pages 407 - 410;;BRAZIDEC, J. MED. CHEM., vol. 47, 2004, pages 3865 - 3873;;JOLLY; MORIMOTO, JNCI, vol. 92, no. 19, 2000, pages 1564 - 1572;;GIANNINI ET AL., MOL CELL BIOL., vol. 24, no. 13, 2004, pages 5667 - 76;;ROE, CELL, vol. 116, 2004, pages 87 - 98;;JAN, L.Y.; JAN, Y.N.: ""A Superfamily of Ion Channels"", NATURE, vol. 345, no. 6277, 1990, pages 672;;SANGUINETTI, M.C.; JIANG, C.; CURRAN, M.E.; KEATING, M.T.: ""A Mechanistic Link Between an Inherited and an Acquired Cardiac Arrhythmia: HERG encodes the Ikr potassium channel"", CELL, vol. 81, 1995, pages 299 - 307;;TRUDEAU, M.C.; WARMKE, J.W.; GANETZKY, B.; ROBERTSON, G.A: ""HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family"", SCIENCE, vol. 269, 1995, pages 92 - 95;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, WILEY, pages: 131 - 133;;""Pharmaceutical Salts: Properties, Selection, and Use"", August 2002, pages: 388;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;JERRY MARCH: ""Advanced Organic Chemistry"", WILEY INTERSCIENCE;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN, INGOLD; PRELOG, ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415;;GORRE, BLOOD, vol. 100, 2002, pages 3041 - 3044;;BALI, CANCER RES., vol. 64, no. 10, 2004, pages 3645 - 52;;BIGNELL, NATURE, vol. 417, no. 6892, 2002, pages 949 - 54;;MITSIADES, BLOOD, vol. 107, 2006, pages 1092 - 1100;;SITTLER, HUMAN MOLECULAR GENETICS, vol. 10, no. 12, 2001, pages 1307 - 1315;;IANARO ET AL., 2004 HUMAN MOLECULAR GENETICS, vol. 10, no. 12, 2001, pages 1307 - 1315;;YEO, BIOCHEM BIOPHYS RES COMMUN., vol. 320, no. 3, 2004, pages 816 - 24;;WAX, RHEUMATISM, vol. 48, no. 2, 2003, pages 541 - 550;;SUN; LIAO, ARTERIOSCLER THROMB VASE BIOL., vol. 24, no. 12, 2004, pages 2238 - 44;;STOELTZING, J NATL CANCER INST, vol. 96, 2004, pages 946 - 956;;LIN, J CELL BIOCHEM., vol. 94, no. 1, 2005, pages 194 - 201;;KOBAYASHI, HYPERTENSION, vol. 44, no. 6, 2004, pages 956 - 62;;WHITNEY, PROC NATL ACAD SCI U S A., vol. 98, no. 24, 2001, pages 13931 - 5;;KAMA, MALAR J., vol. 2, no. 1, 2003, pages 30;;JERRY MARCH: ""Advanced Organic Chemistry"", WILEY INTERSCIENCE, pages: 119;;""Fiesers' Reagents for Organic Synthesis"", vol. 1-17, JOHN WILEY;;""Organic Syntheses"", vol. 1-8, JOHN WILEY;;SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;SYNTHESIS, 1991, pages 469;;PIERFAUSTO SENECI: ""Solid-Phase Synthesis and Combinatorial Technologies"", 2000, WILEY-INTERSCIENCE, pages: XII,637;;J CHEM SOC, CHEM COMMUN, 1985, pages 1134;;J. IND. CHEM. SOC., vol. 30, 1953, pages 269;;""Advanced Organic Chemistry"", WILEY INTERSCIENCE, pages: 119;;J. CHEM. SOC, PERKIN TRANS, vol. 1, 1981, pages 897;;JERRY MARCH: ""Advanced Organic Chemistry"", vol. 119, WILEY INTERSCIENCE;;J. AM. CHEM. SOC., 2003, pages 11148;;N. MIYAURA; A. SUZUKI, CHEM. REV., vol. 95, 1995, pages 2457;;""Fiesers' Reagentsfor Organic Synthesis"", vol. 1-17, JOHN WILEY;;T. GREEN; P. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;ROSENTRETER U; HUBER U.: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9;;R. G. STRICKLY: ""Solubilizing Excipients in oral and injectable formulations"", PHARMACEUTICAL RESEARCH, vol. 21, no. 2, 2004, pages 201 - 230;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC.;;""PCR Protocols: a guide to methods and applications"", 1990, ACADEMIC PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC;;JOHN M. S. BARTLETT: ""Molecular Diagnosis of Cancer, Methods and Protocols"", March 2004, article ""Fluorescence In Situ Hybridization: Technical Overview"", pages: 077 - 088;;DEPRIMO ET AL., BMC CANCER, vol. 3, 2003, pages 3;;TETRAHEDRON, vol. 59, 2003, pages 9173;;JEZ, J.M. ET AL., CHEM BIOL., vol. 10, no. 4, April 2003 (2003-04-01), pages 361 - 8;;TURNBULL W.B.; DARANAS A.H., J. AM. CHEM. SOC., vol. 125, no. 48, 3 December 2003 (2003-12-03), pages 14859 - 66;;SIGURSKJOLD B.W., ANAL BIOCHEM., vol. 277, no. 2, 15 January 2000 (2000-01-15), pages 260 - 6;;NOCIARI, M. M; SHALEV, A.; BENIAS, P.; RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, 1998, pages 157 - 167",ACTIVE
162,EP,B1,EP 2332909 B1,044-752-210-300-596,2014-10-15,2014,EP 11158930 A,2006-04-13,EP 06726780 A;;GB 0507474 A;;US 67089705 P;;GB 0604111 A;;US 77798906 P,2005-04-13,HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90,,ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/044-752-210-300-596,Granted Patent,yes,2,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,ACTIVE
163,DK,T3,DK 2332909 T3,039-319-138-637-021,2014-11-10,2014,DK 11158930 T,2006-04-13,GB 0507474 A;;US 67089705 P;;GB 0604111 A;;US 77798906 P;;EP 06726780 A,2005-04-13,HYDROXYBENZAMIDDERIVATER OG DERES ANVENDELSE SOM INHIBITORER AF HSP90,,ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/039-319-138-637-021,Granted Patent,no,0,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,ACTIVE
164,SI,T1,SI 2332909 T1,115-364-042-388-371,2015-01-30,2015,SI 200631846 T,2006-04-13,GB 0507474 A;;US 67089705 P;;GB 0604111 A;;US 77798906 P;;EP 11158930 A,2005-04-13,HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90,,ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/115-364-042-388-371,Granted Patent,no,0,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/00;;A61K31/00;;C07D215/00;;C07D401/00;;C07D471/00;;C07D491/00,,0,0,,,,ACTIVE
165,PL,T3,PL 2332909 T3,178-360-206-904-588,2015-01-30,2015,PL 11158930 T,2006-04-13,GB 0507474 A;;US 67089705 P;;GB 0604111 A;;US 77798906 P;;EP 11158930 A;;EP 06726780 A,2005-04-13,HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90,,ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/178-360-206-904-588,Patent Application,no,0,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,PENDING
166,CY,T1,CY 1115797 T1,001-040-756-653-873,2017-01-25,2017,CY 141100993 T,2014-11-27,EP 11158930 A;;GB 0507474 A;;US 67089705 A;;GB 0604111 A;;US 77798906 A,2005-04-13,ΠΑΡΑΓΩΓΑ ΥΔΡΟΞΥΒΕΝΖΑΜΙΔΙΟΥ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕIΣ ΤΗΣ HSP90,"Η εφεύρεση παρέχει ενώσεις του τύπου (I): ή άλατα, ταυτομερή, διαλυτώματα και Ν-οξείδια αυτής, όπου το R1 είναι υδροξύλιο ή υδρογόνο, το R2 είναι υδροξυ, μεθόξυ ή υδρογόνο, υπό την προϋπόθεση ότι τουλάχιστον ένα από τα R1 και R2 είναι υδρόξυ. To R3 επιλέγεται από υδρογόνο, αλογόνο, κυανό, προαιρετικά υποκατεστημένο C1-5 υδροκαρβύλιο και προαιρετικά υποκατεστημένο C1-5 υδροκαρβυλοξυ. To R4 επιλέγεται από υδρογόνο, μια ομάδα - (Ο) n-R 7, όπου το n είναι 0 ή 1 και το R7 είναι μία προαιρετικά υποκατεστημένη ακυκλική C1-5 ομάδα υδροκαρβυλίου ή μία μονοκυκλική καρβοκυκλική ή ετεροκυκλική ομάδα που έχει 3 έως 7 μέλη δακτυλίου, αλογόνο, κυανό, υδροξυ, αμινο, και προαιρετικώς υποκατεστημένο μονο- ή δι-C1-5 υδροκαρβυλαμινο, ή τα R3 και R4 μαζί σχηματίζουν ένα μονοκυκλικό καρβοκυκλικό ή ετεροκυκλικό δακτύλιο με 5 έως 7 μέλη δακτυλίου και το NR5R6 σχηματίζει μία προαιρετικώς υποκατεστημένη δικυκλική ετεροκυκλική ομάδα που έχει 8 έως 12 μέλη δακτυλίου εκ των οποίων έως 5 μέλη δακτυλίου είναι ετεροάτομα που επιλέγονται από οξυγόνο, άζωτο και θείο. Οι ενώσεις έχουν δραστικότητα ως αναστολείς της HSP90.",ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/001-040-756-653-873,Granted Patent,no,0,0,1,70,0,,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,ACTIVE
167,RS,B1,RS 53668 B1,023-421-351-083-312,2015-04-30,2015,RS P20140636 A,2006-04-13,GB 0507474 A;;GB 0604111 A;;US 67089705 P;;US 77798906 P,2005-04-13,HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90,"Jedinjenje formule (VII)ili njegova so, solvat, tautomer ili N-oksid;pri čemu n je 0, 1, 2 ili 3;R1 je hidroksi ili vodonik;R2a je hidroksi ili metoksi, uz uslov da je bar jedan od R1 i R2a hidroksi;R3 je izabran između vodonika; halogena; cijano; C1-5 hidrokarbila i C1-5 hidrokarbiloksila; pri čemu je svaki od C1-5 hidrokarbil i C1-5 hidrokarbiloksi radikala opciono supstituisan sa jednim ili više supstituenata izabranih između hidroksi, halogena, C1-2 alkoksi, amino, mono- i di- C1-2 alkilamino, i aril i heteroaril grupa sa 5 do 12 članova prstena;R4a je izabran između vodonika, fluora, hlora i metoksi;R8 je izabran između vodonika i fluora; iR10b je izabran iz grupe koja se sastoji od halogena, OH, NH2, CH2OH, CH2NH2, O- C1-6-alkila, NH- C1-6 alkila, arila, heteroarila, C3-7 cikloalkila, heterociklila, O-heteroarila, O- C3-7 cikloalkila, O-heterocikloalkila, C(=O) C1-6 alkila, C(=O)O C1-6 alkila, C(=O)NH2, C(=O)NH C1-6 alkila, C(=O)N(C1-6 alkila)2, NH(C1-6alkila), N(C1-6 alkila)2, NHC(=O) C1-6alkila, C6 arila, OC6 arila, C(=O)C6arila,-C(=O)OC6arila, C(=O)NH2, C(=O)NHC6arila, C(=O)N(C6 arila)2, NH(C6 arila), N(C6 arila)2, NHC(=O)C6 arila, C5-6 heterociklila, OC5-6 heterociklila, C(=O)C5-6 heterociklila, C(=O) OC5-6 heterociklila, C(=O)NHC5-6 heterociklila, C(=O)N(C5-6 heterociklila)2, NH(C5-6 heterociklila), N(C5-6 heterociklila)2, NHC(=O)C5-6 heterociklila, C(=O)NHC1-6 alkila, C5-6 arila, S(=O) C1-6alkila, S(=O)NH- C1-6alkila i SO2NH-C1-6alkila; i grupe [sol], CH2[sol] ili OCH2CH2[sol], pri čemu je [sol] izabran između sledećih grupaPrijava sadrži još 14 patentnih zahteva.",ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/023-421-351-083-312,Granted Patent,no,0,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,ACTIVE
168,ES,T3,ES 2523565 T3,074-196-010-974-688,2014-11-27,2014,ES 11158930 T,2006-04-13,GB 0507474 A;;US 67089705 P;;GB 0604111 A;;US 77798906 P,2005-04-13,Derivados de hidroxibenzamida y sus usos como inhibidores de la hsp90,"Un compuesto de la fórmula (VII): **Fórmula** o una sal, solvato, tautómero o N--oxido del mismo; en donde n es 0, 1, 2 o 3; R1 es hidroxi o hidrógeno; R2a es hidroxi o metoxi con la condición de que al menos uno de R1 y R2a es hidroxi; R3 es seleccionado de hidrógeno; halógeno; ciano; C1-5 hidrocarbilo y C1-5 hidrocarbiloxi; en donde las unidades estructurales C1-5 hidrocarbilo y C1-5 hidrocarbiloxi son cada una opcionalmente sustituidas por uno o más sustituyentes seleccionados de hidroxi, halógeno, C1-2 alcoxi, amino, mono- y di-C1-2 alquilamino, y grupos arilo y heteroarilo de 5 a 12 miembros de anillo; R4a es seleccionado de hidrógeno, flúor, cloro y metoxi; R8 es seleccionado de hidrógeno y flúor; y R10b es seleccionado de un grupo consistente de halógeno, OH, NH2, CH2OH, CH2NH2, O-C1-6-alquilo, NH-C1-6 alquilo, arilo, heteroarilo, C3-7 cicloalquilo, heterociclilo, O-heteroarilo, O-C3-7 cicloalquilo, O-heterocicloalquilo, C(>=O)C1-6 alquilo, C(>=O)OC1-6 alquilo, C(>=O)NH2, C(>=O)NHC1-6 alquilo, C(>=O)N(C1-6 alquilo, NH(C1-6 alquilo), N(C1-6 alquilo)2, NHC(>=O)C1-6 alquilo, C6 arilo, OC6 arilo, C(>=O)C6arilo, C(>=O)OC6arilo, C(>=O)NH2, C(>=O)NHC6arilo, C(>=O)N(C6 arilo)2, NH(C6 arilo), N(C6 arilo)2, NHC(>=O)C6 arilo, C5-6 heterociclilo, OC5-6 heterociclilo, C(>=O)C5-6 heterociclilo, C(>=O)OC5-6 heterociclilo, C(>=O)NHC5-6 heterociclilo, C(>=O)N(C5-6 heterociclilo)2, NH(C5-6 heterociclilo), N(C5-6 heterociclilo)2, NHC(>=O)C5-6 heterociclilo, C(>=O)NHC1- 6 alquilo, C5-6 arilo, S(>=O)C1-6 alquilo, S(>=O)NH-C1-6 alquilo y SO2NH-C1-6 alquilo; y un grupo [sol], CH2[sol] o OCH2CH2[sol] donde [sol] es seleccionado de los siguientes grupos.",ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;FREDERICKSON MARTYN;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES,,https://lens.org/074-196-010-974-688,Granted Patent,no,0,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,C07D209/44;;A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,ACTIVE
169,ME,B,ME 02051 B,012-507-959-342-018,2015-05-20,2015,ME P14614 A,2006-04-13,GB 0507474 A;;US 67089705 P;;GB 0604111 A;;US 77798906 P;;EP 11158930 A,2005-04-13,HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90,,ASTEX THERAPEUTICS LTD,CHESSARI GIANNI;;CONGREVE MILES STUART;;NAVARRO EVA FIGUEROA;;MURRAY CHRISTOPHER;;WOOLFORD ALISON JO-ANN;;CARR MARIA GRAZIA;;DOWNHAM ROBERT;;O'BRIEN MICHAEL ALISTAIR;;PHILLIPS THERESA RACHEL;;WOODHEAD ANDREW JAMES;;FREDERICKSON MARTYN,,https://lens.org/012-507-959-342-018,Granted Patent,no,0,0,55,70,0,C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/12;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P3/10;;C07D209/44;;C07D471/04;;A61K31/4035;;C07D209/44;;C07D209/08;;C07D209/44;;C07D215/08;;C07D217/06;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/04;;C07D413/04;;C07D413/06;;C07D413/12;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10;;C07D401/12;;C07C65/21,A61K31/403;;A61K31/438;;A61K31/439;;C07D209/08;;C07D209/44;;C07D215/08;;C07D401/04;;C07D401/12;;C07D471/04;;C07D471/10;;C07D491/08;;C07D491/10,,0,0,,,,ACTIVE
170,DK,T3,DK 2305250 T3,102-372-605-294-327,2014-04-22,2014,DK 10195498 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;EP 04743172 A,2003-07-03,BENZIMIDAZOLDERIVATER OG ANVENDELSE HERAF SOM PROTEINKINASEINHIBITORER,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;HOWARD STEVEN;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM;;O'BRIEN MICHAEL ALISTAIR;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;TREWARTHA GARY,,https://lens.org/102-372-605-294-327,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
171,SI,T1,SI 2305250 T1,007-851-807-520-171,2014-06-30,2014,SI 200432146 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;EP 10195498 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/007-851-807-520-171,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00;;A61K31/00;;A61K31/4184;;A61P31/00;;A61P31/10;;A61P35/00;;A61P35/00;;C07D401/14;;C07D403/00;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
172,ES,T3,ES 2457466 T3,111-812-157-418-236,2014-04-25,2014,ES 10195498 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,Derivados de bencimidazol y sus usos como inhibidores de proteína quinasas,"Una combinación que comprende: (i) un compuesto de fórmula (VII): o una sal, N-óxido o solvato del mismo; donde A es -(CH2)m-(B)n-; donde m es 0 o 1, n es 1 y B es C>=O o NRg(C>=O); Rg es hidrógeno; R1d es un grupo R1 donde R1 es hidrógeno, un grupo carbocíclico o heterocíclico que tiene de 3 a 12 miembros en el anillo, o un grupo hidrocarbilo C1-8 opcionalmente sustituido; donde los sustituyentes opcionales para el grupo hidrocarbilo C1-8 se seleccionan entre hidroxi, oxo, alcoxi, carboxi, halógeno, ciano, nitro, amino, mono- o di-hidrocarbilamino C1-4, y grupos carbocíclicos y heterocíclicos monocíclicos o bicíclicos que tienen de 3 a 12 miembros en el anillo; y, donde los grupos carbocíclicos y heterocíclicos en cada caso están sin sustituir o sustituidos con uno o más grupos sustituyentes R10 seleccionados entre halógeno, hidroxi, trifluorometilo, ciano, nitro, carboxi, amino, mono- o di-hidrocarbilamino C1-4, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en el anillo; un grupo Ra-Rb donde Ra es un enlace, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc o NRcSO2; y Rb se selecciona entre hidrógeno, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en el anillo, y un grupo hidrocarbilo C1-8 opcionalmente sustituido con uno o más sustituyentes seleccionados entre hidroxi, oxo, halógeno, ciano, nitro, carboxi, amino, mono- o di-hidrocarbilamino C1-4, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en el anillo y donde uno o más átomos de carbono del grupo hidrocarbilo C1-8 pueden estar opcionalmente reemplazados con O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 o X1C(X2)X1; o dos grupos adyacentes R10, junto con los átomos de carbono o heteroátomos a los que están unidos pueden formar un anillo de heteroarilo de 5 miembros o un anillo carbocíclico o heterocíclico no aromático de 5 o 6 miembros, donde los grupos heteroarilo y heterocíclico mencionados contienen hasta 3 miembros en el anillo que son heteroátomos seleccionados entre N, O y S; Rc se selecciona entre hidrógeno e hidrocarbilo C1-4; y X1 es O, S o NRc y X2 es >=O, >=S o >=NRc; y con la condición de que cuando el grupo sustituyente R10 comprende o incluye un grupo carbocíclico o heterocíclico, el grupo carbocíclico o heterocíclico mencionado puede estar sin sustituir o puede estar sustituido en sí mismo con uno o más grupos sustituyentes adicionales R10 y donde (a) dichos grupos sustituyentes adicionales R10 incluyen grupos carbocíclicos o heterocíclicos, que no están en sí mismos sustituidos adicionalmente; o (b) los sustituyentes adicionales mencionados no incluyen grupos carbocíclicos o heterocíclicos pero se seleccionan de otro modo entre los grupos que se han indicado anteriormente en la definición de R10, y (ii) uno u otros agentes terapéuticos más.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/111-812-157-418-236,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
173,CY,T1,CY 1115093 T1,071-151-217-524-782,2016-12-14,2016,CY 141100311 T,2014-04-28,EP 10195498 A;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,ΠΑΡΑΓΩΓΑ BENZIMIDAZOLE ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΑΝ ΚΑΤΑΣΤΟΛΕΩΝ ΚΙΝΑΣΩΝ (KINASES) ΠΡΩΤΕΪΝΗΣ,"Ένας συνδυασμός που περιλαμβάνει: (i) μία ένωση του τύπου (VII), ή ένα άλας, Ν-οξείδιο ή ένωση διαλύτη με διαλυμένη ουσία αυτού, και (ii) ένα ή περισσότερους άλλους θεραπευτικούς παράγοντες.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/071-151-217-524-782,Granted Patent,no,0,0,7,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D403/04;;A61K31/4155;;A61K31/4184,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
174,PL,T3,PL 2305250 T3,040-164-634-812-281,2014-07-31,2014,PL 10195498 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;EP 10195498 A;;EP 04743172 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/040-164-634-812-281,Patent Application,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,PENDING
175,EP,B1,EP 2305250 B1,096-108-768-301-60X,2014-03-26,2014,EP 10195498 A,2004-07-05,EP 04743172 A;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/096-108-768-301-60X,Granted Patent,yes,1,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,1,0,,,"ESSASSI E M ET AL: ""SYNTHESE ET HEREROCYCLISATION DES (PYRAZOLYL-3(5))-2 BENZIMIDAZOLES EN CATALYSE PAR TRANSFERT DE PHASE"", BULLETIN DES SOCIETES CHIMIQUES BELGES, XX, XX, vol. 96, no. 1, 1987, pages 63-67, XP008005414, ISSN: 0037-9646",ACTIVE
176,PT,E,PT 2305250 E,196-766-902-705-163,2014-05-19,2014,PT 10195498 T,2004-07-05,GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;WYATT PAUL GRAHAM;;CARR MARIA GRAZIA;;WOODHEAD ANDREW JAMES;;HOWARD STEVEN;;O'BRIEN MICHAEL ALISTAIR;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;NAVARRO EVA FIGUEROA,,https://lens.org/196-766-902-705-163,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
177,EP,A1,EP 2305250 A1,090-236-287-148-008,2011-04-06,2011,EP 10195498 A,2004-07-05,EP 04743172 A;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,"A combination comprising: 
(i) a compound of the formula (VII):
  
or a salt, N-oxide or solvate thereof; 
and 
(ii) one or more other therapeutic agents.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/090-236-287-148-008,Patent Application,yes,28,7,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,75,55,012-522-479-506-568;;012-865-156-438-120;;001-661-891-531-467;;015-505-100-135-710;;051-255-997-632-880;;005-521-719-112-587;;009-033-647-751-621;;025-624-292-641-902;;051-098-750-980-596;;040-343-674-829-495;;023-475-764-350-339;;060-784-743-188-505;;029-901-810-393-557;;007-838-854-537-973;;001-226-923-460-944;;002-515-903-844-18X;;028-122-953-422-563;;086-390-749-652-665;;066-013-401-674-717;;004-960-787-208-757;;036-451-583-862-453;;007-838-854-537-973;;160-341-123-989-355;;029-901-810-393-557;;022-498-296-482-829;;160-341-123-989-355;;083-182-706-995-400;;060-784-743-188-505;;005-383-821-091-791;;077-883-857-250-339;;052-908-745-194-978;;016-694-431-273-124;;004-960-787-208-757;;028-122-953-422-563;;023-656-951-495-886;;042-163-039-479-494;;086-272-744-175-380;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;077-365-619-775-156;;004-137-705-827-976;;111-610-126-227-490;;077-295-491-167-117;;046-777-072-258-96X;;007-378-255-811-868;;110-712-435-087-04X;;050-476-538-810-273;;021-634-052-025-91X;;124-153-998-836-964;;056-848-802-620-026;;019-078-987-150-365;;009-760-608-802-570;;027-745-118-667-14X;;007-421-226-677-859,10.1002/bscb.19870960110;;7768349;;0007768349;;10.1096/fasebj.9.8.7768349;;10.1126/science.1862342;;0001862342;;1862342;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(93)90144-f;;8387896;;pmc395100;;8194527;;10.1002/j.1460-2075.1994.tb06519.x;;11166196;;10.1016/s0962-8924(00)01880-8;;11413462;;10.1038/35048096;;10.1023/a:1023789416385;;12884918;;13678575;;10.1016/s0092-8674(03)00685-8;;10.1016/s0092-8674(03)00642-1;;13678582;;10523496;;10.1242/jcs.112.21.3591;;9771714;;10.1038/2496;;10232583;;12019169;;pmc1871005;;7573366;;10.1093/jnci/94.17.1320;;12208897;;10.1093/emboj/17.11.3052;;9606188;;pmc1170645;;10.1111/j.1349-7006.2000.tb00878.x;;11050471;;pmc5926256;;12684414;;10.1054/bjoc.2000.1684;;11259099;;pmc2363814;;10232583;;10.1074/jbc.274.11.7334;;10066797;;9771714;;10.1038/2496;;10.1093/jnci/91.13.1160;;10393726;;10.1074/jbc.274.11.7334;;10066797;;10511710;;10.1016/s0962-8924(99)01658-x;;10523496;;10.1242/jcs.112.21.3591;;12214247;;10.1038/sj.onc.1205775;;10.1002/cncr.11879;;14692019;;14522886;;10.3892/or.10.5.1275;;12883693;;12684414;;10.1093/jnci/94.17.1320;;12208897;;10.1124/mi.3.3.127;;14993419;;10.1016/s1535-6108(02)00235-0;;12559175;;14981513;;10.1038/nm1003;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;10.1007/bf00808679;;10.1002/0471220574;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1038/ng1220;;12881723;;10.1016/0076-6879(87)52071-7;;3657592;;10.1385/1-59259-760-2:077;;15064486;;10.1074/jbc.m313407200;;14701826;;10.1038/nature02313;;14999283;;7805863;;10.1016/0014-5793(94)01298-9;;10559988;;010559988;;10.1038/15674;;12501191;;10.1021/bi0268910;;9692848;;10.1016/s0022-1759(98)00028-3,"ESSASSI E M ET AL: ""SYNTHESE ET HEREROCYCLISATION DES (PYRAZOLYL-3(5))-2 BENZIMIDAZOLES EN CATALYSE PAR TRANSFERT DE PHASE"", BULLETIN DES SOCIETES CHIMIQUES BELGES, XX, XX, vol. 96, no. 1, 1987, pages 63 - 67, XP008005414, ISSN: 0037-9646;;HARDIE, G.; HANKS, S.: ""The Protein Kinase Facts Book"", vol. I, II, 1995, ACADEMIC PRESS;;HANKS, S.K.; HUNTER, T., FASEB J., vol. 9, 1995, pages 576 - 596;;KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596;;GARCIA-BUSTOS ET AL., EMBO J, vol. 13, 1994, pages 2352 - 2361;;ADAMS ET AL., TRENDS CELL BIOL., vol. 11, 2001, pages 49 - 54;;E. A. NIGG, NAT. REV. MOL. CELL BIOL., vol. 2, 2001, pages 21 - 32;;KATAYAMA H; BRINKLEY WR; SEN S.: ""The Aurora kinases: role in cell transformation and tumorigenesis"", CANCER METASTASIS REV., vol. 22, no. 4, December 2003 (2003-12-01), pages 451 - 64;;PRIGENT ET AL., CELL, vol. 114, 2003, pages 531 - 535;;HIROTA ET AL., CELL, vol. 114, 2003, pages 585 - 598;;GIET ET AL., J. CELL. SCI., vol. 112, 1999, pages 3591 - 361;;ZHOU ET AL., NAT. GENET., vol. 20, 1998, pages 189 - 193;;TANAKA ET AL., CANCER RES., vol. 59, 1999, pages 2041 - 2044;;HAN ET AL., CANCER RES., vol. 62, 2002, pages 2890 - 2896;;ISOLA, AMERICAN JOURNAL OF PATHOLOGY, vol. 147, 1995, pages 905 - 911;;SEN ET AL., J. NATL. CANCER INST, vol. 94, 2002, pages 1320 - 1329;;BISCHOFF ET AL., EMBO J., vol. 17, 1998, pages 3052 - 3065;;TAKAHASHI ET AL., JPN. J. CANCER RES., vol. 91, 2000, pages 1007 - 1014;;GRITSKO ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 1420 - 1426;;SAKAKURA ET AL., BRITISH JOURNAL OF CANCER, vol. 84, 2001, pages 824 - 831;;TANAKA ET AL., CANCER RESEARCH, vol. 59, 1999, pages 2041 - 2044;;KIMURA ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 7334 - 7340;;ZHOU ET AL., NATURE GENETICS, vol. 20, 1998, pages 189 - 193;;LI ET AL., CLIN CANCER RES., vol. 9, no. 3, 2003, pages 991 - 7;;KATAYAMA ET AL., GENE, vol. 244, pages 1 - 7;;KATAYAMA ET AL., J. NATL CANCER INST., vol. 91, 1999, pages 1160 - 1162;;KIMURA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 7334 - 7340;;TAKAHASHI ET AL., JPN J. CANCER RES., vol. 91, 2001, pages 1007 - 1014;;BISCHOFF ET AL., TRENDS IN CELL BIOLOGY, vol. 9, 1999, pages 454 - 459;;GIET ET AL., JOURNAL OF CELL SCIENCE, vol. 112, 1999, pages 3591 - 3601;;DUTERTRE ET AL., ONCOGENE, vol. 21, 2002, pages 6175 - 6183;;ROYCE ME; XIA W; SAHIN AA; KATAYAMA H; JOHNSTON DA; HORTOBAGYI G; SEN S; HUNG MC: ""STK15/Aurora-A expression in primary breast tumours is correlated with nuclear grade but not with prognosis"", CANCER, vol. 100, no. 1, 1 January 2004 (2004-01-01), pages 12 - 9;;MORENO-BUENO G; SANCHEZ-ESTEVEZ C; CASSIA R; RODRIGUEZ-PERALES S; DIAZ-URIARTE R; DOMINGUEZ 0; HARDISSON D; ANDUJAR M; PRAT J; MAT, CANCER RES., vol. 63, no. 18, 15 September 2003 (2003-09-15), pages 5697 - 702;;REICHARDT ET AL., ONCOL REP., vol. 10, no. 5, September 2003 (2003-09-01), pages 1275 - 9;;HAMADA ET AL., BR. J. HAEMATOL., vol. L21, no. 3, May 2003 (2003-05-01), pages 439 - 47;;GRITSKO ET AL., CLIN CANCER RES., vol. 9, no. 4, April 2003 (2003-04-01), pages 1420 - 6;;LI ET AL., CLIN. CANCER RES., vol. 9, no. 3, March 2003 (2003-03-01), pages 991 - 7;;J NATL. CANCER INST., vol. 94, no. 17, 4 September 2002 (2002-09-04), pages 1320 - 9;;DUTERTRE S; PRIGENT C.: ""Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint"", MOL. INTERV., vol. 3, no. 3, May 2003 (2003-05-01), pages 127 - 30;;ANAND S; PENRHYN-LOWE S; VENKITARAMAN AR: ""Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol"", CANCER CELL., vol. 3, no. 1, January 2003 (2003-01-01), pages 51 - 62;;HARRINGTON ET AL., NAT MED., vol. 10, no. 3, March 2004 (2004-03-01), pages 262 - 7;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;JERRY MARCH: ""Advanced Organic Chemistry"", WILEY INTERSCIENCE;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN, INGOLD; PRELOG, ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415;;SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525;;L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;""Fiesers'Reagentsfor Organic Synthesis"", vol. 1-17, JOHN WILEY;;""Organic Syntheses"", vol. 1-8, 1995, JOHN WILEY;;JACHAK ET AL., MONTASH. CHEM., vol. 124, no. 2, 1993, pages 199 - 207;;SCHMIDT, HELV. CHIM. ACTA., vol. 39, 1956, pages 986 - 991;;HELV. CHIM. ACTA., vol. 41, 1958, pages 306 - 309;;T. GREEN; P. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;ROSENTRETER U; HUBER U.: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;EWART-TOLAND ET AL., NAT GENET., vol. 34, no. 4, August 2003 (2003-08-01), pages 403 - 12;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC.;;""PCR Protocols: a guide to methods and applications"", 1990, ACADEMIC PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC;;JOHN M. S. BARTLETT: ""Molecular Diagnosis of Cancer, Methods and Protocols"", March 2004, article ""Fluorescence In Situ Hybridization: Technical Overview"", pages: 077 - 088;;HARWELL RM; MULL BB; PORTER DC; KEYOMARSI K., J BIOL CHEM., vol. 279, no. 13, 26 March 2004 (2004-03-26), pages 12695 - 705;;RAJAGOPALAN H; JALLEPALLI PV; RAGO C; VELCULESCU VE; KINZLER KW; VOGELSTEIN B; LENGAUER C., NATURE, vol. 428, no. 6978, 4 March 2004 (2004-03-04), pages 77 - 81;;HELLMICH ET AL., FEBS LETT, vol. 356, 1994, pages 317 - 21;;BROWN ET AL., NAT. CELL BIOL., vol. 1, 1999, pages 438 - 443;;LOWE, E.D. ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 15625 - 15634;;NOCIARI, M. M; SHALEV, A.; BENIAS, P.; RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, 1998, pages 157 - 167",ACTIVE
178,BR,A,BR 9607577 A,194-759-991-359-961,1999-09-14,1999,BR 9607577 A,1996-10-30,US 810895 P;;US 747395 P;;US 899295 P;;US 1374796 P;;US 9617512 W,1995-10-30,Método para inibir catepsina k,"Patente de Invenção: <B>""MéTODO PARA INIBIR CATEPSINA K""<D>. A invenção identifica uma estrutura cristalina nova de catepsina K. Também são descritos métodos para identificar inibidores dessa protease e métodos para inibir catepsina K usando inibidores com determinadas características estruturais, físicas e espaciais.",SMITHKLINE BEECHAM CORP,MEGUID SHERIN SALAHELDIN ABDEL;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHREYL ANN;;MARQUIS ROBERT WELLS JR;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK,,https://lens.org/194-759-991-359-961,Patent Application,no,0,0,1,133,0,,A61K31/16;;A61K31/165;;A61K31/415;;A61K31/425;;A61K38/05;;C12N9/48;;C12N9/64;;C12Q1/37,,0,0,,,,DISCONTINUED
179,US,A1,US 2003/0139970 A1,179-231-184-785-375,2003-07-24,2003,US 94384101 A,2001-08-31,US 94384101 A,2001-08-31,Electronic method for determining procurement business strategy,"
   A method and structure for selecting from a plurality of communication arrangements is performed by inputting a first party's ability to communicate with a second party. The invention evaluates the communication arrangement based on the first party's ability to communicate and repeats the evaluating process for a different communication arrangement if the first party's ability does not match a communication arrangement previously evaluated. The invention performs a cost-benefit analysis with respect to a communication arrangement matching the first party's ability and implements a communication arrangement when the first party's ability matches a communication arrangement. The cost-benefit shows whether the communication arrangement is justified. 
",BADURA TERESA B.;;BARTLETT BONNIE A.;;BURESCH CATHY A.;;CARR THOMAS M.;;CRUZ LUIS;;GILBERT JAMES P.;;KOGUT-O'CONNELL JUDY J.;;O'REILLY CAROL A.;;PLATT DONNA M.;;REESE CHERYL K.;;STORMS ANN T.;;TAMNEY MARY M.;;TESCH PAMELA S.;;WILCZEWSKI JOHN,BADURA TERESA B;;BARTLETT BONNIE A;;BURESCH CATHY A;;CARR THOMAS M;;CRUZ LUIS;;GILBERT JAMES P;;KOGUT-O'CONNELL JUDY J;;O'REILLY CAROL A;;PLATT DONNA M;;REESE CHERYL K;;STORMS ANN T;;TAMNEY MARY M;;TESCH PAMELA S;;WILCZEWSKI JOHN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2001-08-07),https://lens.org/179-231-184-785-375,Patent Application,yes,14,13,1,1,0,G06Q30/06;;G06Q30/06;;G06Q30/0601;;G06Q30/0601,G06Q30/06,705/26,0,0,,,,DISCONTINUED
180,TR,T1,TR 199700560 T1,032-744-781-225-82X,1997-11-21,1997,TR 9700560 T,1996-10-30,US 810895 P;;US 747295 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P,1995-10-30,Cathepsin K'yi önleme (inhibisyon) yöntemi.,"Yeni bir cathepsin K kristalini tanimlanmaktadir. Ayrica bu proteazin inhibitörlerini belirleme ve belirli yapisal, fiziksel ve uzamsal özellikleri olan inhibitörler kullanarak cathepsin K'yi engelleme yöntemleri de açiklanmaktadir.",SMITHKLINE BEECHAM CORP,ABDEL-MEQID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER THIMOTHY FRANCIS;;OH HYE-JA;;THOMSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS;;RU YU;;SMITH WARD WHITLOCK JR;;ZHAO BAOGUANG,,https://lens.org/032-744-781-225-82X,Patent Application,no,0,0,1,133,0,,A61K31/16;;A61K31/165;;A61K31/415;;C12N9/48;;C12Q1/37,,0,0,,,,PENDING
181,HU,A2,HU P9802488 A2,098-207-341-612-931,1999-02-01,1999,HU P9802488 A,1996-10-30,US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1789296 P;;US 1745596 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 810895 P;;US 747395 P,1995-10-30,METHOD OF INHIBITING CATHEPSIN K,"A találmány szerinti megőldással egy új katepszin Kkristályszerkezetet azőnősítőttak. A találmány magában főglalja aprőteáz inhibitőrainak azőnősítási eljárásait is. A találmány kiterjedtővábbá a katepszin K gátlási eljárásaira, amelyek sőrán meghatárőzőttszerkezeti, fizikai és térbeli jellemzőkkel rendelkező inhibitőrőkatalkalmaznak. ŕ",SMITHKLINE BEECHAM CORP,ABDEL-MEQUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER THIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/098-207-341-612-931,Patent Application,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,PENDING
182,NZ,A,NZ 324921 A,015-408-224-361-627,2000-07-28,2000,NZ 32492196 A,1996-10-30,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1374796 P;;US 1376496 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 9617512 W,1995-10-30,Cathepsin K crystal structure and methods of identifying inhibitors of this protease,"The specification describes the crystalline structure of cathepsin K. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial characteristics.",SMITHKLINE BEECHAM CORP,ABDEL-MEDQUID SHERIN SALAHELDI;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/015-408-224-361-627,Patent Application,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,PENDING
183,OA,A,OA 10786 A,191-333-969-548-582,2002-12-24,2002,OA 70040 A,1997-06-27,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P,1995-10-30,Method of inhibiting cathepsin k,,SMITHLINE BEECHAM CORP,ABDEL-MEGUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;JR MARQUIS ROBERT WELLS;;OH HYE-JA;;RU YU;;JR SMITH WARD WHITLOCK;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/191-333-969-548-582,Granted Patent,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,EXPIRED
184,CA,A1,CA 2209109 A1,053-029-985-774-125,1997-05-09,1997,CA 2209109 A,1996-10-30,US 2374296 P;;US 2349496 P;;US 2204796 P;;US 2047896 P;;US 1789296 P;;US 1745596 P;;US 1374796 P;;US 1376496 P;;US 1374896 P;;US 899295 P;;US 747395 P;;US 810895 P,1995-10-30,METHOD OF INHIBITING CATHEPSIN K,"A novel cathepsin K crystalline structure is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial characteristics.",SMITHKLINE BEECHAM CORP,YEN JACK HWEKWO;;VEBER DANIEL FRANK;;ZHAO BAOGUANG;;JANSON CHERYL ANN;;OH HYE-JA;;HALBERT STACIE MARIE;;DESJARLAIS RENEE LOUISE;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;GALLAGHER TIMOTHY FRANCIS;;CARR THOMAS JOSEPH;;MARQUIS ROBERT WELLS JR;;ABDEL-MEGUID SHERIN SALAHELDIN;;YAMASHITA DENNIS SHINJI,,https://lens.org/053-029-985-774-125,Patent Application,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,DISCONTINUED
185,CZ,A3,CZ 206097 A3,002-516-088-881-447,1999-02-17,1999,CZ 206097 A,1996-10-30,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P,1995-10-30,CATHEPSIN K INHIBITION PROCESS,,SMITHKLINE BEECHAM CORP,ABDEL-MEQUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS JR;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/002-516-088-881-447,Patent Application,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,PENDING
186,AU,B2,AU 711014 B2,042-306-048-971-400,1999-10-07,1999,AU 1997/012707 A,1997-02-12,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 9617512 W,1995-10-30,Method of inhibiting cathepsin K,,SMITHKLINE BEECHAM CORP,SHERIN SALAHELDIN ABDEL-MEQUID;;THOMAS JOSEPH CARR;;RENEE LOUISE DESJARLAIS;;THIMOTHY FRANCIS GALLAGHER;;STACIE MARIE HALBERT;;CHERYL ANN JANSON;;ROBERT WELLS MARQUIS JR;;HYE-JA OH;;YU RU;;WARD WHITLOCK SMITH JR;;SCOTT KEVIN THOMPSON;;DANIEL FRANK VEBER;;DENNIS SHINJI YAMASHITA;;JACK HWEKWO YEN;;BAOGUANG ZHAO,,https://lens.org/042-306-048-971-400,Granted Patent,no,2,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,1,0,,,"VELASCO ETAL,THE J. OF BIO.CHEM, 28/10/94,V269,N43,P27136-42",EXPIRED
187,EP,A1,EP 0804180 A1,069-396-985-474-857,1997-11-05,1997,EP 96943476 A,1996-10-30,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1789296 P;;US 1745596 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 9617512 W,1995-10-30,METHOD OF INHIBITING CATHEPSIN K,,SMITHKLINE BEECHAM CORP,ABDEL-MEQUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER THIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS JR;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/069-396-985-474-857,Patent Application,yes,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,5,2,061-993-330-109-087;;078-920-732-510-535,10.1016/0014-5793(94)01349-6;;7805878;;7576232;;10.1515/bchm3.1995.376.6.379,"EPO, JPO, USO: ""Trilateral project WM4. Comparative studies in new technologies (biotechnology, business methods, etc.). Report on comparative study on protein 3-dimensional (3-D) structure related claims."", REPORT - TRILATERAL PROJECT WM4, November 2002 (2002-11-01), pages 1 - 39 + COVER PAGE, XP002990696;;SHI G-P. ET AL.: ""MOLECULAR CLONING OF HUMAN CATHEPSIN O, A NOVEL ENDOPROTEINASE AND HOMOLOGUE OF RABBIT OC2"", FEBS LETTERS, vol. 357, 1995, pages 129 - 134, XP002068032;;BROEMME ET AL.: ""Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution"", BIOL CHEM HOPPE-SEYLER, vol. 376, June 1995 (1995-06-01), pages 376 - 384, XP002078947;;""Cathepsin K data from PDB"", PDB DATABASE, 11 November 2004 (2004-11-11), pages 24 PAGES, XP002990697;;See also references of WO 9716177A1",DISCONTINUED
188,PL,A1,PL 328877 A1,188-344-395-822-479,1999-03-01,1999,PL 32887796 A,1996-10-30,US 9617512 W;;US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P,1995-10-30,METHOD OF INHIBITING CATHEPSIN K,,SMITHKLINE BEECHAM CORP,ABDEL-MEGUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS JR;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/188-344-395-822-479,Patent Application,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,PENDING
189,WO,A1,WO 1997/016177 A1,012-152-918-907-414,1997-05-09,1997,US 9617512 W,1996-10-30,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1789296 P;;US 1745596 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P,1995-10-30,METHOD OF INHIBITING CATHEPSIN K,"A novel cathepsin K crystalline structure is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial characteristics.",SMITHKLINE BEECHAM CORP;;ABDEL MEQUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER THIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS JR;;OH HYE JA;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,ABDEL-MEQUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER THIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS JR;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/012-152-918-907-414,Patent Application,yes,7,24,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,8,5,070-449-744-973-980;;058-632-629-439-564;;178-013-384-166-577;;057-093-743-080-886;;108-612-575-914-756,8647860;;10.1074/jbc.271.21.12517;;3127588;;10.1021/jm00399a006;;8670136;;10.1042/bj3150085;;pmc1217200;;10.1021/jm00101a004;;1447732;;10.1016/s0960-894x(00)80516-8,"""PROTEIN ENGINEERING"", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY., GB, 1 January 1987 (1987-01-01), GB, pages 08, XP002947755, ISSN: 0269-2139;;BOSSARD M. J., ET AL.: ""PROTEOLYTIC ACTIVITY OF HUMAN OSTEOCLAST CATHEPSIN K. EXPRESSION, PURIFICATION, ACTIVATION, AND SUBSTRATE IDENTIFICATION."", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271., no. 21., 24 May 1996 (1996-05-24), US, pages 12517 - 12524., XP002912824, ISSN: 0021-9258, DOI: 10.1074/jbc.271.21.12517;;DESJARLAIS R L, ET AL.: ""USING SHAPE COMPLEMENTARITY AS AN INITIAL SCREEN IN DESIGNING LIGANDS FOR A RECEPTOR BINDING SITE OF KNOWN THREE-DIMENSIONAL STRUCTURE"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 31, no. 04, 1 January 1998 (1998-01-01), US, pages 722 - 729, XP002929885, ISSN: 0022-2623, DOI: 10.1021/jm00399a006;;BROMME D, ET AL.: ""PEPTIDYL VINYL SULPHONES: A NEW CLASS OF POTENT AND SELECTIVE CYSTEINE PROTEASE INHIBITORS S2P2 SPECIFICITY OF HUMAN CATHEPSIN 02 IN COMPARISON WITH CATHEPSINS S AND L"", BIOCHEMICAL JOURNAL, PORTLAND PRESS LTD., GB, vol. 315, 1 January 1996 (1996-01-01), GB, pages 85 - 89, XP002947769, ISSN: 0264-6021;;VELASCO G., ET AL.: ""HUMAN CATHEPSIN O."", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 269., no. 43., 28 October 1994 (1994-10-28), US, pages 27136 - 27142., XP002065342, ISSN: 0021-9258;;MAGRATH J, ABELES R H: ""CYSTEINE PROTEASE INHIBITION BY AZAPEPTIDE ESTERS"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 35, no. 23, 1 January 1992 (1992-01-01), US, pages 4279 - 4283, XP002947746, ISSN: 0022-2623, DOI: 10.1021/jm00101a004;;GRAYBILL T L, ET AL.: ""SYNTHESIS AND EVALUATION OF AZAPEPTIDE-DERIVED INHIBITORS OF SERINE AND CYSTEINE PROTEASES"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 02, no. 11, 1 January 1992 (1992-01-01), AMSTERDAM, NL, pages 1375 - 1380, XP002947770, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(00)80516-8;;See also references of EP 0804180A1",PENDING
190,AU,A,AU 1999/065447 A,029-471-606-650-213,2000-03-16,2000,AU 1999/065447 A,1999-12-23,AU 1999/065447 A,1999-12-23,Method of inhibiting cathepsin K,,SMITHKLINE BEECHAM CORP,ABDEL-MEQUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER THIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS JR;;RU YU;;OH HYE-JA;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/029-471-606-650-213,Patent Application,no,0,0,1,1,0,,A61K31/16;;A61K31/165;;A61K31/415;;A61K31/425;;A61K38/05;;C12N9/48;;C12N9/64;;C12Q1/37,,0,0,,,,DISCONTINUED
191,NO,L,NO 973009 L,099-551-009-262-801,1997-08-27,1997,NO 973009 A,1997-06-27,US 810895 P;;US 747395 P;;US 899295 P;;US 1374796 P;;US 1374896 P;;US 1376496 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 9617512 W,1995-10-30,Fremgangsmåte for å inhibere kathepsin-k,"Det beskrives en ny krystallinsk kathepsin K-struktur. Det beskrives også fremgangsmåter for identifisering av inhibitorer av denne protease, samt fremgangsmåter for inhibering av kathepsin K ved å benytte inhibitorer med bestemte strukturelle, fysiske og romlige karakteristika.",SMITHKLINE BEECHAM CORP,ABDEL-MEGUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS JR ROBERT WELLS;;OH HYE-JA;;RU YU;;SMITH JR WARD WHITLOCK;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/099-551-009-262-801,Abstract,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,DISCONTINUED
192,AU,A,AU 1997/012707 A,149-612-636-929-124,1997-07-17,1997,AU 1997/012707 A,1997-02-12,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 9617512 W,1995-10-30,Method of inhibiting cathepsin K,,SMITHKLINE BEECHAM CORP,SHERIN SALAHELDIN ABDEL-MEQUID;;THOMAS JOSEPH CARR;;RENEE LOUISE DESJARLAIS;;THIMOTHY FRANCIS GALLAGHER;;STACIE MARIE HALBERT;;CHERYL ANN JANSON;;ROBERT WELLS MARQUIS JR;;HYE-JA OH;;YU RU;;WARD WHITLOCK SMITH JR;;SCOTT KEVIN THOMPSON;;DANIEL FRANK VEBER;;DENNIS SHINJI YAMASHITA;;JACK HWEKWO YEN;;BAOGUANG ZHAO,,https://lens.org/149-612-636-929-124,Patent Application,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,EXPIRED
193,NO,D0,NO 973009 D0,199-840-177-502-807,1997-06-27,1997,NO 973009 A,1997-06-27,US 810895 P;;US 747395 P;;US 899295 P;;US 1374796 P;;US 1374896 P;;US 1376496 P;;US 1745596 P;;US 1789296 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 9617512 W,1995-10-30,Fremgangsmåte for å inhibere kathepsin-k,,SMITHKLINE BEECHAM CORP,ABDEL-MEGUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER TIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS JR ROBERT WELLS;;OH HYE-JA;;RU YU;;SMITH JR WARD WHITLOCK;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/199-840-177-502-807,Patent Application,no,0,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,0,0,,,,DISCONTINUED
194,EP,A4,EP 0804180 A4,017-544-207-451-478,2001-09-05,2001,EP 96943476 A,1996-10-30,US 810895 P;;US 747395 P;;US 899295 P;;US 1374896 P;;US 1376496 P;;US 1374796 P;;US 1789296 P;;US 1745596 P;;US 2047896 P;;US 2204796 P;;US 2349496 P;;US 2374296 P;;US 9617512 W,1995-10-30,METHOD OF INHIBITING CATHEPSIN K,,SMITHKLINE BEECHAM CORP,ABDEL-MEQUID SHERIN SALAHELDIN;;CARR THOMAS JOSEPH;;DESJARLAIS RENEE LOUISE;;GALLAGHER THIMOTHY FRANCIS;;HALBERT STACIE MARIE;;JANSON CHERYL ANN;;MARQUIS ROBERT WELLS JR;;OH HYE-JA;;RU YU;;SMITH WARD WHITLOCK JR;;THOMPSON SCOTT KEVIN;;VEBER DANIEL FRANK;;YAMASHITA DENNIS SHINJI;;YEN JACK HWEKWO;;ZHAO BAOGUANG,,https://lens.org/017-544-207-451-478,Search Report,no,1,0,22,133,0,C07C243/34;;C07C311/16;;C07C311/29;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C12N9/6472;;C12Q1/37;;G01N33/573;;A61P19/10;;A61P43/00;;C07D207/273;;C07D333/76;;C07D401/10;;C07C243/34;;C07D213/30;;C07D271/10;;G01N33/573;;C07D295/155;;C07D405/12;;C07D211/96;;C12Q1/37;;C12N9/6472;;C07D249/10;;C07D241/24;;C07D333/34;;C07D211/72;;C07D285/125;;C07D295/215;;C07D401/12;;C07D277/56;;C07C311/29;;C07D285/12;;C07C311/16;;C07D307/91;;C07D401/14;;C07D417/12;;C07D215/36,A61K31/16;;A61K38/55;;A61K45/00;;A61P19/10;;A61P43/00;;C07C243/34;;C07C311/16;;C07C311/29;;C07D207/26;;C07D207/273;;C07D211/72;;C07D211/96;;C07D213/30;;C07D215/36;;C07D241/24;;C07D249/10;;C07D271/10;;C07D277/56;;C07D285/12;;C07D285/125;;C07D295/155;;C07D295/215;;C07D307/91;;C07D333/34;;C07D333/76;;C07D401/10;;C07D401/12;;C07D401/14;;C07D405/12;;C07D417/12;;C07K5/06;;C12N9/64;;C12N9/99;;C12Q1/37;;G01N33/573,,3,1,086-889-913-343-884,10.1021/jm00056a007;;8474103,"DATABASE PROTEIN DATA BANK Research Collaboratory for Structural Bioinformatics; XP002171200;;SHIOSAKI K ET AL: ""POTENT AND SELECTIVE INHIBITORS OF AN ASPARTYL PROTEASE-LIKE ENDOTHELIN CONVERTING ENZYME IDENTIFIED IN RAT LUNG"", JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 36, 1993, pages 468 - 478, XP002064195, ISSN: 0022-2623;;See also references of WO 9716177A1",DISCONTINUED
